{
    "id": 10283,
    "name": "prostate cancer",
    "source": "DOID",
    "definition": "A male reproductive organ cancer that is located_in the prostate. [url:http\\://www.cancer.gov/dictionary?CdrID=445079]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        "514"
    ],
    "termId": "DOID:10283",
    "evidence": [
        {
            "id": 323,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial, Danusertib (PHA-739358) monotherapy was well tolerated, but showed minimal efficacy in patients with castration-resistant prostate cancer (PMID: 22928785).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 716,
                "therapyName": "Danusertib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 69,
                    "pubMedId": 22928785,
                    "title": "Randomized phase II study of danusertib in patients with metastatic castration-resistant prostate cancer after docetaxel failure.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22928785"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 1046,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AR T878A (previously reported as T877A) was activated rather than inhibited by nilutamide in prostate cancer (PMID: 17373727).",
            "molecularProfile": {
                "id": 729,
                "profileName": "AR T878A"
            },
            "therapy": {
                "id": 1506,
                "therapyName": "Nilutamide",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 775,
                    "pubMedId": 17373727,
                    "title": "Effects of steroidal and non-steroidal antiandrogens on wild-type and mutant androgen receptors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17373727"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1047,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In preclinical studies, the antiandrogen Eulexin (flutamide) was reported to inhibit cells expressing AR T878A (aka T877A) in one study (PMID: 19389135), but others found that it activated the mutant receptor (PMID: 9815822, PMID: 10363963).",
            "molecularProfile": {
                "id": 729,
                "profileName": "AR T878A"
            },
            "therapy": {
                "id": 742,
                "therapyName": "Flutamide",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 776,
                    "pubMedId": 9815822,
                    "title": "Functional characterization of mutant androgen receptors from androgen-independent prostate cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/9815822"
                },
                {
                    "id": 777,
                    "pubMedId": 10363963,
                    "title": "Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/10363963"
                },
                {
                    "id": 15294,
                    "pubMedId": 19389135,
                    "title": "Suppression of mutant androgen receptors by flutamide.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19389135"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 1097,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Prunetol (genistein) inhibited MAP2K4 kinase activity in prostate cancer cell lines with MAP2K4 over expression (PMID: 19638505).",
            "molecularProfile": {
                "id": 1858,
                "profileName": "MAP2K4 over exp"
            },
            "therapy": {
                "id": 757,
                "therapyName": "Genistein",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 831,
                    "pubMedId": 19638505,
                    "title": "MEK4 function, genistein treatment, and invasion of human prostate cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19638505"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1295,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the mTOR inhibitor GDC-0349 demonstrated inhibition of tumor growth in cell line xenograft models of solid tumors, including prostate cancer (PMID: 24900569).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1017,
                "therapyName": "GDC-0349",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 1003,
                    "pubMedId": 24900569,
                    "title": "Discovery and Biological Profiling of Potent and Selective mTOR Inhibitor GDC-0349.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24900569"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 1376,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical trial that supported FDA approval, combined with a luteinizing hormone-releasing hormone analogue (LHRH-A) therapy, Casodex (bicalutamide) demonstrated efficacy similar to Eulexin (flutamide), resulted in comparable median time to progression (97 vs 77 weeks, HR=0.93, p=0.41) and survival time (180 vs 148 weeks, HR=0.87, p=0.15) in patients with metastatic prostate cancer (PMID: 9301693).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1507,
                "therapyName": "Bicalutamide",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10764,
                    "pubMedId": 9301693,
                    "title": "Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Casodex Combination Study Group.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/9301693"
                },
                {
                    "id": 15577,
                    "pubMedId": null,
                    "title": "Casodex (bicalutamide) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022310"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 1456,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the siRNA-mediated down-regulation of the cold shock protein genes like CIRBP reduced cell growth in the absence of heat application and enhanced the chemosensitivity in prostate cancer cell lines to Adriamycin (doxorubicin) and Platinol (cisplatin) (PMID: 19277990)",
            "molecularProfile": {
                "id": 2560,
                "profileName": "CIRBP dec exp"
            },
            "therapy": {
                "id": 700,
                "therapyName": "Cisplatin",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1214,
                    "pubMedId": 19277990,
                    "title": "Down-regulating cold shock protein genes impairs cancer cell survival and enhances chemosensitivity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19277990"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1457,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the siRNA-mediated down-regulation of the cold shock protein genes like CIRBP reduced cell growth in the absence of heat application and enhanced the chemosensitivity in prostate cancer cell lines to Adriamycin (doxorubicin) and Platinol (cisplatin) (PMID: 19277990)",
            "molecularProfile": {
                "id": 2560,
                "profileName": "CIRBP dec exp"
            },
            "therapy": {
                "id": 1009,
                "therapyName": "Doxorubicin",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1214,
                    "pubMedId": 19277990,
                    "title": "Down-regulating cold shock protein genes impairs cancer cell survival and enhances chemosensitivity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19277990"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1458,
            "approvalStatus": "Preclinical",
            "evidenceType": "Emerging",
            "efficacyEvidence": "In a preclinical study, the protein-transduction domain TAT fused to BID delivered BID to cancer cell lines and sensitized prostrate cancer cells to TNF-related apoptosis-inducing ligand (TRAIL) or camptothecin (PMID: 25326334).",
            "molecularProfile": {
                "id": 2561,
                "profileName": "BID dec exp"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 1326,
                    "pubMedId": 25326334,
                    "title": "Controlled delivery of BID protein fused with TAT peptide sensitizes cancer cells to apoptosis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25326334"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 1487,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, prostate cancer cells that overexpressed HSBP1 demonstrated resistance to Abraxane (paclitaxel) in androgen-withdrawl cell culture conditions, and in castrated cell line xenograft models (PMID: 20101233)",
            "molecularProfile": {
                "id": 2601,
                "profileName": "HSBP1 over exp"
            },
            "therapy": {
                "id": 1103,
                "therapyName": "Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 1385,
                    "pubMedId": 20101233,
                    "title": "Heat shock protein 27 confers resistance to androgen ablation and chemotherapy in prostate cancer cells through eIF4E.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20101233"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1494,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, overexpression of Id4 in prostate cancer cells increased senescence and improved sensitivity to doxorubicin in culture (PMID: 24122992)",
            "molecularProfile": {
                "id": 2607,
                "profileName": "ID4 over exp"
            },
            "therapy": {
                "id": 1009,
                "therapyName": "Doxorubicin",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1414,
                    "pubMedId": 24122992,
                    "title": "Id4 promotes senescence and sensitivity to doxorubicin-induced apoptosis in DU145 prostate cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24122992"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1549,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical studies, prostate cancer cells overexpressing MUC4 were resistant to Gemzar (gemcitabine)-induced apoptosis in cell culture (PMID: 19738614, PMID: 22580602).",
            "molecularProfile": {
                "id": 2669,
                "profileName": "MUC4 over exp"
            },
            "therapy": {
                "id": 755,
                "therapyName": "Gemcitabine",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 1490,
                    "pubMedId": 19738614,
                    "title": "Pancreatic cancer cells resistance to gemcitabine: the role of MUC4 mucin.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19738614"
                },
                {
                    "id": 1491,
                    "pubMedId": 22580602,
                    "title": "The MUC4 mucin mediates gemcitabine resistance of human pancreatic cancer cells via the Concentrative Nucleoside Transporter family.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22580602"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1595,
            "approvalStatus": "Preclinical",
            "evidenceType": "Emerging",
            "efficacyEvidence": "In a preclinical study, KDM5C was shown to be highly expressed in human prostate cancer. Knockdown of Kdm5c in cultured prostate cancer cells inhibited cell growth and reduced viability suggesting a role for KDM5C as a therapeutic target (PMID: 25016185).",
            "molecularProfile": {
                "id": 2714,
                "profileName": "KDM5C over exp"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 1590,
                    "pubMedId": 25016185,
                    "title": "KDM5C is overexpressed in prostate cancer and is a prognostic marker for prostate-specific antigen-relapse following radical prostatectomy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25016185"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 1598,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SZL-P1-41 decreased Skp2 protein expression, inhibited growth of prostate cancer cell lines through Tp53-independent mechanism in culture and in cell line xenograft models (PMID: 23911321).",
            "molecularProfile": {
                "id": 26070,
                "profileName": "SKP2 positive"
            },
            "therapy": {
                "id": 1932,
                "therapyName": "SZL-P1-41",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1605,
                    "pubMedId": 23911321,
                    "title": "Pharmacological inactivation of Skp2 SCF ubiquitin ligase restricts cancer stem cell traits and cancer progression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23911321"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1697,
            "approvalStatus": "Preclinical",
            "evidenceType": "Emerging",
            "efficacyEvidence": "EPHA10 is over expressed in prostate cancer, and in a preclinical study, treatment of prostate cancer cells with a monoclonal antibody targeting EphA10 resulted in increased complement-dependent cytotoxicity in cell culture, suggesting EPHA10 is a promising therapeutic target (PMID: 24924629).",
            "molecularProfile": {
                "id": 2868,
                "profileName": "EPHA10 positive"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 1190,
                    "pubMedId": 24924629,
                    "title": "Eph receptor A10 has a potential as a target for a prostate cancer therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24924629"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 1758,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BMS-777607 (ASLAN002) demonstrated efficacy in inhibiting migration and invasion of cultured prostate cancer cells expressing wild-type Met (PMID: 20515943).",
            "molecularProfile": {
                "id": 587,
                "profileName": "MET wild-type"
            },
            "therapy": {
                "id": 687,
                "therapyName": "BMS-777607",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2000,
                    "pubMedId": 20515943,
                    "title": "BMS-777607, a small-molecule met kinase inhibitor, suppresses hepatocyte growth factor-stimulated prostate cancer metastatic phenotype in vitro.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20515943"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1790,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SAR405838 inhibited growth of TP53 wild-type prostate cancer cells in culture and resulted in tumor regression in cell line xenograft models (PMID: 25145672).",
            "molecularProfile": {
                "id": 642,
                "profileName": "TP53 wild-type"
            },
            "therapy": {
                "id": 2078,
                "therapyName": "SAR405838",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1886,
                    "pubMedId": 25145672,
                    "title": "SAR405838: an optimized inhibitor of MDM2-p53 interaction that induces complete and durable tumor regression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25145672"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2201,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AP 11014 inhibited Tgfb1 secretion, proliferation, and migration in prostate cancer cells over expressing Tgfb1 (J Clin Oncol: July 2004 vol. 22 no. 14_suppl 3132).",
            "molecularProfile": {
                "id": 6274,
                "profileName": "TGFB1 over exp"
            },
            "therapy": {
                "id": 2706,
                "therapyName": "AP 11014",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2757,
                    "pubMedId": null,
                    "title": "The TGF-beta1 antisense oligonucleotide AP 11014 for the treatment of non-small cell lung, colorectal and prostate cancer: Preclinical studies",
                    "url": "http://meeting.ascopubs.org/cgi/content/short/22/14_suppl/3132"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2217,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Verrucarin A treatment resulted in decreased Ncoa3 (Src-3) protein levels and inhibited growth of prostate cancer cells in culture (PMID: 24743578).",
            "molecularProfile": {
                "id": 6301,
                "profileName": "NCOA3 over exp"
            },
            "therapy": {
                "id": 2715,
                "therapyName": "Verrucarin A",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 2775,
                    "pubMedId": 24743578,
                    "title": "Identification of verrucarin a as a potent and selective steroid receptor coactivator-3 small molecule inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24743578"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14513,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (PROSPER) that supported FDA approval, Xtandi (enzalutamide) significantly improved median metastasis-free survival (36.6 vs 14.7 months, HR=0.29, p<0.0001) compared to placebo in patients with non-metastatic castration-resistant prostate cancer (Journal of Clinical Oncology 36, no. 6_suppl (February 20 2018) 3-3; NCT020032924).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1262,
                "therapyName": "Enzalutamide",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 11720,
                    "pubMedId": null,
                    "title": "PROSPER: A phase 3, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (M0 CRPC).",
                    "url": "http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.6_suppl.3#affiliationsContainer"
                },
                {
                    "id": 15593,
                    "pubMedId": null,
                    "title": "Xtandi (enzalutamide) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203415"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 19545,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Ina Phase III trial (ARCHES) that supported FDA approval, Xtandi (enzalutamide) treatment with androgen deprivation therapy (ADT) significantly reduced the risk of radiographic progression or death compared to ADT plus placebo (HR=0.39, P < .001; median not reached vs 19.0 months) in patients with metastatic hormone-sensitive prostate cancer (PMID: 31329516; NCT02677896).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1262,
                "therapyName": "Enzalutamide",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 15593,
                    "pubMedId": null,
                    "title": "Xtandi (enzalutamide) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203415"
                },
                {
                    "id": 17170,
                    "pubMedId": 31329516,
                    "title": "ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31329516"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 2361,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (AFFIRM) that supported FDA approval, treatment with Xtandi (enzalutamide) resulted in improved median overall survival compared to placebo (18.4 vs 13.6 months HR=0.63, p<0.001) in patients with metastatic castration-resistant prostate cancer (PMID: 22894553; NCT00974311).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1262,
                "therapyName": "Enzalutamide",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10783,
                    "pubMedId": 22894553,
                    "title": "Increased survival with enzalutamide in prostate cancer after chemotherapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22894553"
                },
                {
                    "id": 15593,
                    "pubMedId": null,
                    "title": "Xtandi (enzalutamide) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203415"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 2370,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of AR F877L (also reported as F876L) conferred resistance to Xtandi (enzalutamide) in a prostate cancer cell line in culture and in xenograft models, via a switch of XTANDI (enzalutamide) from androgen receptor antagonist to agonist (PMID: 23842682).",
            "molecularProfile": {
                "id": 26465,
                "profileName": "AR F877L"
            },
            "therapy": {
                "id": 1262,
                "therapyName": "Enzalutamide",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 763,
                    "pubMedId": 23842682,
                    "title": "An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23842682"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2372,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Kisqali (ribociclib) decreased E2F1 target gene expression and inhibited growth of prostate cancer cells harboring AR F877L (also reported as F876L) in culture (PMID: 23842682).",
            "molecularProfile": {
                "id": 26465,
                "profileName": "AR F877L"
            },
            "therapy": {
                "id": 790,
                "therapyName": "Ribociclib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 763,
                    "pubMedId": 23842682,
                    "title": "An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23842682"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2373,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Casodex (bicalutamide) inhibited growth of prostate cancer cells harboring AR F877L (also reported as F876L) in culture (PMID: 23842682).",
            "molecularProfile": {
                "id": 26465,
                "profileName": "AR F877L"
            },
            "therapy": {
                "id": 1507,
                "therapyName": "Bicalutamide",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 763,
                    "pubMedId": 23842682,
                    "title": "An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23842682"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12088,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, the AR F877L variant was not associated with de novo or acquired resistance to Erleada (apalutamide) in patients with castration-resistant prostate cancer, based on its low frequency at baseline and progression (PMID: 28633425; NCT01171898).",
            "molecularProfile": {
                "id": 26465,
                "profileName": "AR F877L"
            },
            "therapy": {
                "id": 1947,
                "therapyName": "Apalutamide",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 10026,
                    "pubMedId": 28633425,
                    "title": "Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28633425"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 2374,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of AR F877L (also reported as F876L) conferred resistance to Erleada (apalutamide) in a castration-resistant prostate cancer cell line in culture and in xenograft models (PMID: 23779130).",
            "molecularProfile": {
                "id": 26465,
                "profileName": "AR F877L"
            },
            "therapy": {
                "id": 1947,
                "therapyName": "Apalutamide",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 3006,
                    "pubMedId": 23779130,
                    "title": "A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23779130"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 2381,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AR W741C conferred resistance to Casodex (bicalutamide) in prostate cancer cells in culture and xenograft models, via a switch of Casodex (bicalutamide) from androgen receptor antagonist to agonist (PMID: 16266977).",
            "molecularProfile": {
                "id": 7398,
                "profileName": "AR W742C"
            },
            "therapy": {
                "id": 1507,
                "therapyName": "Bicalutamide",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3011,
                    "pubMedId": 16266977,
                    "title": "Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/16266977"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2383,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AR W741L conferred resistance to Casodex (bicalutamide) in prostate cancer cells in culture, via a switch of Casodex (bicalutamine) from androgen receptor antagonist to agonist (PMID: 12517791).",
            "molecularProfile": {
                "id": 7399,
                "profileName": "AR W742L"
            },
            "therapy": {
                "id": 1507,
                "therapyName": "Bicalutamide",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3015,
                    "pubMedId": 12517791,
                    "title": "Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/12517791"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2386,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BMS-641988 inhibited tumor growth in a xenograft model of prostate cancer harboring AR H875Y (also reported as H874Y) (PMID: 19654297).",
            "molecularProfile": {
                "id": 2290,
                "profileName": "AR H875Y"
            },
            "therapy": {
                "id": 2819,
                "therapyName": "BMS-641988",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3018,
                    "pubMedId": 19654297,
                    "title": "Discovery of BMS-641988, a novel and potent inhibitor of androgen receptor signaling for the treatment of prostate cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19654297"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2461,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, UC-773587 inhibited ERK activation and growth of prostate cells in culture (PMID: 25825487).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2860,
                "therapyName": "UC-773587",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 3114,
                    "pubMedId": 25825487,
                    "title": "Combined rational design and a high throughput screening platform for identifying chemical inhibitors of a Ras-activating enzyme.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25825487"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 2462,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, UC-773587 inhibited ERK activation and growth of prostate cells in culture (PMID: 25825487).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2861,
                "therapyName": "UC-857993",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 3114,
                    "pubMedId": 25825487,
                    "title": "Combined rational design and a high throughput screening platform for identifying chemical inhibitors of a Ras-activating enzyme.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25825487"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 2505,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I study, Afinitor (everolimus), in combination with Taxotere (docetaxel), demonstrated safety, but minimal efficacy in patients with prostate cancer (PMID: 25450031).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2884,
                "therapyName": "Docetaxel + Everolimus",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 3192,
                    "pubMedId": 25450031,
                    "title": "A phase I study of everolimus and docetaxel in patients with castration-resistant prostate cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25450031"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 2506,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Glucophage (metformin) demonstrated safety and preliminary efficacy in patients with castration-resistant prostate cancer (PMID: 24412228).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1031,
                "therapyName": "Metformin",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 3193,
                    "pubMedId": 24412228,
                    "title": "Metformin in chemotherapy-naive castration-resistant prostate cancer: a multicenter phase 2 trial (SAKK 08/09).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24412228"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 13119,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Sapanisertib (MLN0128) treatment demonstrated limited efficacy, with a median time on treatment of 11 weeks and stable disease as best response (PMID: 29508246).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1282,
                "therapyName": "Sapanisertib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10988,
                    "pubMedId": 29508246,
                    "title": "A phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration resistant prostate cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29508246"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 2507,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sapanisertib (MLN0128) inhibited cell proliferation, induced apoptosis, and prevented metastasis in xenograft models with prostate cancer (PMID: 22367541).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1282,
                "therapyName": "Sapanisertib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 3194,
                    "pubMedId": 22367541,
                    "title": "The translational landscape of mTOR signalling steers cancer initiation and metastasis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22367541"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 2509,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, VS-5584 inhibited PI3K/mTOR signaling and cell proliferation in a human prostate cancer cell line harboring a PTEN deletion in culture, and inhibited PI3K/MTOR signaling and tumor growth in xenograft models (PMID: 23270925).",
            "molecularProfile": {
                "id": 2408,
                "profileName": "PTEN del"
            },
            "therapy": {
                "id": 960,
                "therapyName": "VS-5584",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 351,
                    "pubMedId": 23270925,
                    "title": "VS-5584, a novel and highly selective PI3K/mTOR kinase inhibitor for the treatment of cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23270925"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2691,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Emerging",
            "efficacyEvidence": "In a preclinical study, inhibition of over expressed Nsd2 in human prostate cancer cells via siRNA resulted in decreased cell proliferation due to apoptotic induction and suppressed tumor growth in mouse models, suggesting Nsd2 is a promising therapeutic target (PMID: 22645312).",
            "molecularProfile": {
                "id": 10237,
                "profileName": "NSD2 over exp"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 3408,
                    "pubMedId": 22645312,
                    "title": "Histone methyltransferase NSD2/MMSET mediates constitutive NF-\u03baB signaling for cancer cell proliferation, survival, and tumor growth via a feed-forward loop.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22645312"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 2698,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Lynparza (olaparib) induced DNA damage and inhibited invasion, metastasis, and growth of prostate cancer cells harboring the TMPRSS2-ERG fusion in culture and in cell line xenograft models (PMID: 21575865).",
            "molecularProfile": {
                "id": 10069,
                "profileName": "TMPRSS2 - ERG"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 3390,
                    "pubMedId": 21575865,
                    "title": "Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21575865"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 20783,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Lynparza (olaparib) did not inhibit proliferation of prostate cancer cell lines harboring TMPRSS2-ERG fusion in culture, only induced apoptosis through cytotoxic effects (PMID: 29465803).",
            "molecularProfile": {
                "id": 10069,
                "profileName": "TMPRSS2 - ERG"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 18040,
                    "pubMedId": 29465803,
                    "title": "Olaparib is effective in combination with, and as maintenance therapy after, first-line endocrine therapy in prostate cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29465803"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 2699,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Lynparza (olaparib) and Temodar (temozolomide) inhibited tumor growth of prostate cancer cells harboring the TMPRSS2-ERG fusion in cell line xenograft models (PMID: 21575865).",
            "molecularProfile": {
                "id": 10069,
                "profileName": "TMPRSS2 - ERG"
            },
            "therapy": {
                "id": 1438,
                "therapyName": "Olaparib + Temozolomide",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3390,
                    "pubMedId": 21575865,
                    "title": "Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21575865"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2700,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Rubraca (rucaparib) induced senescence and increased radiosensitivity in PTEN null prostate cancer cells in culture (PMID: 23565244).",
            "molecularProfile": {
                "id": 2408,
                "profileName": "PTEN del"
            },
            "therapy": {
                "id": 906,
                "therapyName": "Rucaparib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3425,
                    "pubMedId": 23565244,
                    "title": "PARP inhibition sensitizes to low dose-rate radiation TMPRSS2-ERG fusion gene-expressing and PTEN-deficient prostate cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23565244"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2701,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Rubraca (rucaparib) induced senescence and increased radiosensitivity in prostate cancer cells harboring the TMPRSS2-ERG fusion in culture (PMID: 23565244).",
            "molecularProfile": {
                "id": 10069,
                "profileName": "TMPRSS2 - ERG"
            },
            "therapy": {
                "id": 6652,
                "therapyName": "Radiotherapy + Rucaparib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3425,
                    "pubMedId": 23565244,
                    "title": "PARP inhibition sensitizes to low dose-rate radiation TMPRSS2-ERG fusion gene-expressing and PTEN-deficient prostate cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23565244"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2736,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AS605240 reduced invasiveness of prostate cancer cells in culture (PMID: 24416348).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2517,
                "therapyName": "AS605240",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 3446,
                    "pubMedId": 24416348,
                    "title": "Promotion of cancer cell invasiveness and metastasis emergence caused by olfactory receptor stimulation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24416348"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 2772,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TGX-221 inhibited proliferation and decreased Akt phosphorylation in human cell line xenograft models of prostate cancer (PMID: 25620467).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2514,
                "therapyName": "TGX-221",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 3468,
                    "pubMedId": 25620467,
                    "title": "Nanomicellar TGX221 blocks xenograft tumor growth of prostate cancer in nude mice.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25620467"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 2941,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CH5132799 inhibited proliferation of prostate cancer cells with PIK3CA mutations in culture (PMID: 21558396).",
            "molecularProfile": {
                "id": 429,
                "profileName": "PIK3CA mutant"
            },
            "therapy": {
                "id": 2152,
                "therapyName": "CH5132799",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1985,
                    "pubMedId": 21558396,
                    "title": "The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21558396"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2953,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CH5132799 inhibited proliferation of prostate cancer cells harboring PIK3CA Q546R in culture (PMID: 21558396).",
            "molecularProfile": {
                "id": 2658,
                "profileName": "PIK3CA Q546R"
            },
            "therapy": {
                "id": 2152,
                "therapyName": "CH5132799",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1985,
                    "pubMedId": 21558396,
                    "title": "The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21558396"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2972,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CH5132799 inhibited tumor growth in xenograft models of a human prostate cancer cell line with deletion of PTEN (PMID: 21558396).",
            "molecularProfile": {
                "id": 2408,
                "profileName": "PTEN del"
            },
            "therapy": {
                "id": 2152,
                "therapyName": "CH5132799",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1985,
                    "pubMedId": 21558396,
                    "title": "The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21558396"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3009,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GDC-0941 and Zolinza (vorinostat) acted synergistically to inhibit growth of a human prostate cancer cell line harboring a PTEN deletion in culture (PMID: 9661880, PMID: 22693356).",
            "molecularProfile": {
                "id": 2408,
                "profileName": "PTEN del"
            },
            "therapy": {
                "id": 3070,
                "therapyName": "Pictilisib + Vorinostat",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1018,
                    "pubMedId": 22693356,
                    "title": "Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22693356"
                },
                {
                    "id": 3569,
                    "pubMedId": 9661880,
                    "title": "Frequent inactivation of PTEN in prostate cancer cell lines and xenografts.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/9661880"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3138,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gedatolisib (PKI-587) inhibited growth of human prostate cancer cells harboring PTEN deletion in culture (PMID: 21325073, PMID: 14737113).",
            "molecularProfile": {
                "id": 2408,
                "profileName": "PTEN del"
            },
            "therapy": {
                "id": 1040,
                "therapyName": "Gedatolisib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 220,
                    "pubMedId": 21325073,
                    "title": "Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21325073"
                },
                {
                    "id": 3644,
                    "pubMedId": 14737113,
                    "title": "PTEN inhibits cell proliferation and induces apoptosis by downregulating cell surface IGF-IR expression in prostate cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/14737113"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3284,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial, 100% (7/7) of metastatic castration-resistant prostate cancer patients with BRCA2 loss demonstrated response to Lynparza (olaparib) treatment (PMID: 26510020).",
            "molecularProfile": {
                "id": 1788,
                "profileName": "BRCA2 loss"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3921,
                    "pubMedId": 26510020,
                    "title": "DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26510020"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 3285,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial, 80% (4/5) of metastatic castration-resistant prostate cancer patients with ATM truncation mutations demonstrated response to Lynparza (olaparib) treatment (Cancer Res August 1, 2015 75:CT322).",
            "molecularProfile": {
                "id": 3274,
                "profileName": "ATM mutant"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3712,
                    "pubMedId": null,
                    "title": "DNA repair defects and antitumor activity with PARP inhibition: TOPARP, a phase II trial of olaparib in metastatic castration resistant prostate cancer",
                    "url": "http://cancerres.aacrjournals.org/content/75/15_Supplement/CT322.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 3286,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial, 86.7% (13/15) of metastatic castration-resistant prostate cancer patients with mutations in DNA repair genes demonstrated response to Lynparza (olaparib) treatment (Cancer Res August 1, 2015 75:CT322).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 3712,
                    "pubMedId": null,
                    "title": "DNA repair defects and antitumor activity with PARP inhibition: TOPARP, a phase II trial of olaparib in metastatic castration resistant prostate cancer",
                    "url": "http://cancerres.aacrjournals.org/content/75/15_Supplement/CT322.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 3515,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed human prostate cells expressing SLC45A3-BRAF were sensitive to Nexavar (sorafenib), resulting in decreased cell proliferation (PMID: 20526349).",
            "molecularProfile": {
                "id": 13288,
                "profileName": "SLC45A3 - BRAF"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3753,
                    "pubMedId": 20526349,
                    "title": "Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20526349"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3519,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed human prostate cells expressing SLC45A3-BRAF were sensitive to U0126, resulting in decreased cell proliferation and invasion (PMID: 20526349).",
            "molecularProfile": {
                "id": 13288,
                "profileName": "SLC45A3 - BRAF"
            },
            "therapy": {
                "id": 2427,
                "therapyName": "U0126",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3753,
                    "pubMedId": 20526349,
                    "title": "Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20526349"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3627,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK525762 inhibited tumor growth in prostate cancer cell line xenograft models with MYC over expression (PMID: 24293458).",
            "molecularProfile": {
                "id": 4715,
                "profileName": "MYC over exp"
            },
            "therapy": {
                "id": 784,
                "therapyName": "GSK525762",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 826,
                    "pubMedId": 24293458,
                    "title": "Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24293458"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20457,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II (TOPARP-B) trial, Lynparza (olaparib) treatment resulted in a composite overall response rate of 36.8% (7/19) and a RECIST objective response rate of 8.3% (1/12) in patients with castration-resistant prostate cancer harboring deleterious ATM mutations (PMID: 31806540; NCT01682772).",
            "molecularProfile": {
                "id": 522,
                "profileName": "ATM inact mut"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17849,
                    "pubMedId": 31806540,
                    "title": "Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31806540"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 3635,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial, 80% (4/5) of metastatic, castration-resistant prostate cancer patients harboring an ATM inactivating mutation responded to Lynparza (olaparib) (PMID: 26510020).",
            "molecularProfile": {
                "id": 522,
                "profileName": "ATM inact mut"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 3921,
                    "pubMedId": 26510020,
                    "title": "DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26510020"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 3636,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II study, a patient with metastatic castration-resistant prostate cancer harboring PALB2 mutation had a response to Lynparza (olaparib), which lasted for 39 weeks (PMID: 26510020).",
            "molecularProfile": {
                "id": 3275,
                "profileName": "PALB2 mutant"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3921,
                    "pubMedId": 26510020,
                    "title": "DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26510020"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 3637,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II study, a patient with metastatic castration-resistant prostate cancer harboring an HDAC2 mutation had a response to Lynparza (olaparib), which lasted for 39 weeks (PMID: 26510020).",
            "molecularProfile": {
                "id": 14077,
                "profileName": "HDAC2 mutant"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3921,
                    "pubMedId": 26510020,
                    "title": "DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26510020"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 3676,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD1208 treatment decreased proliferation, increased apoptosis, and inhibited growth of tumor grafts derived from mouse primary prostate epithelial cells over-expressing Myc and Pim1 (PMID: 25505253).",
            "molecularProfile": {
                "id": 14616,
                "profileName": "MYC over exp PIM1 over exp"
            },
            "therapy": {
                "id": 3224,
                "therapyName": "AZD1208",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3983,
                    "pubMedId": 25505253,
                    "title": "PIM kinase inhibitor AZD1208 for treatment of MYC-driven prostate cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25505253"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3677,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, inhibited tumor growth in MYC-over expressing prostate cancer mouse allograft models (PMID: 25505253).",
            "molecularProfile": {
                "id": 4715,
                "profileName": "MYC over exp"
            },
            "therapy": {
                "id": 3224,
                "therapyName": "AZD1208",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3983,
                    "pubMedId": 25505253,
                    "title": "PIM kinase inhibitor AZD1208 for treatment of MYC-driven prostate cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25505253"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3732,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, one patient with PIK3CB L1049R and PTEN deficient prostate cancer had a favorable response to GSK2636771 for 33 weeks (PMID: 26117819).",
            "molecularProfile": {
                "id": 15028,
                "profileName": "PIK3CB L1049R PTEN del"
            },
            "therapy": {
                "id": 765,
                "therapyName": "GSK2636771",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4036,
                    "pubMedId": 26117819,
                    "title": "Drugging PI3K in cancer: refining targets and therapeutic strategies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26117819"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3733,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, one patient with PIK3CB amplification and PTEN deficient prostate cancer had a partial response to GSK2636771 (PMID: 26117819).",
            "molecularProfile": {
                "id": 15029,
                "profileName": "PIK3CB amp PTEN del"
            },
            "therapy": {
                "id": 765,
                "therapyName": "GSK2636771",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4036,
                    "pubMedId": 26117819,
                    "title": "Drugging PI3K in cancer: refining targets and therapeutic strategies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26117819"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3748,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of BI2536 and Metformin worked synergistically to inhibit tumor growth in patient-derived prostate cancer xenograft models (PMID: 25505174).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3223,
                "therapyName": "BI2536 + Metformin",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 3947,
                    "pubMedId": 25505174,
                    "title": "Inhibition of polo-like kinase 1 (Plk1) enhances the antineoplastic activity of metformin in prostate cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25505174"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 3749,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD1208 inhibited tumor growth in castrate-resistant prostate cancer cell line xenograft models (PMID: 25505253).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3224,
                "therapyName": "AZD1208",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 3983,
                    "pubMedId": 25505253,
                    "title": "PIM kinase inhibitor AZD1208 for treatment of MYC-driven prostate cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25505253"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 3766,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD8186 inhibited tumor growth of PTEN deficient prostate xenografts models (PMID: 25514658).",
            "molecularProfile": {
                "id": 479,
                "profileName": "PTEN loss"
            },
            "therapy": {
                "id": 992,
                "therapyName": "AZD8186",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4117,
                    "pubMedId": 25514658,
                    "title": "Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K\u03b2 and PI3K\u03b4 for the treatment of PTEN-deficient cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25514658"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3769,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, AZD8186 demonstrated preliminary efficacy in patients with tumor types with prevalent PTEN-deficiency, including prostate cancer (AACR; Cancer Res 2015;75(15 Suppl):Abstract nr CT329).",
            "molecularProfile": {
                "id": 2408,
                "profileName": "PTEN del"
            },
            "therapy": {
                "id": 992,
                "therapyName": "AZD8186",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4118,
                    "pubMedId": null,
                    "title": "Phase I study of the PI3K?/? inhibitor AZD8186 in patients with advanced castration resistant prostate cancer, triple negative breast cancer, squamous non-small cell lung cancer or PTEN deficient solid tumors: update from dose-finding",
                    "url": "http://cancerres.aacrjournals.org/content/75/15_Supplement/CT329.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3772,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Panulisib (P7170) inhibited tumor growth in PTEN null prostate cancer cell xenograft models (PMID: 25700704).",
            "molecularProfile": {
                "id": 479,
                "profileName": "PTEN loss"
            },
            "therapy": {
                "id": 857,
                "therapyName": "Panulisib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3487,
                    "pubMedId": 25700704,
                    "title": "P7170: A Novel Molecule with Unique Profile of mTORC1/C2 and Activin Receptor-like Kinase 1 Inhibition Leading to Antitumor and Antiangiogenic Activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25700704"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3779,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with ABC294640 resulted in decreased AR and MYC expression and downstream signaling, and decreased growth of AR-positive prostate cancer cell lines in culture, and inhibited tumor growth in prostate cancer cell line xenograft models (PMID: 26271487).",
            "molecularProfile": {
                "id": 2795,
                "profileName": "AR positive"
            },
            "therapy": {
                "id": 3301,
                "therapyName": "ABC294640",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4127,
                    "pubMedId": 26271487,
                    "title": "Downregulation of Critical Oncogenes by the Selective SK2 Inhibitor ABC294640 Hinders Prostate Cancer Progression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26271487"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3781,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial, a patient with a metastatic, castration-resistant prostate cancer harboring deletions in BRCA1 and FANCA responded to Lynparza (olaparib) as demonstrated by a reduction in circulating tumor cells (PMID: 26510020).",
            "molecularProfile": {
                "id": 14075,
                "profileName": "BRCA1 del FANCA del"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3921,
                    "pubMedId": 26510020,
                    "title": "DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26510020"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 3782,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I clinical trial, 8 patients with metastatic, castration-resistant prostate cancer harboring a loss of PTEN did not respond to MK-2206 therapy, but prolonged stable disease was observed in 2 patients (PMID: 26187616).",
            "molecularProfile": {
                "id": 479,
                "profileName": "PTEN loss"
            },
            "therapy": {
                "id": 816,
                "therapyName": "MK2206",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 4136,
                    "pubMedId": 26187616,
                    "title": "A Phase I Trial of Combined Ridaforolimus and MK-2206 in Patients with Advanced Malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26187616"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4296,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MEDI5117 inhibited the growth of human IL6-stimulated prostate cancer cells with IL6R and IL6 expression in culture and inhibited tumor growth in xenograft models (PMID: 26744529).",
            "molecularProfile": {
                "id": 20372,
                "profileName": "IL6 over exp IL6R pos"
            },
            "therapy": {
                "id": 3481,
                "therapyName": "MEDI5117",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4491,
                    "pubMedId": 26744529,
                    "title": "A Novel IL6 Antibody Sensitizes Multiple Tumor Types to Chemotherapy Including Trastuzumab-Resistant Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26744529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4302,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sylvant (siltuximab) inhibited the growth of IL6-stimulated human prostate cancer cells with IL6 and IL6R expression in culture and inhibited tumor growth in cell line xenograft models (PMID: 26744529).",
            "molecularProfile": {
                "id": 20372,
                "profileName": "IL6 over exp IL6R pos"
            },
            "therapy": {
                "id": 3485,
                "therapyName": "siltuximab",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4491,
                    "pubMedId": 26744529,
                    "title": "A Novel IL6 Antibody Sensitizes Multiple Tumor Types to Chemotherapy Including Trastuzumab-Resistant Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26744529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4306,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MEDI5117 in combination with Taxotere (docetaxel) resulted in tumor regression in human prostate cancer xenograft models (PMID: 26744529).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3484,
                "therapyName": "Docetaxel + MEDI5117",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4491,
                    "pubMedId": 26744529,
                    "title": "A Novel IL6 Antibody Sensitizes Multiple Tumor Types to Chemotherapy Including Trastuzumab-Resistant Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26744529"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 4335,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SH5-07 inhibited proliferation of prostate cancer cell lines harboring constitutively active Stat3 in culture (PMID: 26088127).",
            "molecularProfile": {
                "id": 17818,
                "profileName": "STAT3 act mut"
            },
            "therapy": {
                "id": 3494,
                "therapyName": "SH5-07",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4499,
                    "pubMedId": 26088127,
                    "title": "Hydroxamic Acid and Benzoic Acid-Based STAT3 Inhibitors Suppress Human Glioma and Breast Cancer Phenotypes In Vitro and In Vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26088127"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4345,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SH4-54 inhibited proliferation of prostate cancer cell lines harboring constitutively active Stat3 in culture (PMID: 26088127).",
            "molecularProfile": {
                "id": 17818,
                "profileName": "STAT3 act mut"
            },
            "therapy": {
                "id": 3493,
                "therapyName": "SH4-54",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4499,
                    "pubMedId": 26088127,
                    "title": "Hydroxamic Acid and Benzoic Acid-Based STAT3 Inhibitors Suppress Human Glioma and Breast Cancer Phenotypes In Vitro and In Vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26088127"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4434,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LQZ-7F treatment in prostate cancer cells over expressing Birc5 (survivin) resulted in reduced cell survival and inhibition of tumor growth in culture and in xenograft models (PMID: 26744521).",
            "molecularProfile": {
                "id": 13340,
                "profileName": "BIRC5 over exp"
            },
            "therapy": {
                "id": 3506,
                "therapyName": "LQZ-7F",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4545,
                    "pubMedId": 26744521,
                    "title": "Effective Targeting of the Survivin Dimerization Interface with Small-Molecule Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26744521"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4686,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a prostate cancer cell line treated with PHM16 demonstrated inhibition of Fak autophosphorylation and decreased cell proliferation in culture (PMID: 24657306).",
            "molecularProfile": {
                "id": 18706,
                "profileName": "PTK2 positive"
            },
            "therapy": {
                "id": 3595,
                "therapyName": "PHM16",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4667,
                    "pubMedId": 24657306,
                    "title": "Inhibition of both focal adhesion kinase and fibroblast growth factor receptor 2 pathways induces anti-tumor and anti-angiogenic activities.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24657306"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4698,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PF-00562271 re-sensitized chemoresistant prostate cancer cells to Taxotere (docetaxel) in culture, resulting in decreased phosphorylation of Ptk2 (Fak) and increased autophagy (PMID: 24194567).",
            "molecularProfile": {
                "id": 18706,
                "profileName": "PTK2 positive"
            },
            "therapy": {
                "id": 3598,
                "therapyName": "Docetaxel + PF-00562271",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4671,
                    "pubMedId": 24194567,
                    "title": "Phosphoproteomic profiling identifies focal adhesion kinase as a mediator of docetaxel resistance in castrate-resistant prostate cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24194567"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4749,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, C6-ceramide treatment of prostate cancer cells prevented the association between SET and PP2A, which resulted in cell death in culture (PMID: 24025258).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3603,
                "therapyName": "C6-ceramide",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4692,
                    "pubMedId": 24025258,
                    "title": "Targeting inhibitor 2 of protein phosphatase 2A as a therapeutic strategy for prostate cancer treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24025258"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 4750,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, carnosic acid treatment of prostate cancer cells led to activation of PP2A, which resulted in apoptosis and inhibition of cell proliferation (PMID: 22453599).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3604,
                "therapyName": "Carnosic acid",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4693,
                    "pubMedId": 22453599,
                    "title": "Carnosic acid modulates Akt/IKK/NF-\u03baB signaling by PP2A and induces intrinsic and extrinsic pathway mediated apoptosis in human prostate carcinoma PC-3 cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22453599"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 4751,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, prostate cancer cells treated with Forskolin demonstrated PP2A activation and inhibition of cell proliferation in culture (PMID: 26023836).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3605,
                "therapyName": "Forskolin",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4695,
                    "pubMedId": 26023836,
                    "title": "Activation of the Tumor Suppressor PP2A Emerges as a Potential Therapeutic Strategy for Treating Prostate Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26023836"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 4755,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, prostate cancer mouse models deficient for Pten demonstrated inhibition of the PI3K/Akt signaling pathway and a decrease in both tumor size and cell proliferation when treated with OP449 (PMID: 26563471).",
            "molecularProfile": {
                "id": 479,
                "profileName": "PTEN loss"
            },
            "therapy": {
                "id": 3606,
                "therapyName": "OP449",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4697,
                    "pubMedId": 26563471,
                    "title": "Inhibition of Pten deficient Castration Resistant Prostate Cancer by Targeting of the SET - PP2A Signaling axis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26563471"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4781,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KU-60019 blocked tumor growth in PTEN-deficient human prostate cancer xenograft models (PMID: 25870146).",
            "molecularProfile": {
                "id": 479,
                "profileName": "PTEN loss"
            },
            "therapy": {
                "id": 3652,
                "therapyName": "KU-60019",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4736,
                    "pubMedId": 25870146,
                    "title": "Mechanistic Rationale to Target PTEN-Deficient Tumor Cells with Inhibitors of the DNA Damage Response Kinase ATM.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25870146"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4785,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AT13148 inhibited tumor growth in a PTEN-deficient human prostate cancer cell line xenograft model (PMID: 22781553).",
            "molecularProfile": {
                "id": 479,
                "profileName": "PTEN loss"
            },
            "therapy": {
                "id": 3653,
                "therapyName": "AT13148",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 204,
                    "pubMedId": 22781553,
                    "title": "AT13148 is a novel, oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22781553"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4814,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, prostate cancer cells were sensitive to BX-912, resulting in a moderate decrease of Pdpk1 activity and inhibition of cell growth in culture (PMID: 15772071).",
            "molecularProfile": {
                "id": 19233,
                "profileName": "PDPK1 positive"
            },
            "therapy": {
                "id": 3657,
                "therapyName": "BX-912",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4745,
                    "pubMedId": 15772071,
                    "title": "Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15772071"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4886,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, prostate cancer cells over expressing PIM1 were sensitive to TP-3654 both in culture and in human cell line xenograft models, resulting in decreased tumor growth (PMID: 24953177).",
            "molecularProfile": {
                "id": 14615,
                "profileName": "PIM1 over exp"
            },
            "therapy": {
                "id": 3672,
                "therapyName": "TP-3654",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4769,
                    "pubMedId": 24953177,
                    "title": "A small-molecule inhibitor of PIM kinases as a potential treatment for urothelial carcinomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24953177"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4896,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CX-6258 inhibited tumor growth in human prostate cancer cell line xenograft models (PMID: 24900437).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3675,
                "therapyName": "CX-6258",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4774,
                    "pubMedId": 24900437,
                    "title": "Discovery of CX-6258. A Potent, Selective, and Orally Efficacious pan-Pim Kinases Inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24900437"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 4906,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Alpelisib (BYL719) inhibited Akt signaling and cell migration in prostate cancer cells expressing PTEN A126G in culture (PMID: 26504226).",
            "molecularProfile": {
                "id": 19788,
                "profileName": "PTEN A126G"
            },
            "therapy": {
                "id": 691,
                "therapyName": "Alpelisib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4785,
                    "pubMedId": 26504226,
                    "title": "Discovery and functional characterization of a neomorphic PTEN mutation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26504226"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4907,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD6482 inhibited Akt signaling and cell migration in prostate cancer cell lines overexpressing PTEN A126G (PMID: 26504226).",
            "molecularProfile": {
                "id": 19788,
                "profileName": "PTEN A126G"
            },
            "therapy": {
                "id": 659,
                "therapyName": "AZD6482",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4785,
                    "pubMedId": 26504226,
                    "title": "Discovery and functional characterization of a neomorphic PTEN mutation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26504226"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4928,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, 53% (10/19) of patients with metastatic castrate resistant prostate cancer progressing on Xtandi (enzalutamide) had amplified AR in cell-free DNA (PMID: 25712683).",
            "molecularProfile": {
                "id": 19120,
                "profileName": "AR amp"
            },
            "therapy": {
                "id": 1262,
                "therapyName": "Enzalutamide",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 4735,
                    "pubMedId": 25712683,
                    "title": "Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25712683"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4929,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, seven metastatic castration-resistant prostate cancer patients with AR H875Y (reported as H874Y) or T878A (reported as T877A) detected in cell-free DNA had progressed on or had received prior treatment with Zytiga (abiraterone) (PMID: 25712683).",
            "molecularProfile": {
                "id": 2290,
                "profileName": "AR H875Y"
            },
            "therapy": {
                "id": 1805,
                "therapyName": "Abiraterone",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 4735,
                    "pubMedId": 25712683,
                    "title": "Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25712683"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4931,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, 34% (10/29) of patients with metastatic castrate resistant prostate cancer patients progressing on Zytiga (abiraterone) had copy number gain or amplification of AR in cell-free DNA (PMID: 25712683).",
            "molecularProfile": {
                "id": 19120,
                "profileName": "AR amp"
            },
            "therapy": {
                "id": 1805,
                "therapyName": "Abiraterone",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 4735,
                    "pubMedId": 25712683,
                    "title": "Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25712683"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6941,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, prostate cancer patients harboring either AR amplification or AR T878A or AR L702H prior to Zytiga (abiraterone) treatment demonstrated they were less likely to experience a greater than or equal to 50% to 90% PSA decline and showed a worse overall survial (HR=7.33) and progression-free survival (HR=3.73) (PMID: 26537258).",
            "molecularProfile": {
                "id": 19120,
                "profileName": "AR amp"
            },
            "therapy": {
                "id": 1805,
                "therapyName": "Abiraterone",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 5973,
                    "pubMedId": 26537258,
                    "title": "Plasma AR and abiraterone-resistant prostate cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26537258"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4973,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD6482 inhibited viability of prostate cancer cell lines harboring PTEN deficiency in culture (PMID: 23674493).",
            "molecularProfile": {
                "id": 479,
                "profileName": "PTEN loss"
            },
            "therapy": {
                "id": 659,
                "therapyName": "AZD6482",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3345,
                    "pubMedId": 23674493,
                    "title": "PI3K pathway dependencies in endometrioid endometrial cancer cell lines.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23674493"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4975,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK2636771 inhibited viability of prostate cancer cell lines harboring PTEN deficiency in culture (PMID: 23674493).",
            "molecularProfile": {
                "id": 479,
                "profileName": "PTEN loss"
            },
            "therapy": {
                "id": 765,
                "therapyName": "GSK2636771",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3345,
                    "pubMedId": 23674493,
                    "title": "PI3K pathway dependencies in endometrioid endometrial cancer cell lines.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23674493"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5000,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SAN1GSC inhibited growth of GnRH-R-positive prostate cancer cells in culture and in cell line xenograft models (PMID: 26645560).",
            "molecularProfile": {
                "id": 19848,
                "profileName": "GNRHR positive"
            },
            "therapy": {
                "id": 3722,
                "therapyName": "SAN1GSC",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4829,
                    "pubMedId": 26645560,
                    "title": "Peptide-Drug Conjugate GnRH-Sunitinib Targets Angiogenesis Selectively at the Site of Action to Inhibit Tumor Growth.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26645560"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5016,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ganetespib inhibited growth of human prostate cancer cells harboring TP53 P223L and V274F in culture (PMID: 26009011).",
            "molecularProfile": {
                "id": 19855,
                "profileName": "TP53 P223L TP53 V274F"
            },
            "therapy": {
                "id": 745,
                "therapyName": "Ganetespib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4831,
                    "pubMedId": 26009011,
                    "title": "Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26009011"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5025,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, IST5-002 inhibited Stat5a dimerization, DNA binding, and transcriptional activity in prostate cancer cells expressing Stat5a, and inhibited growth of prostate cancer cell lines with activated Stat5a/5b in culture (PMID: 26026053).",
            "molecularProfile": {
                "id": 20013,
                "profileName": "STAT5A wild-type"
            },
            "therapy": {
                "id": 3702,
                "therapyName": "IST5-002",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4451,
                    "pubMedId": 26026053,
                    "title": "Structure-Based Screen Identifies a Potent Small Molecule Inhibitor of Stat5a/b with Therapeutic Potential for Prostate Cancer and Chronic Myeloid Leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26026053"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5046,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Custirsen (OGX-011) treatment resulted in dose-dependent decrease of clusterin expression in prostate tumors in patients (PMID: 16145049).",
            "molecularProfile": {
                "id": 19099,
                "profileName": "CLU positive"
            },
            "therapy": {
                "id": 3643,
                "therapyName": "Custirsen",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4857,
                    "pubMedId": 16145049,
                    "title": "A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/16145049"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5050,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, JNJ-54302833 inhibited growth of prostate cancer cells in culture ( Cancer Res October 1, 2014 74; 4747 ).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3742,
                "therapyName": "JNJ-54302833",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4864,
                    "pubMedId": null,
                    "title": "Design and synthesis of a series highly potent and bioavailable FASN KR domain inhibitors for cancer",
                    "url": "http://cancerres.aacrjournals.org/content/74/19_Supplement/4747"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5091,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD8186 and Alpelisib (BYL719) combination treatment resulted in minor inhibition of tumor growth in animal models of prostate cancer harboring PTEN gene deletion (PMID: 25544636).",
            "molecularProfile": {
                "id": 2408,
                "profileName": "PTEN del"
            },
            "therapy": {
                "id": 3749,
                "therapyName": "Alpelisib + AZD8186",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4876,
                    "pubMedId": 25544636,
                    "title": "Feedback suppression of PI3K\u03b1 signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3K\u03b2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25544636"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5092,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD8186, Alpelisib (BYL719), and Xtandi (enzalutamide) combination treatment resulted in near-complete suppression of tumor growth in animal models of prostate cancer harboring PTEN gene deletion (PMID: 25544636).",
            "molecularProfile": {
                "id": 2408,
                "profileName": "PTEN del"
            },
            "therapy": {
                "id": 3750,
                "therapyName": "Alpelisib + AZD8186 + Enzalutamide",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4876,
                    "pubMedId": 25544636,
                    "title": "Feedback suppression of PI3K\u03b1 signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3K\u03b2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25544636"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5093,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD8186 and Xtandi (enzalutamide) combination treatment resulted in suppression of tumor growth in animal models of prostate cancer harboring PTEN gene deletion (PMID: 25544636).",
            "molecularProfile": {
                "id": 2408,
                "profileName": "PTEN del"
            },
            "therapy": {
                "id": 3752,
                "therapyName": "AZD8186 + Enzalutamide",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4876,
                    "pubMedId": 25544636,
                    "title": "Feedback suppression of PI3K\u03b1 signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3K\u03b2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25544636"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5222,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, prostate cancer cells treated with TAK-960 demonstrated a decrease in tumor size in cell line xenograft models (PMID: 22188812).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3780,
                "therapyName": "TAK-960",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4929,
                    "pubMedId": 22188812,
                    "title": "TAK-960, a novel, orally available, selective inhibitor of polo-like kinase 1, shows broad-spectrum preclinical antitumor activity in multiple dosing regimens.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22188812"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5296,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BGB0324 and Glucophage (metformin) worked synergistically to inhibit growth of metformin-resistant prostate cancer cell lines harboring elevated Axl protein level in culture (PMID: 26036314).",
            "molecularProfile": {
                "id": 2905,
                "profileName": "AXL over exp"
            },
            "therapy": {
                "id": 3823,
                "therapyName": "BGB-324 + Metformin",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4997,
                    "pubMedId": 26036314,
                    "title": "Axl receptor tyrosine kinase is up-regulated in metformin resistant prostate cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26036314"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5297,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BGB0324 inhibited growth of prostate cancer cell lines harboring elevated Axl protein level in culture (PMID: 26036314).",
            "molecularProfile": {
                "id": 2905,
                "profileName": "AXL over exp"
            },
            "therapy": {
                "id": 2660,
                "therapyName": "BGB-324",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4997,
                    "pubMedId": 26036314,
                    "title": "Axl receptor tyrosine kinase is up-regulated in metformin resistant prostate cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26036314"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5314,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SPC3042 decreased Survivin expression and induced apoptosis of prostate cancer cells in culture (PMID: 18790754).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3827,
                "therapyName": "SPC3042",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5012,
                    "pubMedId": 18790754,
                    "title": "SPC3042: a proapoptotic survivin inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18790754"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5315,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of SPC3042 and Taxol (paclitaxel) worked synergistically to inhibit tumor growth in prostate cancer cell line xenograft models, with increased activity over either agent alone (PMID: 18790754).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3828,
                "therapyName": "Paclitaxel + SPC3042",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5012,
                    "pubMedId": 18790754,
                    "title": "SPC3042: a proapoptotic survivin inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18790754"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5403,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Lynparza (olaparib) decreased tumor volume in both cell line and patient-derived xenograft models of prostate cancer harboring an ETV1 fusion (PMID: 21575865).",
            "molecularProfile": {
                "id": 17090,
                "profileName": "ETV1 fusion"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3390,
                    "pubMedId": 21575865,
                    "title": "Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21575865"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5443,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BBI608 inhibited proliferation of high stemness prostate cancer cells as indicated by surface expression of Cd44 and Prom1 (Cd133) in culture, and suppressed tumor growth in xenograft models (PMID: 26899963).",
            "molecularProfile": {
                "id": 20911,
                "profileName": "CD44 pos PROM1 pos"
            },
            "therapy": {
                "id": 2057,
                "therapyName": "Napabucasin",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5056,
                    "pubMedId": 26899963,
                    "title": "Suppression of prostate cancer progression by cancer cell stemness inhibitor napabucasin.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26899963"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5474,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, YK-4-279 inhibited invasion of a prostate cancer cell line harboring TMPRSS2-ERG in culture (PMID: 21559405).",
            "molecularProfile": {
                "id": 10069,
                "profileName": "TMPRSS2 - ERG"
            },
            "therapy": {
                "id": 3419,
                "therapyName": "YK-4-279",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4357,
                    "pubMedId": 21559405,
                    "title": "YK-4-279 inhibits ERG and ETV1 mediated prostate cancer cell invasion.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21559405"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5475,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, YK-4-279 inhibited invasion and motility of a prostate cancer cell line with an ETV1 rearrangement in culture (PMID: 21559405).",
            "molecularProfile": {
                "id": 20932,
                "profileName": "ETV1 rearrange"
            },
            "therapy": {
                "id": 3419,
                "therapyName": "YK-4-279",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4357,
                    "pubMedId": 21559405,
                    "title": "YK-4-279 inhibits ERG and ETV1 mediated prostate cancer cell invasion.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21559405"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5839,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Casodex (bicalutamide) and Afinitor (everolimus) combination treatment resulted in PSA response in 75% (18/24) of patients with castration-resistant prostate cancer, with a median overall survival of 28 months (PMID: 27019001).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3952,
                "therapyName": "Bicalutamide + Everolimus",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5178,
                    "pubMedId": 27019001,
                    "title": "A phase 2 clinical trial of everolimus plus bicalutamide for castration-resistant prostate cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27019001"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5883,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, G1T38 treatment resulted in cell cycle arrest and growth inhibition in AR wild-type prostate cancer cell lines in culture (AACR, Cancer Res: April 2016; Volume 57, Abstract #2820).",
            "molecularProfile": {
                "id": 360,
                "profileName": "AR wild-type"
            },
            "therapy": {
                "id": 3970,
                "therapyName": "G1T38",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5183,
                    "pubMedId": null,
                    "title": "Effects of a CDK 4/6 inhibitor, G1T38, in androgen receptor sensitive and resistant models of castrate resistant prostate cancer",
                    "url": "http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=4017&sKey=12eab58f-9b3f-418d-ad0c-e55a553a95b9&cKey=90cf56d3-fe9d-4b4d-8477-6867a79402af&mKey=1d10d749-4b6a-4ab3-bcd4-f80fb1922267"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5884,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, G1T38 treatment resulted in cell cycle arrest and growth inhibition in prostate cancer cell lines harboring AR F877L (also reported as F876L) in culture and tumor suppression in xenograft models (AACR, Cancer Res: April 2016; Volume 57, Abstract #2820).",
            "molecularProfile": {
                "id": 26465,
                "profileName": "AR F877L"
            },
            "therapy": {
                "id": 3970,
                "therapyName": "G1T38",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5183,
                    "pubMedId": null,
                    "title": "Effects of a CDK 4/6 inhibitor, G1T38, in androgen receptor sensitive and resistant models of castrate resistant prostate cancer",
                    "url": "http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=4017&sKey=12eab58f-9b3f-418d-ad0c-e55a553a95b9&cKey=90cf56d3-fe9d-4b4d-8477-6867a79402af&mKey=1d10d749-4b6a-4ab3-bcd4-f80fb1922267"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5885,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, G1T38 did not inhibit growth of AR and RB1-negative prostate cancer cell lines in culture (AACR, Cancer Res: April 2016; Volume 57, Abstract #2820).",
            "molecularProfile": {
                "id": 21979,
                "profileName": "AR neg RB1 neg"
            },
            "therapy": {
                "id": 3970,
                "therapyName": "G1T38",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5183,
                    "pubMedId": null,
                    "title": "Effects of a CDK 4/6 inhibitor, G1T38, in androgen receptor sensitive and resistant models of castrate resistant prostate cancer",
                    "url": "http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=4017&sKey=12eab58f-9b3f-418d-ad0c-e55a553a95b9&cKey=90cf56d3-fe9d-4b4d-8477-6867a79402af&mKey=1d10d749-4b6a-4ab3-bcd4-f80fb1922267"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5886,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, G1T38 treatment resulted in growth inhibition in AR-negative, RB1-positive prostate cancer cell lines in culture (AACR, Cancer Res: April 2016; Volume 57, Abstract #2820).",
            "molecularProfile": {
                "id": 21980,
                "profileName": "AR neg RB1 pos"
            },
            "therapy": {
                "id": 3970,
                "therapyName": "G1T38",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5183,
                    "pubMedId": null,
                    "title": "Effects of a CDK 4/6 inhibitor, G1T38, in androgen receptor sensitive and resistant models of castrate resistant prostate cancer",
                    "url": "http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=4017&sKey=12eab58f-9b3f-418d-ad0c-e55a553a95b9&cKey=90cf56d3-fe9d-4b4d-8477-6867a79402af&mKey=1d10d749-4b6a-4ab3-bcd4-f80fb1922267"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5887,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, G1T38 and Xtandi (enzalutamide) worked synergistically to inhibit growth in AR-positive prostate cancer cell lines in culture (AACR, Cancer Res: April 2016; Volume 57, Abstract #2820).",
            "molecularProfile": {
                "id": 2795,
                "profileName": "AR positive"
            },
            "therapy": {
                "id": 3971,
                "therapyName": "Enzalutamide + G1T38",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5183,
                    "pubMedId": null,
                    "title": "Effects of a CDK 4/6 inhibitor, G1T38, in androgen receptor sensitive and resistant models of castrate resistant prostate cancer",
                    "url": "http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=4017&sKey=12eab58f-9b3f-418d-ad0c-e55a553a95b9&cKey=90cf56d3-fe9d-4b4d-8477-6867a79402af&mKey=1d10d749-4b6a-4ab3-bcd4-f80fb1922267"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5888,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, G1T38 and Xtandi (enzalutamide) worked synergistically to inhibit growth in prostate cancer cell lines harboring AR F877L (also reported as F876L) in culture (AACR, Cancer Res: April 2016; Volume 57, Abstract #2820).",
            "molecularProfile": {
                "id": 26465,
                "profileName": "AR F877L"
            },
            "therapy": {
                "id": 3971,
                "therapyName": "Enzalutamide + G1T38",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5183,
                    "pubMedId": null,
                    "title": "Effects of a CDK 4/6 inhibitor, G1T38, in androgen receptor sensitive and resistant models of castrate resistant prostate cancer",
                    "url": "http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=4017&sKey=12eab58f-9b3f-418d-ad0c-e55a553a95b9&cKey=90cf56d3-fe9d-4b4d-8477-6867a79402af&mKey=1d10d749-4b6a-4ab3-bcd4-f80fb1922267"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5894,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ODM-207 inhibited proliferation of AR-positive prostate cancer cell lines in culture and suppressed tumor growth in patient-derived xenograft models (AACR, Cancer Res: April 2016; Volume 57, Abstract #4649).",
            "molecularProfile": {
                "id": 2795,
                "profileName": "AR positive"
            },
            "therapy": {
                "id": 3974,
                "therapyName": "ODM-207",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5186,
                    "pubMedId": null,
                    "title": "ODM-207, a novel BET-bromodomain inhibitor as a therapeutic approach for the treatment of prostate and breast cancer",
                    "url": "http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=4017&sKey=177af784-a1f1-406c-9aa8-67b47302d29b&cKey=a3591182-1c63-4601-8452-da8fc4cf389d&mKey=1d10d749-4b6a-4ab3-bcd4-f80fb1922267"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5902,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, KX2-391 at tested dose did not demonstrate anti-tumor effects in patients with castration-resistant prostate cancer, resulted in 8% progression free survival (PFS) at 24 weeks and median PFS of 18.6 weeks, but had modest effects on bone turnover markers (PMID: 23314737).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 786,
                "therapyName": "KX2-391",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5192,
                    "pubMedId": 23314737,
                    "title": "A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23314737"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6091,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, the combination of AT-101 and Casodex (bicalutamide) resulted in an undetectable PSA in 31% (17/55) of patients with castration resistant prostate cancer, however, the percentage did not reach the prespecified level and thus, the theraputic combination will not be pursued further (PMID: 26476589).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4039,
                "therapyName": "AT-101 + Bicalutamide",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 5298,
                    "pubMedId": 26476589,
                    "title": "A Phase II Study of AT-101 to Overcome Bcl-2--Mediated Resistance to Androgen Deprivation Therapy in Patients With Newly Diagnosed Castration-Sensitive Metastatic Prostate Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26476589"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6194,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, NSC156529 inhibited growth of human prostate cancer cell lines in culture, induced expression of differentiation markers and inhibited tumor growth in cell line xenograft models (PMID: 26294745).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4085,
                "therapyName": "NSC156529",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5386,
                    "pubMedId": 26294745,
                    "title": "A Novel Inhibitor of AKT1-PDPK1 Interaction Efficiently Suppresses the Activity of AKT Pathway and Restricts Tumor Growth In Vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26294745"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6197,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, EC-70124 inhibited proliferation, colony formation, Stat3 activity, and NFkappaB activity in prostate cancer cells and prostate cancer stem cells in culture and inhibited tumor growth in cell line xenografts (PMID: 26826115).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4090,
                "therapyName": "EC-70124",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5423,
                    "pubMedId": 26826115,
                    "title": "EC-70124, a Novel Glycosylated Indolocarbazole Multikinase Inhibitor, Reverts Tumorigenic and Stem Cell Properties in Prostate Cancer by Inhibiting STAT3 and NF-\u03baB.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26826115"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6198,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, EC-70124 inhibited tumor growth in cell line xenograft models of prostate cancer with ELF3 over expression (PMID: 26826115).",
            "molecularProfile": {
                "id": 22797,
                "profileName": "ELF3 over exp"
            },
            "therapy": {
                "id": 4090,
                "therapyName": "EC-70124",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5423,
                    "pubMedId": 26826115,
                    "title": "EC-70124, a Novel Glycosylated Indolocarbazole Multikinase Inhibitor, Reverts Tumorigenic and Stem Cell Properties in Prostate Cancer by Inhibiting STAT3 and NF-\u03baB.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26826115"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6417,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, prostate cancer cells expressing Pvrl4 (Nectin-4) demonstrated sensitivity to Padcev (enfortumab vedotin-ejfv) in culture, resulting in decreased cell survival (PMID: 27013195).",
            "molecularProfile": {
                "id": 23363,
                "profileName": "NECTIN4 positive"
            },
            "therapy": {
                "id": 4125,
                "therapyName": "Enfortumab vedotin-ejfv",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5571,
                    "pubMedId": 27013195,
                    "title": "Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27013195"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6706,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Galeterone treatment resulted in more than 50% decrease of PSA in 86% (6/7) of castration-resistant prostate cancer patients harboring AR C-terminal truncation mutations, compared to 57% (31/54) in patients without the mutation (J Clin Oncol 34, 2016 (suppl; abstr 5064)).",
            "molecularProfile": {
                "id": 1778,
                "profileName": "AR act mut"
            },
            "therapy": {
                "id": 1508,
                "therapyName": "galeterone",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5755,
                    "pubMedId": null,
                    "title": "Galeterone in treatment-na\u00efve patients with castration-resistant prostate cancer with C-terminal androgen receptor loss: Results from ARMOR2.",
                    "url": "http://abstracts.asco.org/176/AbstView_176_170683.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 6821,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, treatment with Avastin (bevacizumab) combined with Taxotere (docetaxel) in mCRPC patients did not result in an improved OS (22.6 mo vs 21.5 mo) and demonstrated increased toxicities when compared to Taxotere (docetaxel) plus placebo (PMID: 22454414).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4264,
                "therapyName": "Bevacizumab + Docetaxel",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 5836,
                    "pubMedId": 22454414,
                    "title": "Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22454414"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 6855,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial, Veliparib (ABT-888) demonstrated preliminary clinical activity in patients with BRCA2-mutant metastatic castration resistant prostate cancer, with an overall response rate of 66% (2/3) and clinical benefit rate of 100% (3/3) (J Clin Oncol 33, 2015 (suppl 7; abstr 170)).",
            "molecularProfile": {
                "id": 1206,
                "profileName": "BRCA2 mutant"
            },
            "therapy": {
                "id": 954,
                "therapyName": "Veliparib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5880,
                    "pubMedId": null,
                    "title": "Preliminary activity of veliparib (V) in BRCA2-mutated metastatic castration-resistant prostate cancer (mCRPC).",
                    "url": "http://meetinglibrary.asco.org/content/141499-159"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 6860,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Talazoparib (BMN-673) treatment demonstrated safety and preliminary efficacy in patients with advanced solid tumors harboring deleterious BRCA1/2 mutations, including one patient with prostate cancer (J Clin Oncol 31, 2013 (suppl; abstr 2580)).",
            "molecularProfile": {
                "id": 1283,
                "profileName": "BRCA2 inact mut"
            },
            "therapy": {
                "id": 682,
                "therapyName": "Talazoparib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5875,
                    "pubMedId": null,
                    "title": "First-in-human trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors",
                    "url": "http://meetinglibrary.asco.org/content/111725-132"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6940,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, prostate cancer patients harboring either AR amplification or AR T878A or AR L702H prior to Zytiga (abiraterone) treatment demonstrated they were less likely to experience a greater than or equal to 50% to 90% PSA decline and showed a worse overall survial (HR=7.33) and progression-free survival (HR=3.73) (PMID: 26537258).",
            "molecularProfile": {
                "id": 23387,
                "profileName": "AR L702H"
            },
            "therapy": {
                "id": 1805,
                "therapyName": "Abiraterone",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 5973,
                    "pubMedId": 26537258,
                    "title": "Plasma AR and abiraterone-resistant prostate cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26537258"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 13820,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, seven metastatic castration-resistant prostate cancer patients with AR H875Y (reported as H874Y) or T878A (reported as T877A) detected in cell-free DNA had progressed on or had received prior treatment with Zytiga (abiraterone) (PMID: 25712683).",
            "molecularProfile": {
                "id": 729,
                "profileName": "AR T878A"
            },
            "therapy": {
                "id": 1805,
                "therapyName": "Abiraterone",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 4735,
                    "pubMedId": 25712683,
                    "title": "Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25712683"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6942,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, prostate cancer patients harboring either AR amplification or AR T878A or AR L702H prior to Zytiga (abiraterone) treatment demonstrated they were less likely to experience a greater than or equal to 50% to 90% PSA decline and showed a worse overall survial (HR=7.33) and progression-free survival (HR=3.73) (PMID: 26537258).",
            "molecularProfile": {
                "id": 729,
                "profileName": "AR T878A"
            },
            "therapy": {
                "id": 1805,
                "therapyName": "Abiraterone",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 5973,
                    "pubMedId": 26537258,
                    "title": "Plasma AR and abiraterone-resistant prostate cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26537258"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7195,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, U0126 inhibited phosphorylation of MEK and ERK and reduced growth and invasion of prostate epithelial cells expressing ESRP1-RAF1 in culture (PMID: 20526349).",
            "molecularProfile": {
                "id": 15465,
                "profileName": "ESRP1 - RAF1"
            },
            "therapy": {
                "id": 2427,
                "therapyName": "U0126",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3753,
                    "pubMedId": 20526349,
                    "title": "Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20526349"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7196,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Nexavar (sorafenib) inhibited growth and invasion of prostate epithelial cells expressing ESRP1-RAF1 in culture (PMID: 20526349).",
            "molecularProfile": {
                "id": 15465,
                "profileName": "ESRP1 - RAF1"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3753,
                    "pubMedId": 20526349,
                    "title": "Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20526349"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7245,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a prostate cancer cell line with hypoxia-induced increased expression of Pim1 and Pim2 demonstrated sensitivity to AZD1208 in culture and in xenograft models (PMID: 27196781).",
            "molecularProfile": {
                "id": 24804,
                "profileName": "PIM1 over exp PIM2 over exp"
            },
            "therapy": {
                "id": 3224,
                "therapyName": "AZD1208",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6257,
                    "pubMedId": 27196781,
                    "title": "PIM Kinase Inhibitors Kill Hypoxic Tumor Cells by Reducing Nrf2 Signaling and Increasing Reactive Oxygen Species.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27196781"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7278,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, prostate cancer cell lines expressing SPOP F133V had increased sensitivity to Lynparza (olaparib) (PMID: 26374986).",
            "molecularProfile": {
                "id": 24948,
                "profileName": "SPOP F133V"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6290,
                    "pubMedId": 26374986,
                    "title": "SPOP mutation leads to genomic instability in prostate cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26374986"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7508,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with CmpdA in prostate cancer xenograft models resulted in inhibition of Ikbkb phosphorylation, apoptotic induction, and repression of tumor growth (PMID: 27196761).",
            "molecularProfile": {
                "id": 25652,
                "profileName": "IKBKB wild-type"
            },
            "therapy": {
                "id": 4503,
                "therapyName": "CmpdA",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6383,
                    "pubMedId": 27196761,
                    "title": "Targeting I\u03baB Kinase \u03b2/NF-\u03baB Signaling in Human Prostate Cancer by a Novel I\u03baB Kinase \u03b2 Inhibitor CmpdA.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27196761"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7846,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, prostate cancer cell lines over expressing SKP2 W97A demonstrated reduced sensitivity to SZL-P1-41 in culture (PMID: 23911321).",
            "molecularProfile": {
                "id": 26071,
                "profileName": "SKP2 W97A"
            },
            "therapy": {
                "id": 1932,
                "therapyName": "SZL-P1-41",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 1605,
                    "pubMedId": 23911321,
                    "title": "Pharmacological inactivation of Skp2 SCF ubiquitin ligase restricts cancer stem cell traits and cancer progression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23911321"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7847,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, prostate cancer cell lines over expressing SKP2 D98A demonstrated reduced sensitivity to SZL-P1-41 in culture (PMID: 23911321).",
            "molecularProfile": {
                "id": 26072,
                "profileName": "SKP2 D98A"
            },
            "therapy": {
                "id": 1932,
                "therapyName": "SZL-P1-41",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 1605,
                    "pubMedId": 23911321,
                    "title": "Pharmacological inactivation of Skp2 SCF ubiquitin ligase restricts cancer stem cell traits and cancer progression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23911321"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8142,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, WANT3 treatment resulted in suppression of cell invasion of prostate cancer cells in culture (PMID: 27432794).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4640,
                "therapyName": "WANT3",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6553,
                    "pubMedId": 27432794,
                    "title": "The WASF3-NCKAP1-CYFIP1 Complex Is Essential for Breast Cancer Metastasis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27432794"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8146,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PKI-179 inhibited growth of prostate cancer cells harboring PIK3CA mutations and PTEN loss in culture (PMID: 20797855).",
            "molecularProfile": {
                "id": 19846,
                "profileName": "PIK3CA mut PTEN loss"
            },
            "therapy": {
                "id": 872,
                "therapyName": "PKI-179",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1040,
                    "pubMedId": 20797855,
                    "title": "PKI-179: an orally efficacious dual phosphatidylinositol-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20797855"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8162,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MOR209/ES414 induced T-cell-mediated cytotoxicity towards FOLH1 (PSMA)-positive prostate cancer cell lines in culture, and inhibited tumor growth, prolonged survival in cell line xenograft models (PMID: 27406985).",
            "molecularProfile": {
                "id": 26143,
                "profileName": "FOLH1 positive"
            },
            "therapy": {
                "id": 4651,
                "therapyName": "MOR209/ES414",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6564,
                    "pubMedId": 27406985,
                    "title": "MOR209/ES414, a Novel Bispecific Antibody Targeting PSMA for the Treatment of Metastatic Castration-Resistant Prostate Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27406985"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8271,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PF-562271 inhibited PTK2 signaling, resulted in apoptosis and tumor regression in prostate cancer cell line xenograft models (PMID: 18339875).",
            "molecularProfile": {
                "id": 18706,
                "profileName": "PTK2 positive"
            },
            "therapy": {
                "id": 2087,
                "therapyName": "PF-562271",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1919,
                    "pubMedId": 18339875,
                    "title": "Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18339875"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8288,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Acalisib (GS-9820) resulted in tumor growth inhibition in xenograft models of prostate cancer with PTEN deficiency (Mol Cancer Ther 2009;8(12 Suppl):B136).",
            "molecularProfile": {
                "id": 479,
                "profileName": "PTEN loss"
            },
            "therapy": {
                "id": 1021,
                "therapyName": "GS-9820",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1019,
                    "pubMedId": null,
                    "title": "Abstract B136: CAL?120, a novel dual p110beta/p110delta phosphatidylinositol?3?kinase (PI3K) inhibitor, attenuates PI3K signaling and demonstrates potent in vivo antitumor activity against solid tumors",
                    "url": "http://mct.aacrjournals.org/content/8/12_Supplement/B136.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8316,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, AGS-1C4D4 treatment in castration resistant prostate cancer patients was well-tolerated and resulted in stable disease at 24 weeks in 46% (6/13) of patients, but did not reduce PSA (PMID: 22020316).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4697,
                "therapyName": "AGS-1C4D4",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6603,
                    "pubMedId": 22020316,
                    "title": "Phase I rapid dose-escalation study of AGS-1C4D4, a human anti-PSCA (prostate stem cell antigen) monoclonal antibody, in patients with castration-resistant prostate cancer: a PCCTC trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22020316"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8319,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib/II trial, AGS-PSCA treatment was deemed safe, but only resulted in limited antitumor activity in patients with castration resistant prostate cancer (PMID: 22553195).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4699,
                "therapyName": "AGS-PSCA",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6604,
                    "pubMedId": 22553195,
                    "title": "A phase I/IIA study of AGS-PSCA for castration-resistant prostate cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22553195"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8333,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, Zibotentan (ZD4054) did not demonstrate a survival benefit compared to placebo in patients with prostate cancer, and the trial was discontinued at the interim analysis (PMID: 23381694).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4706,
                "therapyName": "Zibotentan",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6620,
                    "pubMedId": 23381694,
                    "title": "Phase III, randomized, placebo-controlled study of once-daily oral zibotentan (ZD4054) in patients with non-metastatic castration-resistant prostate cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23381694"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 8550,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Cometriq (cabozantinib) inhibited Abiraterone-induced Igf1r activation, resulted in enhanced growth inhibition in prostate cancer cell lines in culture and in cell line xenograft models (PMID: 26289068).",
            "molecularProfile": {
                "id": 16581,
                "profileName": "IGF1R positive"
            },
            "therapy": {
                "id": 4770,
                "therapyName": "Abiraterone + Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6685,
                    "pubMedId": 26289068,
                    "title": "Cabozantinib Inhibits Abiraterone's Upregulation of IGFIR Phosphorylation and Enhances Its Anti-Prostate Cancer Activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26289068"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8785,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ML364 induced Ccnd1 degradation and inhibited survival of prostate cancer cells in a dose-dependent manner in culture (PMID: 27681596).",
            "molecularProfile": {
                "id": 2445,
                "profileName": "CCND1 positive"
            },
            "therapy": {
                "id": 4811,
                "therapyName": "ML364",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6749,
                    "pubMedId": 27681596,
                    "title": "Small Molecule Inhibition of the Ubiquitin-specific Protease USP2 Accelerates cyclin D1 Degradation and Leads to Cell Cycle Arrest in Colorectal Cancer and Mantle Cell Lymphoma Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27681596"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8810,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BAY1125976 inhibited proliferation of a prostate cancer cell line harboring AKT E17K and NRAS G12D in culture, and demonstrated antitumor activity in xenograft models (PMID: 27699769).",
            "molecularProfile": {
                "id": 26446,
                "profileName": "AKT1 E17K NRAS G12D"
            },
            "therapy": {
                "id": 994,
                "therapyName": "BAY1125976",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6757,
                    "pubMedId": 27699769,
                    "title": "BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27699769"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8821,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BAY1125976 inhibited proliferation of a prostate cancer cell line harboring KRAS G12V and PTEN K6fs*4 in culture (PMID: 27699769).",
            "molecularProfile": {
                "id": 26456,
                "profileName": "KRAS G12V PTEN K6fs"
            },
            "therapy": {
                "id": 994,
                "therapyName": "BAY1125976",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6757,
                    "pubMedId": 27699769,
                    "title": "BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27699769"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8844,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Xtandi (enzalutamide) demonstrated increased binding affinity for the AR T878A/F877L double mutant, acted as a full agonist for androgen-receptor signaling, and did not inhibit proliferation of prostate cancer cells expressing the AR T878A/F877L double mutant in culture (PMID: 27196756).",
            "molecularProfile": {
                "id": 26464,
                "profileName": "AR F877L AR T878A"
            },
            "therapy": {
                "id": 1262,
                "therapyName": "Enzalutamide",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6007,
                    "pubMedId": 27196756,
                    "title": "The Effect of F877L and T878A Mutations on Androgen Receptor Response to Enzalutamide.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27196756"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8845,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Zytiga (abiratirone) inhibited proliferation of prostate cancer cells expressing the AR T878A/L877L double mutant in culture (PMID: 27196756).",
            "molecularProfile": {
                "id": 26464,
                "profileName": "AR F877L AR T878A"
            },
            "therapy": {
                "id": 1805,
                "therapyName": "Abiraterone",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6007,
                    "pubMedId": 27196756,
                    "title": "The Effect of F877L and T878A Mutations on Androgen Receptor Response to Enzalutamide.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27196756"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8846,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, prostate cancer cells expressing the AR F877L/T878A double mutant were resistant to growth inhibition by hydroxyflutamide in culture (PMID: 27196756).",
            "molecularProfile": {
                "id": 26464,
                "profileName": "AR F877L AR T878A"
            },
            "therapy": {
                "id": 742,
                "therapyName": "Flutamide",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6007,
                    "pubMedId": 27196756,
                    "title": "The Effect of F877L and T878A Mutations on Androgen Receptor Response to Enzalutamide.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27196756"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8965,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, prostate cancer cell line xenograft models with PTEN deletion demonstrated sensitivity to treatment with Ipatasertib (GDC-0068), resulting in inhibition of tumor growth (PMID: 24141624).",
            "molecularProfile": {
                "id": 2408,
                "profileName": "PTEN del"
            },
            "therapy": {
                "id": 747,
                "therapyName": "Ipatasertib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 191,
                    "pubMedId": 24141624,
                    "title": "Evaluation and clinical analyses of downstream targets of the Akt inhibitor GDC-0068.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24141624"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9081,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PF-03084014 and Taxotere (docetaxel) in combination inhibited growth of Notch1-expressing Taxotere (docetaxel)-resistant prostate cancer cell lines in culture, and inhibited both soft tissue and bony tumor growth in Taxotere (docetaxel)-resistant prostate cancer cell line xenograft models, with increased efficacy over either agent alone (PMID: 26202948).",
            "molecularProfile": {
                "id": 5943,
                "profileName": "NOTCH1 positive"
            },
            "therapy": {
                "id": 1115,
                "therapyName": "Docetaxel + PF-03084014",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6897,
                    "pubMedId": 26202948,
                    "title": "Notch Pathway Inhibition Using PF-03084014, a \u03b3-Secretase Inhibitor (GSI), Enhances the Antitumor Effect of Docetaxel in Prostate Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26202948"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9101,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with RK-33 decreased viability and induced cell-cycle arrest in prostate cancer cell lines expressing high levels of DDX3X in culture (PMID: 27634756).",
            "molecularProfile": {
                "id": 26735,
                "profileName": "DDX3X over exp"
            },
            "therapy": {
                "id": 4898,
                "therapyName": "RK-33",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6908,
                    "pubMedId": 27634756,
                    "title": "RK-33 Radiosensitizes Prostate Cancer Cells by Blocking the RNA Helicase DDX3.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27634756"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9102,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RK-33 in combination with radiotherapy worked synergistically to inhibit proliferation and reduce DNA damage response in DDX3X-over expressing prostate cancer cell lines, and to inhibited tumor growth in DDX3X-over expressing prostate cancer cell lines (PMID: 27634756).",
            "molecularProfile": {
                "id": 26735,
                "profileName": "DDX3X over exp"
            },
            "therapy": {
                "id": 4899,
                "therapyName": "Radiotherapy + RK-33",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6908,
                    "pubMedId": 27634756,
                    "title": "RK-33 Radiosensitizes Prostate Cancer Cells by Blocking the RNA Helicase DDX3.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27634756"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9155,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ASG-5ME inhibited tumor growth in prostate cancer cell line xenograft models and patient-derived xenograft (PDX) models expressing SLC44A4 (PMID: 27550944).",
            "molecularProfile": {
                "id": 26752,
                "profileName": "SLC44A4 positive"
            },
            "therapy": {
                "id": 4914,
                "therapyName": "ASG-5ME",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6935,
                    "pubMedId": 27550944,
                    "title": "The Discovery and Preclinical Development of ASG-5ME, an Antibody-Drug Conjugate Targeting SLC44A4-Positive Epithelial Tumors Including Pancreatic and Prostate Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27550944"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9157,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of ASG-5ME and Abraxane (nab-paclitaxel) inhibited tumor growth in a SLC44A4-expressing patient-derived xenograft (PDX) model of prostate cancer, with increased efficacy compared to either agent alone (PMID: 27550944).",
            "molecularProfile": {
                "id": 26752,
                "profileName": "SLC44A4 positive"
            },
            "therapy": {
                "id": 4915,
                "therapyName": "ASG-5ME + Nab-paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6935,
                    "pubMedId": 27550944,
                    "title": "The Discovery and Preclinical Development of ASG-5ME, an Antibody-Drug Conjugate Targeting SLC44A4-Positive Epithelial Tumors Including Pancreatic and Prostate Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27550944"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9304,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CX-5461 inhibited anchorage-independent growth, but did not induce cell death in prostate cancer cells with high Myc expression and no TP53 expression in culture (PMID: 27486174).",
            "molecularProfile": {
                "id": 26815,
                "profileName": "MYC over exp TP53 neg"
            },
            "therapy": {
                "id": 4963,
                "therapyName": "CX-5461",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 7070,
                    "pubMedId": 27486174,
                    "title": "The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27486174"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9305,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CX-5461 inhibited anchorage-independent growth, but did not induce cell death in prostate cancer cells with high Myc expression and inactivating TP53 mutations in culture (PMID: 27486174).",
            "molecularProfile": {
                "id": 26816,
                "profileName": "MYC over exp TP53 inact mut"
            },
            "therapy": {
                "id": 4963,
                "therapyName": "CX-5461",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 7070,
                    "pubMedId": 27486174,
                    "title": "The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27486174"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9306,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CX-5461 inhibited anchorage-independent growth and induced cell death in prostate cancer cells with high Myc expression and functional TP53 in culture (PMID: 27486174).",
            "molecularProfile": {
                "id": 26817,
                "profileName": "MYC over exp TP53 wild-type"
            },
            "therapy": {
                "id": 4963,
                "therapyName": "CX-5461",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7070,
                    "pubMedId": 27486174,
                    "title": "The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27486174"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9307,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CX-5461 treatment resulted in cell cycle arrest in prostate cancer cells derived from MYC-driven transgenic animal models in culture, inhibited tumor growth, decreased the number of invasive lesions in animal models (PMID: 27486174).",
            "molecularProfile": {
                "id": 4715,
                "profileName": "MYC over exp"
            },
            "therapy": {
                "id": 4963,
                "therapyName": "CX-5461",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 7070,
                    "pubMedId": 27486174,
                    "title": "The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27486174"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9318,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RO6839921 demonstrated anti-tumor activity in prostate cancer cell line xenograft models (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr A156).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2155,
                "therapyName": "RO6839921",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 7077,
                    "pubMedId": null,
                    "title": "Preclinical activity of MDM2 antagonist RO6839921, a pegylated prodrug for intravenous administration",
                    "url": "http://mct.aacrjournals.org/content/14/12_Supplement_2/A156.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9321,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CX-6258 inhibited anchorage-independent growth in prostate cancer cells with high Myc expression and no TP53 expression in culture (PMID: 27486174).",
            "molecularProfile": {
                "id": 26815,
                "profileName": "MYC over exp TP53 neg"
            },
            "therapy": {
                "id": 3675,
                "therapyName": "CX-6258",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7070,
                    "pubMedId": 27486174,
                    "title": "The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27486174"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9322,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CX-6258 inhibited anchorage-independent growth in prostate cancer cells with high Myc expression and inactivating TP53 mutations in culture (PMID: 27486174).",
            "molecularProfile": {
                "id": 26816,
                "profileName": "MYC over exp TP53 inact mut"
            },
            "therapy": {
                "id": 3675,
                "therapyName": "CX-6258",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7070,
                    "pubMedId": 27486174,
                    "title": "The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27486174"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9323,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CX-6258 induced cell cycle arrest in prostate cancer cells with high Myc expression and functional TP53 in culture (PMID: 27486174).",
            "molecularProfile": {
                "id": 26817,
                "profileName": "MYC over exp TP53 wild-type"
            },
            "therapy": {
                "id": 3675,
                "therapyName": "CX-6258",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7070,
                    "pubMedId": 27486174,
                    "title": "The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27486174"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9324,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CX-6258 and CX-5461 combination treatment resulted in enhanced inhibition of anchorage-independent growth compared to single agent in prostate cancer cells with high Myc expression and no TP53 expression in culture (PMID: 27486174).",
            "molecularProfile": {
                "id": 26815,
                "profileName": "MYC over exp TP53 neg"
            },
            "therapy": {
                "id": 4969,
                "therapyName": "CX-5461 + CX-6258",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7070,
                    "pubMedId": 27486174,
                    "title": "The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27486174"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9325,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CX-6258 and CX-5461 combination treatment resulted in enhanced inhibition of anchorage-independent growth compared to single agent in prostate cancer cells with high Myc expression and inactivating TP53 mutations in culture (PMID: 27486174).",
            "molecularProfile": {
                "id": 26816,
                "profileName": "MYC over exp TP53 inact mut"
            },
            "therapy": {
                "id": 4969,
                "therapyName": "CX-5461 + CX-6258",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7070,
                    "pubMedId": 27486174,
                    "title": "The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27486174"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9326,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CX-6258 and CX-5461 combination treatment resulted in enhanced cell cycle arrest compared to single agent in prostate cancer cells with high Myc expression and functional TP53 in culture (PMID: 27486174).",
            "molecularProfile": {
                "id": 26817,
                "profileName": "MYC over exp TP53 wild-type"
            },
            "therapy": {
                "id": 4969,
                "therapyName": "CX-5461 + CX-6258",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7070,
                    "pubMedId": 27486174,
                    "title": "The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27486174"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9327,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CX-6258 and CX-5461 combination treatment resulted in enhanced cell death in prostate cancer cells derived from MYC-driven transgenic animal models in culture, and inhibited tumor growth in both transgenic and patient-derived xenograft animal models (PMID: 27486174).",
            "molecularProfile": {
                "id": 4715,
                "profileName": "MYC over exp"
            },
            "therapy": {
                "id": 4969,
                "therapyName": "CX-5461 + CX-6258",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7070,
                    "pubMedId": 27486174,
                    "title": "The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27486174"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9328,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CX-6258 treatment resulted in cell cycle arrest in prostate cancer cells derived from MYC-driven transgenic animal model in culture, but did not affect the number of invasive lesions in animal models (PMID: 27486174).",
            "molecularProfile": {
                "id": 4715,
                "profileName": "MYC over exp"
            },
            "therapy": {
                "id": 3675,
                "therapyName": "CX-6258",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 7070,
                    "pubMedId": 27486174,
                    "title": "The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27486174"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9330,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CX-6258 treatment resulted in decreased carcinoma in situ in PTEN deficient transgenic animal model of prostate cancer (PMID: 27486174).",
            "molecularProfile": {
                "id": 479,
                "profileName": "PTEN loss"
            },
            "therapy": {
                "id": 3675,
                "therapyName": "CX-6258",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 7070,
                    "pubMedId": 27486174,
                    "title": "The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27486174"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9331,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CX-6258 and CX-5461 combination treatment resulted in decreased tumor burden in PTEN deficient transgenic animal model of prostate cancer (PMID: 27486174).",
            "molecularProfile": {
                "id": 479,
                "profileName": "PTEN loss"
            },
            "therapy": {
                "id": 4969,
                "therapyName": "CX-5461 + CX-6258",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 7070,
                    "pubMedId": 27486174,
                    "title": "The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27486174"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9332,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CX-5461 treatment did not result in histological change in PTEN deficient transgenic animal model of prostate cancer (PMID: 27486174).",
            "molecularProfile": {
                "id": 479,
                "profileName": "PTEN loss"
            },
            "therapy": {
                "id": 4963,
                "therapyName": "CX-5461",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 7070,
                    "pubMedId": 27486174,
                    "title": "The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27486174"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9338,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, J591 resulted in antitumor activity in 57% (20/35) of prostate cancer patients, with four patients demonstrating a decrease in PSA levels and sixteen patients experiencing PSA stabilization (PMID: 15837970).",
            "molecularProfile": {
                "id": 26143,
                "profileName": "FOLH1 positive"
            },
            "therapy": {
                "id": 4981,
                "therapyName": "J591",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7104,
                    "pubMedId": 15837970,
                    "title": "Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15837970"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9362,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Emerging",
            "efficacyEvidence": "In a preclinical study, siRNA knockdown of NSD2 combined with Glucophage (metformin) treatment in prostate cancer cells resulted in decreased cell migration and invasion in culture, suggesting that NSD2 may be a promising therapeutic target for prostate cancer (PMID: 27404348).",
            "molecularProfile": {
                "id": 26831,
                "profileName": "NSD2 positive"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 7127,
                    "pubMedId": 27404348,
                    "title": "Metformin Elicits Antitumor Effects and Downregulates the Histone Methyltransferase Multiple Myeloma SET Domain (MMSET) in Prostate Cancer Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27404348"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9509,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mivebresib (ABBV-075) inhibited proliferation of prostate cancer cells expressing AR F876L (AACR 107th Annual Meeting; April 16-20, 2016, Abstract 4694).",
            "molecularProfile": {
                "id": 26465,
                "profileName": "AR F877L"
            },
            "therapy": {
                "id": 4028,
                "therapyName": "Mivebresib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7243,
                    "pubMedId": null,
                    "title": "ABBV-075, a novel BET family inhibitor, disrupts critical transcription programs that drive prostate cancer growth to induce potent anti-tumor activity in vitro and in vivo",
                    "url": "http://cancerres.aacrjournals.org/content/76/14_Supplement/4694"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9510,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ABBV-075 (Mivebresib) inhibited proliferation of prostate cancer cells with Ar L702H in multiple models (AACR 107th Annual Meeting; April 16-20, 2016, Abstract 4694).",
            "molecularProfile": {
                "id": 23387,
                "profileName": "AR L702H"
            },
            "therapy": {
                "id": 4028,
                "therapyName": "Mivebresib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7243,
                    "pubMedId": null,
                    "title": "ABBV-075, a novel BET family inhibitor, disrupts critical transcription programs that drive prostate cancer growth to induce potent anti-tumor activity in vitro and in vivo",
                    "url": "http://cancerres.aacrjournals.org/content/76/14_Supplement/4694"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9537,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, AZD8186 demonstrated preliminary activity in patients with select solid tumors, including castration-resistant prostate cancer (CRPC), with one CRPC patient achieving stable disease and symptomatic improvement (Cancer Res August 1 2015 (75) (15 Supplement) CT329).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 992,
                "therapyName": "AZD8186",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4118,
                    "pubMedId": null,
                    "title": "Phase I study of the PI3K?/? inhibitor AZD8186 in patients with advanced castration resistant prostate cancer, triple negative breast cancer, squamous non-small cell lung cancer or PTEN deficient solid tumors: update from dose-finding",
                    "url": "http://cancerres.aacrjournals.org/content/75/15_Supplement/CT329.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9558,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Zejula (niraparib) treatment resulted in stable diseases with a median duration of 254 days in 43% (9/21) of patients with castration-resistant prostate cancer (PMID: 23810788; NCT00749502).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 832,
                "therapyName": "Niraparib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 1986,
                    "pubMedId": 23810788,
                    "title": "The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23810788"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9617,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Navitoclax (ABT-263) combined with Buparlisib (BKM120) resulted in a synergistic effect, demonstrating increased apoptotic activity in PTEN deficient prostate cancer cells expressing ITGA5 in culture (PMID: 27590631).",
            "molecularProfile": {
                "id": 26937,
                "profileName": "ITGA5 pos PTEN loss"
            },
            "therapy": {
                "id": 5105,
                "therapyName": "Buparlisib + Navitoclax",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7353,
                    "pubMedId": 27590631,
                    "title": "Synthetic Lethality in PTEN-Mutant Prostate Cancer Is Induced by Combinatorial PI3K/Akt and BCL-XL Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27590631"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9618,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Navitoclax (ABT-263) resulted in some apoptotic activity, but only at high doses in PTEN deficient prostate cancer cells expressing ITGA5 in culture (PMID: 27590631).",
            "molecularProfile": {
                "id": 26937,
                "profileName": "ITGA5 pos PTEN loss"
            },
            "therapy": {
                "id": 825,
                "therapyName": "Navitoclax",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 7353,
                    "pubMedId": 27590631,
                    "title": "Synthetic Lethality in PTEN-Mutant Prostate Cancer Is Induced by Combinatorial PI3K/Akt and BCL-XL Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27590631"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9619,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PTEN deficient prostate cancer cells expressing ITGA5 did not benefit from Buparlisib (BKM120) treatment in culture, demonstrating little to no apoptotic activity (PMID: 27590631).",
            "molecularProfile": {
                "id": 26937,
                "profileName": "ITGA5 pos PTEN loss"
            },
            "therapy": {
                "id": 680,
                "therapyName": "Buparlisib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 7353,
                    "pubMedId": 27590631,
                    "title": "Synthetic Lethality in PTEN-Mutant Prostate Cancer Is Induced by Combinatorial PI3K/Akt and BCL-XL Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27590631"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9620,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Navitoclax (ABT-263) combined with Ipatasertib (GDC-0068) resulted in a synergistic effect, demonstrating increased apoptotic activity in PTEN deficient prostate cancer cells expressing ITGA5 in culture (PMID: 27590631).",
            "molecularProfile": {
                "id": 26937,
                "profileName": "ITGA5 pos PTEN loss"
            },
            "therapy": {
                "id": 5106,
                "therapyName": "Ipatasertib + Navitoclax",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7353,
                    "pubMedId": 27590631,
                    "title": "Synthetic Lethality in PTEN-Mutant Prostate Cancer Is Induced by Combinatorial PI3K/Akt and BCL-XL Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27590631"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9621,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PTEN deficient prostate cancer cells expressing ITGA5 did not benefit from Ipatasertib (GDC-0068) treatment in culture, demonstrating no apoptotic activity (PMID: 27590631).",
            "molecularProfile": {
                "id": 26937,
                "profileName": "ITGA5 pos PTEN loss"
            },
            "therapy": {
                "id": 747,
                "therapyName": "Ipatasertib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 7353,
                    "pubMedId": 27590631,
                    "title": "Synthetic Lethality in PTEN-Mutant Prostate Cancer Is Induced by Combinatorial PI3K/Akt and BCL-XL Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27590631"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9622,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Navitoclax (ABT-263) and Buparlisib (BKM120) did not result in efficacy in PTEN wild-type prostate cancer cells expressing ITGA5 (PMID: 27590631).",
            "molecularProfile": {
                "id": 26938,
                "profileName": "ITGA5 pos PTEN wild-type"
            },
            "therapy": {
                "id": 5105,
                "therapyName": "Buparlisib + Navitoclax",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 7353,
                    "pubMedId": 27590631,
                    "title": "Synthetic Lethality in PTEN-Mutant Prostate Cancer Is Induced by Combinatorial PI3K/Akt and BCL-XL Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27590631"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9623,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Venclexta (venetoclax) and Buparlisib (BKM120) did not result in efficacy in PTEN wild-type prostate cancer cells expressing ITGA5 in culture (PMID: 27590631).",
            "molecularProfile": {
                "id": 26938,
                "profileName": "ITGA5 pos PTEN wild-type"
            },
            "therapy": {
                "id": 5107,
                "therapyName": "Buparlisib + Venetoclax",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 7353,
                    "pubMedId": 27590631,
                    "title": "Synthetic Lethality in PTEN-Mutant Prostate Cancer Is Induced by Combinatorial PI3K/Akt and BCL-XL Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27590631"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9624,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Venclexta (venetoclax) and Pictilisib (GDC-0941) did not result in efficacy in PTEN wild-type prostate cancer cells expressing ITGA5 in culture (PMID: 27590631).",
            "molecularProfile": {
                "id": 26938,
                "profileName": "ITGA5 pos PTEN wild-type"
            },
            "therapy": {
                "id": 5108,
                "therapyName": "Pictilisib + Venetoclax",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 7353,
                    "pubMedId": 27590631,
                    "title": "Synthetic Lethality in PTEN-Mutant Prostate Cancer Is Induced by Combinatorial PI3K/Akt and BCL-XL Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27590631"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9625,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Buparlisib (BKM120) did not result in efficacy in PTEN wild-type prostate cancer cells expressing ITGA5 in culture (PMID: 27590631).",
            "molecularProfile": {
                "id": 26938,
                "profileName": "ITGA5 pos PTEN wild-type"
            },
            "therapy": {
                "id": 680,
                "therapyName": "Buparlisib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 7353,
                    "pubMedId": 27590631,
                    "title": "Synthetic Lethality in PTEN-Mutant Prostate Cancer Is Induced by Combinatorial PI3K/Akt and BCL-XL Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27590631"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9626,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pictilisib (GDC-0941) did not result in efficacy in PTEN wild-type prostate cancer cells expressing ITGA5 in culture (PMID: 27590631).",
            "molecularProfile": {
                "id": 26938,
                "profileName": "ITGA5 pos PTEN wild-type"
            },
            "therapy": {
                "id": 749,
                "therapyName": "Pictilisib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 7353,
                    "pubMedId": 27590631,
                    "title": "Synthetic Lethality in PTEN-Mutant Prostate Cancer Is Induced by Combinatorial PI3K/Akt and BCL-XL Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27590631"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9627,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of A-1331852 and Buparlisib (BKM120) resulted in a synergistic effect, demonstrating increased apoptotic activity in PTEN deficient prostate cancer cells expressing ITGA5 in culture (PMID: 27590631).",
            "molecularProfile": {
                "id": 26937,
                "profileName": "ITGA5 pos PTEN loss"
            },
            "therapy": {
                "id": 5111,
                "therapyName": "A-1331852 + Buparlisib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7353,
                    "pubMedId": 27590631,
                    "title": "Synthetic Lethality in PTEN-Mutant Prostate Cancer Is Induced by Combinatorial PI3K/Akt and BCL-XL Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27590631"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9628,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of A-1331852 and Ipatasertib (GDC-0068) resulted in a synergistic effect, demonstrating increased apoptotic activity in PTEN deficient prostate cancer cells expressing ITGA5 in culture (PMID: 27590631).",
            "molecularProfile": {
                "id": 26937,
                "profileName": "ITGA5 pos PTEN loss"
            },
            "therapy": {
                "id": 5109,
                "therapyName": "A-1331852 + Ipatasertib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7353,
                    "pubMedId": 27590631,
                    "title": "Synthetic Lethality in PTEN-Mutant Prostate Cancer Is Induced by Combinatorial PI3K/Akt and BCL-XL Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27590631"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9629,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, A-1331852 resulted in minimal apoptotic activity in PTEN deficient prostate cancer cells expressing ITGA5 in culture (PMID: 27590631).",
            "molecularProfile": {
                "id": 26937,
                "profileName": "ITGA5 pos PTEN loss"
            },
            "therapy": {
                "id": 2578,
                "therapyName": "A-1331852",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 7353,
                    "pubMedId": 27590631,
                    "title": "Synthetic Lethality in PTEN-Mutant Prostate Cancer Is Induced by Combinatorial PI3K/Akt and BCL-XL Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27590631"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9630,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of A-1210477 and A-1331852 did not result in efficacy in PTEN deficient prostate cancer cells expressing ITGA5 in culture (PMID: 27590631).",
            "molecularProfile": {
                "id": 26937,
                "profileName": "ITGA5 pos PTEN loss"
            },
            "therapy": {
                "id": 5110,
                "therapyName": "A-1210477 + A-1331852",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 7353,
                    "pubMedId": 27590631,
                    "title": "Synthetic Lethality in PTEN-Mutant Prostate Cancer Is Induced by Combinatorial PI3K/Akt and BCL-XL Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27590631"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9696,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mivebresib (ABBV-075) inhibited AR and ETS-family target gene expression in a hormone-dependent prostate cancer cell line harboring AR T878A and an ETV1 fusion in culture, and inhibited tumor growth in xenograft models (PMID: 27707886).",
            "molecularProfile": {
                "id": 26984,
                "profileName": "ETV1 fusion AR T878A"
            },
            "therapy": {
                "id": 4028,
                "therapyName": "Mivebresib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7485,
                    "pubMedId": 27707886,
                    "title": "Exploitation of Castration-Resistant Prostate Cancer Transcription Factor Dependencies by the Novel BET Inhibitor ABBV-075.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27707886"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9698,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mivebresib (ABBV-075) decreased expression of KLK3 and UBE2C and inhibited proliferation of a prostate cancer cell line with acquired resistance to Xtandi (enzalutamide) harboring both AR T878A and AR F877L, in culture (PMID: 27707886).",
            "molecularProfile": {
                "id": 26464,
                "profileName": "AR F877L AR T878A"
            },
            "therapy": {
                "id": 4028,
                "therapyName": "Mivebresib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7485,
                    "pubMedId": 27707886,
                    "title": "Exploitation of Castration-Resistant Prostate Cancer Transcription Factor Dependencies by the Novel BET Inhibitor ABBV-075.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27707886"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9701,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mivebresib (ABBV-075) inhibited ETS-family target gene expression and proliferation of an Xtandi (enzalutamide)-resistant prostate cancer cell line harboring AR T878A and AR L702H as well as an ETV1 fusion in culture (PMID: 27707886).",
            "molecularProfile": {
                "id": 26987,
                "profileName": "ETV1 fusion AR L702H AR T878A"
            },
            "therapy": {
                "id": 4028,
                "therapyName": "Mivebresib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7485,
                    "pubMedId": 27707886,
                    "title": "Exploitation of Castration-Resistant Prostate Cancer Transcription Factor Dependencies by the Novel BET Inhibitor ABBV-075.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27707886"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9712,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, a patient with castration resistant prostate cancer harboring a loss of PTEN demonstrated an improved prostate specific antigen when treated with Ipatasertib (GDC-0068) (PMID: 27872130).",
            "molecularProfile": {
                "id": 479,
                "profileName": "PTEN loss"
            },
            "therapy": {
                "id": 747,
                "therapyName": "Ipatasertib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7487,
                    "pubMedId": 27872130,
                    "title": "A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27872130"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10002,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, high-dose Dutasteride following Zytiga (abiraterone) treatment resulted in more than 50% reduction of prostate-specific antigen level in 60% (24/40) of patients with metastatic castration-resistant prostate cancer, 94% (29/31) of tested tumor were positive for nuclear Ar (PMID: 27683182).",
            "molecularProfile": {
                "id": 2795,
                "profileName": "AR positive"
            },
            "therapy": {
                "id": 5340,
                "therapyName": "Abiraterone + Dutasteride",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7893,
                    "pubMedId": 27683182,
                    "title": "A Phase II Trial of Abiraterone Combined with Dutasteride for Men with Metastatic Castration-Resistant Prostate Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27683182"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 10246,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, the combination of Ipatasertib (GDC-0068) and Zytiga (abiraterone) resulted in a better progression-free survival in metastatic castration resistant prostate cancer patients with PTEN loss when compared to placebo combined with Zytiga (PMID: 30037818; NCT01485861).",
            "molecularProfile": {
                "id": 479,
                "profileName": "PTEN loss"
            },
            "therapy": {
                "id": 5438,
                "therapyName": "Abiraterone + Ipatasertib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8227,
                    "pubMedId": null,
                    "title": "PTEN loss as a predictive biomarker for the Akt inhibitor ipatasertib combined with abiraterone acetate in patients with metastatic castration-resistant prostate cancer (mCRPC)",
                    "url": "https://academic.oup.com/annonc/article/27/suppl_6/718O/2799456/PTEN-loss-as-a-predictive-biomarker-for-the-Akt"
                },
                {
                    "id": 14127,
                    "pubMedId": 30037818,
                    "title": "Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30037818"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 10353,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination of myeloid-derived suppressor cell-targeting with Cometriq (cabozantinib) and immune checkpoint blockade with anti-CTLA4 and anti-PD-1 antibodies resulted in synergistic inhibition of tumor growth and metastasis in transgenic mouse models of metastatic castration-resistant prostate cancer (PMID: 28321130).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5490,
                "therapyName": "Cabozantinib + unspecified CTLA4 antibody + unspecified PD-1 antibody",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 8359,
                    "pubMedId": 28321130,
                    "title": "Effective combinatorial immunotherapy for castration-resistant prostate cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28321130"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 10354,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination of myeloid-derived suppressor cell-targeting with BEZ235 and immune checkpoint blockade with anti-CTLA4 and anti-PD-1 antibodies resulted in synergistic inhibition of tumor growth and metastasis in transgenic mouse models of metastatic castration-resistant prostate cancer (PMID: 28321130).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5491,
                "therapyName": "BEZ235 + unspecified CTLA4 antibody + unspecified PD-1 antibody",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 8359,
                    "pubMedId": 28321130,
                    "title": "Effective combinatorial immunotherapy for castration-resistant prostate cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28321130"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 10538,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, prostate cancer cells treated with DCBCI0901 demonstrated inhibition of cell proliferation in culture and inhibition of tumor growth in cell-line xenograft models (Mol Cancer Ther 2013;12(11 Suppl):Abstract nr C270).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2017,
                "therapyName": "DCBCI0901",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 3453,
                    "pubMedId": null,
                    "title": "Abstract C270: In vitro and in vivo antitumor activity of DCBCI0901, a potent PI3K/mTORC1/mTORC2 inhibitor.",
                    "url": "http://mct.aacrjournals.org/content/12/11_Supplement/C270.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 10701,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a prostate cancer cell line with PTEN loss was sensitive to XL765 (SAR245409) treatment, demonstrating inhibition of the PI3K pathway and decreased colony formation in culture, and inhibition of tumor growth and reduced tumor vascularization in cell line xenograft models (PMID: 24634413).",
            "molecularProfile": {
                "id": 479,
                "profileName": "PTEN loss"
            },
            "therapy": {
                "id": 1051,
                "therapyName": "SAR245409",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8768,
                    "pubMedId": 24634413,
                    "title": "Characterization of the activity of the PI3K/mTOR inhibitor XL765 (SAR245409) in tumor models with diverse genetic alterations affecting the PI3K pathway.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24634413"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10710,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a glioblastoma cell line harboring PTEN loss (PMID: 24634413) was sensitive to SF1126, demonstrating a 76% decrease in tumor growth in cell line xenograft models (PMID: 18172313).",
            "molecularProfile": {
                "id": 479,
                "profileName": "PTEN loss"
            },
            "therapy": {
                "id": 915,
                "therapyName": "SF1126",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8768,
                    "pubMedId": 24634413,
                    "title": "Characterization of the activity of the PI3K/mTOR inhibitor XL765 (SAR245409) in tumor models with diverse genetic alterations affecting the PI3K pathway.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24634413"
                },
                {
                    "id": 8775,
                    "pubMedId": 18172313,
                    "title": "A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18172313"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10722,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with X480 in prostate cancer cell lines resulted in reduced cell proliferation and induced apoptotic activity in culture, and decreased tumor load and metastasis in cell line xenograft models (Eur J Cancer, 2012, 48, S5:235).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3858,
                "therapyName": "X480",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5043,
                    "pubMedId": null,
                    "title": "976 Effects of Dual PI3K and mTOR Inhibition on Incidence and Local Growth of Prostate Cancer Bone Metastases",
                    "url": "http://www.sciencedirect.com/science/article/pii/S0959804912715940"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 10819,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BGP-15 induced apoptosis and inhibited growth of prostate cancer cells in culture (PMID: 22661288).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2537,
                "therapyName": "BGP-15",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 2481,
                    "pubMedId": 22661288,
                    "title": "Inhibition of cancer growth and induction of apoptosis by BGP-13 and BGP-15, new calcipotriene-derived vitamin D3 analogs, in-vitro and in-vivo studies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22661288"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 10887,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with AZD5363 decreased AKT phosphorylation and downstream signaling and reduced tumor burden in mouse models of PTEN-deficient prostate cancer, including both castration-naive and castration resistant models (PMID: 26910118).",
            "molecularProfile": {
                "id": 479,
                "profileName": "PTEN loss"
            },
            "therapy": {
                "id": 655,
                "therapyName": "Capivasertib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8893,
                    "pubMedId": 26910118,
                    "title": "Efficacy of targeted AKT inhibition in genetically engineered mouse models of PTEN-deficient prostate cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26910118"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10888,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with AZD5363 improved overall survival and progression-free survival in mouse models of prostate cancer with inactivated PTEN and TP53 (PMID: 26910118).",
            "molecularProfile": {
                "id": 27832,
                "profileName": "PTEN loss TP53 loss"
            },
            "therapy": {
                "id": 655,
                "therapyName": "Capivasertib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8893,
                    "pubMedId": 26910118,
                    "title": "Efficacy of targeted AKT inhibition in genetically engineered mouse models of PTEN-deficient prostate cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26910118"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10962,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, a patient with prostate cancer demonstrated stable disease when treated with OPB-111077 (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr B118).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5739,
                "therapyName": "OPB-111077",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 8960,
                    "pubMedId": null,
                    "title": "Abstract B118: A phase 1, open-label multiple dose escalation trial to determine safety and tolerability of once daily OPB-111077 in subjects with advanced cancer",
                    "url": "http://mct.aacrjournals.org/content/14/12_Supplement_2/B118.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11022,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, 60.7% (17/28) of prostate cancer patients positive for FOLH1 (PSMA) demonstrated a reduced PSA >50% when treated with 131I-MIP-1095 (PMID: 24577951).",
            "molecularProfile": {
                "id": 26143,
                "profileName": "FOLH1 positive"
            },
            "therapy": {
                "id": 5804,
                "therapyName": "131I-MIP-1095",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9013,
                    "pubMedId": 24577951,
                    "title": "Radiation dosimetry and first therapy results with a (124)I/ (131)I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24577951"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11068,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with CCS1477 resulted in decreased expression of full length AR, AR-V7, and c-MYC, and inhibited proliferation of prostate cancer cells in culture and inhibited tumor growth in xenograft models (J Clin Oncol 35, 2017 (suppl; abstr 11590)).",
            "molecularProfile": {
                "id": 2795,
                "profileName": "AR positive"
            },
            "therapy": {
                "id": 5852,
                "therapyName": "CCS1477",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9061,
                    "pubMedId": null,
                    "title": "Characterisation of CCS1477: A novel small molecule inhibitor of p300/CBP for the treatment of castration resistant prostate cancer.",
                    "url": "http://abstracts.asco.org/199/AbstView_199_189631.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11125,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, the combination of AZD8186 and Vistusertib (AZD2014) resulted in a partial response in a patient with castration resistant prostate cancer (J Clin Oncol 35, 2017 (suppl; abstr 2570)).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5868,
                "therapyName": "AZD8186 + Vistusertib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9097,
                    "pubMedId": null,
                    "title": "A first in human phase I study of AZD8186, a potent and selective inhibitor of PI3K in patients with advanced solid tumours as monotherapy and in combination with the dual mTORC1/2 inhibitor vistusertib (AZD2014) or abiraterone acetate",
                    "url": "http://abstracts.asco.org/199/AbstView_199_183406.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11240,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II (NCI 9012) trial, addition of Veliparib (ABT-888) to Zytiga (abiraterone) and Prednisone did not improve PSA response rate (72.4% vs 63.9%, p=0.27), measurable disease response rate (52.2% vs 45.0%, p=0.51), or median progression-free survival (10.1 vs 11.0 months, p=0.99) in patients with metastatic castration-resistant prostate cancer (PMID: 29261439; NCT01576172).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5913,
                "therapyName": "Abiraterone + Prednisone + Veliparib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 18044,
                    "pubMedId": 29261439,
                    "title": "Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29261439"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 18490,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (TITAN) that supported FDA approval, treatment with Erleada (apalutamide) plus androgen-deprivation therapy (ADT) resulted in a radiographic progression-free survival at 24 months in 68.2% (358/525) of patients with metastatic castration-sensitive prostate cancer, compared to 47.5% (250/527) in patients treated with ADT and placebo (HR=0.48, p<0.001), and improved overall survival at 24 months (82.4% vs 73.5%, HR=0.89, p=0.005) (PMID: 31150574; NCT02489318).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1947,
                "therapyName": "Apalutamide",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 15655,
                    "pubMedId": null,
                    "title": "Erleada (apalutamide) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210951"
                },
                {
                    "id": 16269,
                    "pubMedId": 31150574,
                    "title": "Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31150574"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11495,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, Erleada (apalutamide) demonstrated safety and efficacy, resulted in 12-week PSA response rate of 88% (22/25) and 22% (4/18), median time to PSA progression of 18.2 months and 3.7 months, in castration-resistant prostate cancer patients that were treatment-naive or those received prior abiraterone and prednisone (PMID: 28213364).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1947,
                "therapyName": "Apalutamide",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9556,
                    "pubMedId": 28213364,
                    "title": "Safety and Antitumor Activity of Apalutamide (ARN-509) in Metastatic Castration-Resistant Prostate Cancer with and without Prior Abiraterone Acetate and Prednisone.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28213364"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12863,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial that supported FDA approval, treatment with Erleada (apalutamide) resulted in a median metastasis-free survival of 40.5 months in patients with non-metastatic castration-resistant prostate cancer, compared to 16.2 months with placebo (HR=0.28) (PMID: 29420164; NCT01946204).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1947,
                "therapyName": "Apalutamide",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10811,
                    "pubMedId": 29420164,
                    "title": "Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29420164"
                },
                {
                    "id": 15655,
                    "pubMedId": null,
                    "title": "Erleada (apalutamide) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210951"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11539,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Tanespimycin (17-AAG) and Xtandi (enzalutamide) resulted in decreased AR expression and signaling, increased cell death, and decreased growth of prostate cancer cell lines in culture, and decreased tumor growth in patient-derived xenograft (PDX) models compared to either agent alone (PMID: 27390342).",
            "molecularProfile": {
                "id": 2795,
                "profileName": "AR positive"
            },
            "therapy": {
                "id": 6022,
                "therapyName": "Enzalutamide + Tanespimycin",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9608,
                    "pubMedId": 27390342,
                    "title": "Cotargeting HSP90 and Its Client Proteins for Treatment of Prostate Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27390342"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11598,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BCI-121 selectively inhibited growth of prostate cancer cell lines with high Smyd3 expression level in culture (PMID: 25728514).",
            "molecularProfile": {
                "id": 2747,
                "profileName": "SMYD3 over exp"
            },
            "therapy": {
                "id": 6073,
                "therapyName": "BCI-121",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9659,
                    "pubMedId": 25728514,
                    "title": "A SMYD3 Small-Molecule Inhibitor Impairing Cancer Cell Growth.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25728514"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11607,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a prostate cancer patient demonstrated tumor regression in the primary tumor and metastatic lesions when treated with ONC201 (TIC-10) (PMID: 28331050).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1687,
                "therapyName": "ONC201",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9666,
                    "pubMedId": 28331050,
                    "title": "First-in-Human Clinical Trial of Oral ONC201 in Patients with Refractory Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28331050"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11669,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MK-0752 reduced migration of a prostate cancer cell line harboring TMPRSS2-ERG in culture (PMID: 28783165).",
            "molecularProfile": {
                "id": 10069,
                "profileName": "TMPRSS2 - ERG"
            },
            "therapy": {
                "id": 815,
                "therapyName": "MK0752",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9696,
                    "pubMedId": 28783165,
                    "title": "TMPRSS2-ERG fusion co-opts master transcription factors and activates NOTCH signaling in primary prostate cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28783165"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11689,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of TAK-901 and Navitoclax (ABT-263) resulted in a synergistic effect, demonstrating reduced cell viability of prostate cancer cells in culture (PMID: 28179288).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5955,
                "therapyName": "Navitoclax + TAK-901",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9704,
                    "pubMedId": 28179288,
                    "title": "Aurora B Inhibitor TAK-901 Synergizes with BCL-xL Inhibition by Inducing Active BAX in Cancer Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28179288"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11692,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Barasertib (AZD1152) and Navitoclax (ABT-263) resulted in synergy, inhibiting proliferation of prostate cancer cells in culture (PMID: 28179288).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6112,
                "therapyName": "Barasertib + Navitoclax",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9704,
                    "pubMedId": 28179288,
                    "title": "Aurora B Inhibitor TAK-901 Synergizes with BCL-xL Inhibition by Inducing Active BAX in Cancer Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28179288"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11822,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, AZZD5363 in combination with Taxotere (docetaxel) and Prednisone resulted in more than 50% PSA reduction at 12 weeks in 70% (7/10) of patients with metastatic castration resistant prostate cancer (PMID: 28144789; NCT02121639).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6166,
                "therapyName": "Capivasertib + Docetaxel + Prednisone",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9861,
                    "pubMedId": 28144789,
                    "title": "ProCAID: a phase I clinical trial to combine the AKT inhibitor AZD5363 with docetaxel and prednisolone chemotherapy for metastatic castration resistant prostate cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28144789"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12126,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, a castration-resistant prostate cancer patient harboring PIK3CB amplification demonstrated a partial response for more than a year when treated with GSK2636771 (PMID: 28645941).",
            "molecularProfile": {
                "id": 4415,
                "profileName": "PIK3CB amp"
            },
            "therapy": {
                "id": 765,
                "therapyName": "GSK2636771",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10101,
                    "pubMedId": 28645941,
                    "title": "A First-Time-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28645941"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12127,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, two patients with castration-resistant prostate cancer harboring PIK3CB mutations demonstrated durable clinical benefit when treated with GSK2636771 (PMID: 28645941).",
            "molecularProfile": {
                "id": 4485,
                "profileName": "PIK3CB mutant"
            },
            "therapy": {
                "id": 765,
                "therapyName": "GSK2636771",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10101,
                    "pubMedId": 28645941,
                    "title": "A First-Time-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28645941"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12128,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, a castration-resistant prostate cancer patient harboring PIK3CB L1049R demonstrated prolonged stable disease when treated with GSK2636771 (PMID: 28645941).",
            "molecularProfile": {
                "id": 15027,
                "profileName": "PIK3CB L1049R"
            },
            "therapy": {
                "id": 765,
                "therapyName": "GSK2636771",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10101,
                    "pubMedId": 28645941,
                    "title": "A First-Time-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28645941"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12206,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, A-485 treatment in AR positive castration-resistant prostate cancer cells inhibited proliferation in culture, and induced tumor growth inhibition by 54% in cell line xenograft models (PMID: 28953875).",
            "molecularProfile": {
                "id": 2795,
                "profileName": "AR positive"
            },
            "therapy": {
                "id": 6354,
                "therapyName": "A-485",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10155,
                    "pubMedId": 28953875,
                    "title": "Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28953875"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12207,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Relugolix (TAK-385) resulted in decreased testosterone levels and greatly reduced prostate specific antigen levels after 24 weeks in prostate cancer patients (J Clin Oncol 34, 2016 (suppl 2S; abstr 200)).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5492,
                "therapyName": "Relugolix",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10156,
                    "pubMedId": null,
                    "title": "Second interim analysis (IA2) results from a phase II trial of TAK-385, an oral GnRH antagonist, in prostate cancer patients (pts).",
                    "url": "https://meetinglibrary.asco.org/record/119581/abstract"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12229,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with GNE-049 reduced AR target gene expression and growth of AR-expressing prostate cancer cell lines in culture, and inhibited tumor growth in AR-expressing patient-derived xenograft (PDX) models of prostate cancer, including castration-resistant prostate cancer models (PMID: 28819026).",
            "molecularProfile": {
                "id": 2795,
                "profileName": "AR positive"
            },
            "therapy": {
                "id": 6371,
                "therapyName": "GNE-049",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10185,
                    "pubMedId": 28819026,
                    "title": "Therapeutic Targeting of the CBP/p300 Bromodomain Blocks the Growth of Castration-Resistant Prostate Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28819026"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12230,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with GNE-049 reduced AR target gene expression and decreased proliferation of a prostate cancer cell line overexpressing AR F877L in culture (PMID: 28819026).",
            "molecularProfile": {
                "id": 28573,
                "profileName": "AR F877L AR over exp"
            },
            "therapy": {
                "id": 6371,
                "therapyName": "GNE-049",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10185,
                    "pubMedId": 28819026,
                    "title": "Therapeutic Targeting of the CBP/p300 Bromodomain Blocks the Growth of Castration-Resistant Prostate Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28819026"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12231,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with GNE-049 reduced AR target gene expression and decreased proliferation of prostate cancer cells overexpressing AR in culture (PMID: 28819026).",
            "molecularProfile": {
                "id": 28572,
                "profileName": "AR over exp"
            },
            "therapy": {
                "id": 6371,
                "therapyName": "GNE-049",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10185,
                    "pubMedId": 28819026,
                    "title": "Therapeutic Targeting of the CBP/p300 Bromodomain Blocks the Growth of Castration-Resistant Prostate Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28819026"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12334,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Glesatinib (MGCD265) treatment resulted in only partial growth inhibition in cell line xenograft models of MET wild-type prostate caner (PMID: 28765324).",
            "molecularProfile": {
                "id": 587,
                "profileName": "MET wild-type"
            },
            "therapy": {
                "id": 809,
                "therapyName": "Glesatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 9757,
                    "pubMedId": 28765324,
                    "title": "Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28765324"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12338,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, UT-155 promoted degradation of AR F877L (F876L) and inhibited proliferation of an Xtandi (enzalutamide)-resistant prostate cancer cell line harboring AR F877L (F876L) in culture (PMID: 28978635).",
            "molecularProfile": {
                "id": 26465,
                "profileName": "AR F877L"
            },
            "therapy": {
                "id": 6460,
                "therapyName": "UT-155",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10333,
                    "pubMedId": 28978635,
                    "title": "Novel Selective Agents for the Degradation of Androgen Receptor Variants to Treat Castration-Resistant Prostate Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28978635"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12339,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, UT-155 decreased AR expression and transcriptional activity and inhibited proliferation prostate cancer cell lines expressing full length AR and/or AR splice variants, and inhibited tumor growth in xenograft models (PMID: 28978635).",
            "molecularProfile": {
                "id": 2795,
                "profileName": "AR positive"
            },
            "therapy": {
                "id": 6460,
                "therapyName": "UT-155",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10333,
                    "pubMedId": 28978635,
                    "title": "Novel Selective Agents for the Degradation of Androgen Receptor Variants to Treat Castration-Resistant Prostate Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28978635"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12618,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In two Phase I trials, AZD3514 treatment resulted in more than 50% decrease of PSA level in 13% (9/70) of patients with castration-resistant prostate cancer, and an objective soft tissue response in 17% (4/24) of patients in one of the trials (PMID: 25920479).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2826,
                "therapyName": "AZD3514",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10499,
                    "pubMedId": 25920479,
                    "title": "AZD3514, an oral selective androgen receptor down-regulator in patients with castration-resistant prostate cancer - results of two parallel first-in-human phase I studies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25920479"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12648,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, AMG208 treatment resulted in complete response in 1 and partial response in 2 patients with prostate cancer (PMID: 26155941; NCT00813384).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 630,
                "therapyName": "AMG208",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10534,
                    "pubMedId": 26155941,
                    "title": "A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26155941"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12659,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib trial, the combination of Zytiga (abiraterone) and Buparlisib (BKM120) did not demonstrate significant clinical activity in patients with castration-resistant prostate cancer, resulting in a best overall response of stable disease in 15% (3/20) patients treated at the 100 mg QD Buparlisib (BKM120) dose level, and further study of this combination is not planned (PMID: 28282611; NCT01634061).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6552,
                "therapyName": "Abiraterone + Buparlisib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 10547,
                    "pubMedId": 28282611,
                    "title": "Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28282611"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12660,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib trial, the combination of Zytiga (abiraterone) and Dactolisib (BEZ235) did not demonstrate positive safety and tolerability, and further study of this combination is not planned (PMID: 28282611; NCT01634061).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6553,
                "therapyName": "Abiraterone + BEZ235",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 10547,
                    "pubMedId": 28282611,
                    "title": "Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28282611"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12682,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, overexpression of FANCA S1088F in FANCA-null cells derived from Fanconi anemia patients resulted in increased sensitivity to Lynparza (olaparib) in culture, and a patient-derived xenograft (PDX) model of prostate cancer harboring germline FANCA S1088F demonstrated enhanced sensitivity to Lynparza (olaparib) treatment (PMID: 28864460).",
            "molecularProfile": {
                "id": 17161,
                "profileName": "FANCA S1088F"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10575,
                    "pubMedId": 28864460,
                    "title": "A germline FANCA alteration that is associated with increased sensitivity to DNA damaging agents.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28864460"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12907,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, SM-88 treatment resulted in stable (4/10) or rising (5/10) testosterone levels, and none of the toxicity commonly associated with androgen deprivation therapy in patients with non-metastatic recurrent prostate cancer (J Clin Oncol 36, 2018 (suppl 6S; abstr 175); NCT02796898).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5866,
                "therapyName": "SM88",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10863,
                    "pubMedId": null,
                    "title": "Phase II trial of SM 88 in non-metastatic biochemical recurrent prostate cancer.",
                    "url": "https://meetinglibrary.asco.org/record/157315/abstract"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 13415,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (LATITUDE) that supported FDA approval, treatment with the combination of Zytiga (abiraterone) and Predisone, along with androgen-deprivation therapy, resulted in improved median overall survival (not reached vs. 34.7 months; HR=0.62) and median progression-free survival (33.0 months vs. 14.8 months; HR=0.47) compared to treatment with placebos in patients with metastatic castration-sensitive prostate cancer (PMID: 28578607; NCT01715285).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2748,
                "therapyName": "Abiraterone + Prednisone",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 11097,
                    "pubMedId": 28578607,
                    "title": "Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28578607"
                },
                {
                    "id": 15657,
                    "pubMedId": null,
                    "title": "Zytiga (abiraterone) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202379"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 13551,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AR-mTOR-26 treatment resulted in antitumor activity in prostate cancer xenograft models with PTEN loss (Cancer Res 2010;70(8 Suppl):Abstract nr 4484).",
            "molecularProfile": {
                "id": 479,
                "profileName": "PTEN loss"
            },
            "therapy": {
                "id": 3850,
                "therapyName": "AR-mTOR-26",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5033,
                    "pubMedId": null,
                    "title": "Abstract 4484: AR-mTOR-26 - A potent, selective mTORC 1/2 kinase inhibitor for the treatment of malignancy",
                    "url": "http://cancerres.aacrjournals.org/content/70/8_Supplement/4484.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13555,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, prostate cancer cell line xenograft models demonstrated inhibition of tumor growth when treated with CC214-2 (PMID: 23414803).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3854,
                "therapyName": "CC214-2",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5036,
                    "pubMedId": 23414803,
                    "title": "Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23414803"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 13951,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, the AR T878A variant was not associated with de novo or acquired resistance to Erleada (apalutamide) in patients with castration-resistant prostate cancer, based on its low frequency at baseline and progression (PMID: 28633425; NCT01171898).",
            "molecularProfile": {
                "id": 729,
                "profileName": "AR T878A"
            },
            "therapy": {
                "id": 1947,
                "therapyName": "Apalutamide",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "unknown",
            "references": [
                {
                    "id": 10026,
                    "pubMedId": 28633425,
                    "title": "Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28633425"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 14119,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, PAN-301-1 demonstrated safety and preliminary efficacy, resulted in dose-dependent ASPH (HAAH)-specific B- and T-cell responses, and decreased PSA levels in prostate cancer patients who received treatment for 3 months or longer (Journal of Clinical Oncology 36, no. 15_suppl; NCT03120832).",
            "molecularProfile": {
                "id": 27891,
                "profileName": "ASPH positive"
            },
            "therapy": {
                "id": 5704,
                "therapyName": "PAN-301-1",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11468,
                    "pubMedId": null,
                    "title": "Phase 1 open-label trial to evaluate the safety and immunogenicity of PAN-301-1, a novel nanoparticle therapeutic vaccine, in patients with biochemically relapsed prostate cancer.",
                    "url": "http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.e15166"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14199,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Tisotumab vedotin treatment resulted in prolonged stable disease in 2 patients with prostate cancer (Journal of Clinical Oncology 33, no. 15_suppl (May 20 2015) 2570-2570; NCT02001623).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6113,
                "therapyName": "Tisotumab Vedotin",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 11505,
                    "pubMedId": null,
                    "title": "A phase I, first-in-human study to evaluate the tolerability, pharmacokinetics and preliminary efficacy of HuMax-tissue factor-ADC (TF-ADC) in patients with solid tumors.",
                    "url": "http://ascopubs.org/doi/abs/10.1200/jco.2015.33.15_suppl.2570"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 14233,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Zytiga (abiraterone) and PCM-075 synergistically inhibited growth of prostate cancer cells in cell line xenograft models (J Clin Oncol 36, 2018 (suppl 6S; abstr 369)).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 7084,
                "therapyName": "Abiraterone + PCM-075",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 11559,
                    "pubMedId": null,
                    "title": "Combination of selective polo-like kinase 1 (PLK1) inhibitor PCM-075 with abiraterone in prostate cancer and non-androgen-driven cancer models.",
                    "url": "https://meetinglibrary.asco.org/record/157544/abstract"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 14363,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, 50% (2/4) of prostate cancer patients with mutant CDK12 responded to an unspecified checkpoint inhibitor immunotherapy and had a corresponding decrease in prostate specific antigen (PMID: 29906450).",
            "molecularProfile": {
                "id": 27346,
                "profileName": "CDK12 mutant"
            },
            "therapy": {
                "id": 3890,
                "therapyName": "unspecified PD-1 antibody",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11609,
                    "pubMedId": 29906450,
                    "title": "Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29906450"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14498,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Selinexor demonstrated preliminary efficacy and poor toxicity profile in patients with abiraterone- and/or enzalutamide-refractory metastatic castration-resistant prostate cancer, resulted in partial response in 25% (2/8) and stable disease in 50% (4/8) of evaluable patients (PMID: 29487219).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1749,
                "therapyName": "Selinexor",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 11651,
                    "pubMedId": 29487219,
                    "title": "A Phase II Trial of Selinexor, an Oral Selective Inhibitor of Nuclear Export Compound, in Abiraterone- and/or Enzalutamide-Refractory Metastatic Castration-Resistant Prostate Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29487219"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 14549,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, treatment with the combination of Lynparza (olaparib) and Zytiga (abiraterone) resulted in a prolonged median radiographic progression-free survival of 13.8 months, compared to 8.2 months with placebo plus Zytiga (abiraterone), in patients with metastatic castration-resistant prostate cancer (PMID: 29880291; NCT01972217).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 7168,
                "therapyName": "Abiraterone + Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 11741,
                    "pubMedId": 29880291,
                    "title": "Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29880291"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 14997,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ABBV-744 inhibited growth of prostate cancer cells in culture and in cell line xenograft models (Cancer Res 2018;78(13 Suppl):Abstract nr DDT01-05).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 7366,
                "therapyName": "ABBV-744",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 12053,
                    "pubMedId": null,
                    "title": "ABBV-744: A first-in-class highly BDII-selective BET bromodomain inhibitor",
                    "url": "http://cancerres.aacrjournals.org/content/78/13_Supplement/DDT01-05"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 15308,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a prostate cancer cell line, overexpressing Spop W131R, was resistant to JQ1, as demonstrated by sustained cell viability and cell proliferation (PMID: 28805820).",
            "molecularProfile": {
                "id": 30975,
                "profileName": "SPOP W131R"
            },
            "therapy": {
                "id": 1574,
                "therapyName": "JQ1",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 13047,
                    "pubMedId": 28805820,
                    "title": "Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28805820"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15309,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a prostate cancer cell line, overexpressing Spop W131G, was resistant to JQ1, as demonstrated by sustained cell viability and cell proliferation (PMID: 28805820).",
            "molecularProfile": {
                "id": 24945,
                "profileName": "SPOP W131G"
            },
            "therapy": {
                "id": 1574,
                "therapyName": "JQ1",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 13047,
                    "pubMedId": 28805820,
                    "title": "Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28805820"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15310,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a prostate cancer cell line, overexpressing Spop F102C, was resistant to JQ1, as demonstrated by sustained cell viability and cell proliferation (PMID: 28805820, PMID: 28805821).",
            "molecularProfile": {
                "id": 24943,
                "profileName": "SPOP F102C"
            },
            "therapy": {
                "id": 1574,
                "therapyName": "JQ1",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 13047,
                    "pubMedId": 28805820,
                    "title": "Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28805820"
                },
                {
                    "id": 13048,
                    "pubMedId": 28805821,
                    "title": "Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28805821"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15318,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a prostate cancer cell line, overexpressing Spop Y87C, was resistant to JQ1, as demonstrated by sustained cell viability and cell proliferation (PMID: 28805821).",
            "molecularProfile": {
                "id": 24946,
                "profileName": "SPOP Y87C"
            },
            "therapy": {
                "id": 1574,
                "therapyName": "JQ1",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 13048,
                    "pubMedId": 28805821,
                    "title": "Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28805821"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15319,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a prostate cancer cell line, overexpressing Spop F133L, was resistant to JQ1, as demonstrated by sustained cell viability and cell proliferation (PMID: 28805821).",
            "molecularProfile": {
                "id": 24951,
                "profileName": "SPOP F133L"
            },
            "therapy": {
                "id": 1574,
                "therapyName": "JQ1",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 13048,
                    "pubMedId": 28805821,
                    "title": "Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28805821"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15320,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, prostate cancer patients with CDH1 loss and mutated SPOP, had a higher likelihood of favorably responding to Zytiga (abiraterone) (PMID: 30068710).",
            "molecularProfile": {
                "id": 30980,
                "profileName": "CDH1 loss SPOP mut"
            },
            "therapy": {
                "id": 1805,
                "therapyName": "Abiraterone",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 13052,
                    "pubMedId": 30068710,
                    "title": "SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30068710"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15327,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, prostate cancer cells with targeted loss of SLFN11 demonstrated resistance to treatment with Lynparza (olaparib) in culture (PMID: 27708213).",
            "molecularProfile": {
                "id": 30987,
                "profileName": "SLFN11 loss"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 13105,
                    "pubMedId": 27708213,
                    "title": "Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27708213"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15330,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, prostate cancer cells with targeted loss of SLFN11 demonstrated resistance to treatment with Talzenna (talazoparib) in culture (PMID: 27708213).",
            "molecularProfile": {
                "id": 30987,
                "profileName": "SLFN11 loss"
            },
            "therapy": {
                "id": 682,
                "therapyName": "Talazoparib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 13105,
                    "pubMedId": 27708213,
                    "title": "Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27708213"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15333,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Talzenna (talazoparib) combined with Temodar (temozolomide) resulted in a synergistic effect in MGMT-proficient prostate cancer cells with overexpression of SLFN11, demonstrating reduced cell viability in culture (PMID: 27708213).",
            "molecularProfile": {
                "id": 30985,
                "profileName": "SLFN11 over exp"
            },
            "therapy": {
                "id": 1377,
                "therapyName": "Talazoparib + Temozolomide",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13105,
                    "pubMedId": 27708213,
                    "title": "Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27708213"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15336,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Talzenna (talazoparib) to Temodar (temozolomide) treatment resulted in no benefit in MGMT-proficient prostate cancer cells with targeted loss of SLFN11 when compared to Temodar (temozolomide) treatment alone (PMID: 27708213).",
            "molecularProfile": {
                "id": 30987,
                "profileName": "SLFN11 loss"
            },
            "therapy": {
                "id": 1377,
                "therapyName": "Talazoparib + Temozolomide",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 13105,
                    "pubMedId": 27708213,
                    "title": "Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27708213"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15339,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, VE-821 treatment combined with Talzenna (talazoparib) resulted in a synergistic effect in prostate cancer cells with targeted loss of SLFN11, demonstrating reduced cell viability in culture (PMID: 27708213).",
            "molecularProfile": {
                "id": 30987,
                "profileName": "SLFN11 loss"
            },
            "therapy": {
                "id": 7562,
                "therapyName": "Talazoparib + VE-821",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13105,
                    "pubMedId": 27708213,
                    "title": "Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27708213"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15342,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, VE-821 treatment combined with Lynparza (olaparib) resulted in a synergistic effect in prostate cancer cells with targeted loss of SLFN11, demonstrating reduced cell viability in culture (PMID: 27708213).",
            "molecularProfile": {
                "id": 30987,
                "profileName": "SLFN11 loss"
            },
            "therapy": {
                "id": 7563,
                "therapyName": "Olaparib + VE-821",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13105,
                    "pubMedId": 27708213,
                    "title": "Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27708213"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15351,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, VE-821 treatment combined with Talzenna (talazoparib) resulted in a synergistic effect in prostate cancer cells with overexpression of SLFN11, demonstrating greater reduced cell viability compared to Talzenna (talazoparib) treatment alone in culture and increased apoptotic activity (PMID: 27708213).",
            "molecularProfile": {
                "id": 30985,
                "profileName": "SLFN11 over exp"
            },
            "therapy": {
                "id": 7562,
                "therapyName": "Talazoparib + VE-821",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13105,
                    "pubMedId": 27708213,
                    "title": "Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27708213"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15354,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, VE-821 treatment combined with Lynparza (olaparib) resulted in a synergistic effect in prostate cancer cells with overexpression of SLFN11, demonstrating greater reduced cell viability compared to Lynparza (olaparib) treatment alone in culture (PMID: 27708213).",
            "molecularProfile": {
                "id": 30985,
                "profileName": "SLFN11 over exp"
            },
            "therapy": {
                "id": 7563,
                "therapyName": "Olaparib + VE-821",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13105,
                    "pubMedId": 27708213,
                    "title": "Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27708213"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15363,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with the combination of AB928 and Adriamycin (doxorubicin) resulted in a increase in tumor cell specific CD8+ T cells and increased tumor growth inhibition compared to chemotherapy alone in prostate cancer cell line xenograft models (European Journal of Cancer, Vol 92, S14-S15).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 7586,
                "therapyName": "AB928 + Doxorubicin",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 13108,
                    "pubMedId": null,
                    "title": "AB928, a dual antagonist of the A2aR and A2bR adenosine receptors, leads to greater immune activation and reduced tumor growth when combined with chemotherapy",
                    "url": "https://www.ejcancer.com/article/S0959-8049(18)30051-0/abstract"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 15364,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with the combination of AB928 and Eloxatin (oxaliplatin) resulted in a increase in tumor cell specific CD8+ T cells and increased tumor growth inhibition compared to chemotherapy alone in prostate cancer cell line xenograft models (European Journal of Cancer, Vol 92, S14-S15).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 7585,
                "therapyName": "AB928 + Oxaliplatin",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 13108,
                    "pubMedId": null,
                    "title": "AB928, a dual antagonist of the A2aR and A2bR adenosine receptors, leads to greater immune activation and reduced tumor growth when combined with chemotherapy",
                    "url": "https://www.ejcancer.com/article/S0959-8049(18)30051-0/abstract"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 15365,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BAY 2315497 (PSMA-TTC) inhibited tumor growth in prostate cancer cell line xenograft models expressing high or medium-low levels of FOLH1 (PSMA), and prevented tumor growth in a PSMA-expressing prostate cancer cell line orthotopic bone xenograft model (Cancer Res July 1 2017 (77) (13 Supplement) 5200).",
            "molecularProfile": {
                "id": 26143,
                "profileName": "FOLH1 positive"
            },
            "therapy": {
                "id": 7573,
                "therapyName": "BAY 2315497",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 13109,
                    "pubMedId": null,
                    "title": "Abstract 5200: Preclinical pharmacology of the PSMA-targeted thorium-227 conjugate PSMA-TTC: a novel targeted alpha therapeutic for the treatment of prostate cancer",
                    "url": "http://cancerres.aacrjournals.org/content/77/13_Supplement/5200"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15419,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, LFA102 treatment of patients (n=73) with PRLR-positive metastatic breast cancer or metastatic castration-resistant prostate cancer, did not result in clinical efficacy at any of five tested doses (PMID: 27091421, NCT01338831).",
            "molecularProfile": {
                "id": 31028,
                "profileName": "PRLR positive"
            },
            "therapy": {
                "id": 7615,
                "therapyName": "LFA102",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 13205,
                    "pubMedId": 27091421,
                    "title": "Phase I Study of the Prolactin Receptor Antagonist LFA102 in Metastatic Breast and Castration-Resistant Prostate Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27091421"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15870,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a minority (3.1%, 32/1033) of patients with castration-resistant advanced prostate cancer were microsatellite instability-high (MSI-H, 23/32) or mismatch repair-deficient (dMMR, 9/32), however, among 11 MSI-H/dMMR patients treated with anti-PD1/PD-L1 therapy, 54.5% (6/11) achieved more than 50% decrease of PSA levels, and 36.4% (4/11) reached radiographic responses (PMID: 30589920).",
            "molecularProfile": {
                "id": 29714,
                "profileName": "MSI high"
            },
            "therapy": {
                "id": 3890,
                "therapyName": "unspecified PD-1 antibody",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 13876,
                    "pubMedId": 30589920,
                    "title": "Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30589920"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15871,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a minority (3.1%, 32/1033) of patients with castration-resistant advanced prostate cancer were microsatellite instability-high (MSI-H, 23/32) or mismatch repair-deficient (dMMR, 9/32), however, among 11 MSI-H/dMMR patients treated with anti-PD1/PD-L1 therapy, 54.5% (6/11) achieved more than 50% decrease of PSA levels, and 36.4% (4/11) reached radiographic responses (PMID: 30589920).",
            "molecularProfile": {
                "id": 29714,
                "profileName": "MSI high"
            },
            "therapy": {
                "id": 5248,
                "therapyName": "unspecified PD-L1 antibody",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 13876,
                    "pubMedId": 30589920,
                    "title": "Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30589920"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16055,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, 27% (8/30) of patients with castration resistant prostate cancer demonstrated resistance to treatment with Xtandi (enzalutamide) and were found, via cell-free DNA testing, to have either an increased frequency of AR L702H from baseline or acquired AR L702H during treatment (PMID: 27148695).",
            "molecularProfile": {
                "id": 23387,
                "profileName": "AR L702H"
            },
            "therapy": {
                "id": 1262,
                "therapyName": "Enzalutamide",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 14168,
                    "pubMedId": 27148695,
                    "title": "Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27148695"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16056,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Alisertib (MLN8237) treatment of patients with neuroendocrine prostate cancer (NEPC) or castration-resistant prostate adenocarcinoma (CRPAC) resulted in a 6-month radiological progression-free survival (PFS) of 13.4% (8/60, 16.7% of NEPC, 5.3% of CRPAC), a median PFS of 2.2 months (2.3 months in NEPC, 2.0 months in CRPAC), and an overall survival of 9.5 months, and 30% (18/60) of patients had stable disease at the third treatment cycle (PMID: 30232224; NCT30232224).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 626,
                "therapyName": "Alisertib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 14171,
                    "pubMedId": 30232224,
                    "title": "A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30232224"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16201,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (ARAMIS) that supported FDA approval, treatment with Nubeqa (darolutamide) resulted in improved median metastasis-free survival (40.4 vs 18.4 months, HR=0.41, p<0.001), overall survival (HR=0.71, 95% CI, 0.5-0.99, p=0.045), and time to pain progression (40.3 vs 25.4 months, HR=0.65, p<0.001) compared to placebo in non-metastatic castration-resistant prostate cancer patients (PMID: 30763142; NCT02200614).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 836,
                "therapyName": "Darolutamide",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 14325,
                    "pubMedId": 30763142,
                    "title": "Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30763142"
                },
                {
                    "id": 15838,
                    "pubMedId": null,
                    "title": "Nubeqa (darolutamide) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212099"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16440,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, Zytiga (abiraterone) treatment was associated with better responses as measured by 50% PSA falls (p=0.03) and decreased likelihood of progression (odds ratio 14.5, p=0.001) in patients with castration-resistant hormone-naive prostate cancer harboring SPOP mutations compared to patients with wild-type SPOP (PMID: 30068710).",
            "molecularProfile": {
                "id": 30978,
                "profileName": "SPOP mutant"
            },
            "therapy": {
                "id": 1805,
                "therapyName": "Abiraterone",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 13052,
                    "pubMedId": 30068710,
                    "title": "SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30068710"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16483,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MC180295 decreased proliferation of prostate cancer cell lines in culture (PMID: 30454645).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 8055,
                "therapyName": "MC180295",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 14528,
                    "pubMedId": 30454645,
                    "title": "Targeting CDK9 Reactivates Epigenetically Silenced Genes in Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30454645"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16493,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tertomotide (GV1001) inhibited growth of AR-positive prostate cancer cells in culture and induced apoptosis in cell line xenograft models (PMID: 30400054).",
            "molecularProfile": {
                "id": 2795,
                "profileName": "AR positive"
            },
            "therapy": {
                "id": 8067,
                "therapyName": "Tertomotide",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14562,
                    "pubMedId": 30400054,
                    "title": "Anti-cancer effect of GV1001 for prostate cancer: function as a ligand of GnRHR.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30400054"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16778,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, treatment with either Xtandi (enzalutamide) or Zytiga (abiraterone) in patients with metastatic castration-resistant prostate cancer harboring a TP53 inactivating mutation, detected via circulating tumor cells, demonstrated a shorter progression-free survival (3.0 vs 8.7mo; P<0.0001) and overall survival (7.8 vs 26.7mo; P<0.0001) and fewer patients with a PSA response greater than or equal to 50% (15.4 vs 46.8%; P=0.008) compared to those patients with wild-type TP53 (PMID: 30209161).",
            "molecularProfile": {
                "id": 489,
                "profileName": "TP53 inact mut"
            },
            "therapy": {
                "id": 1262,
                "therapyName": "Enzalutamide",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 14904,
                    "pubMedId": 30209161,
                    "title": "TP53 Outperforms Other Androgen Receptor Biomarkers to Predict Abiraterone or Enzalutamide Outcome in Metastatic Castration-Resistant Prostate Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30209161"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16779,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, treatment with either Xtandi (enzalutamide) or Zytiga (abiraterone) in patients with metastatic castration-resistant prostate cancer harboring a TP53 inactivating mutation, detected via circulating tumor cells, demonstrated a shorter progression-free survival (3.0 vs 8.7mo; P<0.0001) and overall survival (7.8 vs 26.7mo; P<0.0001) and fewer patients with a PSA response greater than or equal to 50% (15.4 vs 46.8%; P=0.008) compared to those patients with wild-type TP53 (PMID: 30209161).",
            "molecularProfile": {
                "id": 489,
                "profileName": "TP53 inact mut"
            },
            "therapy": {
                "id": 1805,
                "therapyName": "Abiraterone",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 14904,
                    "pubMedId": 30209161,
                    "title": "TP53 Outperforms Other Androgen Receptor Biomarkers to Predict Abiraterone or Enzalutamide Outcome in Metastatic Castration-Resistant Prostate Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30209161"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17319,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Imfinzi (durvalumab) plus Lynparza (olaparib) resulted in a decrease in PSA greater than or equal to 50% in 53% (9/17) of patients with metastatic castrate-resistant prostate cancer, with radiographic response in 4 of those 9, a median radiographic progression-free survival (PFS) of 16.1 mo., and a 12-mo. PFS probability of 83.3% in patients with mutations in DNA damage response (DDR) genes, compared to 36.4% in patients without DDR gene mutations (PMID: 30514390; NCT02484404).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2894,
                "therapyName": "Durvalumab + Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 15371,
                    "pubMedId": 30514390,
                    "title": "Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30514390"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 17320,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Imfinzi (durvalumab) plus Lynparza (olaparib) resulted in a decrease in PSA greater than or equal to 50% in 53% (9/17) of patients with metastatic castrate-resistant prostate cancer, with one responder with an ongoing response at 12 mo harboring a deleterious mutation in the DNA damage response (DDR) gene NBN, and resulted in a 12-mo. PFS probability of 83.3% in patients with mutations in DDR genes, compared to 36.4% in patients without a DDR gene mutation (PMID: 30514390; NCT02484404).",
            "molecularProfile": {
                "id": 16862,
                "profileName": "NBN inact mut"
            },
            "therapy": {
                "id": 2894,
                "therapyName": "Durvalumab + Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15371,
                    "pubMedId": 30514390,
                    "title": "Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30514390"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17321,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Imfinzi (durvalumab) plus Lynparza (olaparib) resulted in PSA decrease of at least 50% in 53% (9/17) of metastatic castrate-resistant prostate cancer patients, with 3 responders harboring germline frameshift BRCA2 mutations and somatic deletion of the other allele, and 2 others with homozygous BRCA2 alterations, and resulted in a 12-mo. PFS probability of 83.3% in patients with mutations in DNA damage repair genes, compared to 36.4% in patients without (PMID: 30514390; NCT02484404).",
            "molecularProfile": {
                "id": 32502,
                "profileName": "BRCA2 del BRCA2 inact mut"
            },
            "therapy": {
                "id": 2894,
                "therapyName": "Durvalumab + Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15371,
                    "pubMedId": 30514390,
                    "title": "Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30514390"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17711,
            "approvalStatus": "Guideline",
            "evidenceType": "Risk Factor",
            "efficacyEvidence": "Germline BRCA1/2 mutations are associated with increased risk of developing prostate cancer (NCCN.org).",
            "molecularProfile": {
                "id": 1205,
                "profileName": "BRCA1 mutant"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 17713,
            "approvalStatus": "Guideline",
            "evidenceType": "Risk Factor",
            "efficacyEvidence": "Germline BRCA1/2 mutations are associated with increased risk of developing prostate cancer (NCCN.org).",
            "molecularProfile": {
                "id": 1206,
                "profileName": "BRCA2 mutant"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 17714,
            "approvalStatus": "Guideline",
            "evidenceType": "Risk Factor",
            "efficacyEvidence": "Germline ATM mutations are associated with increased risk of developing prostate cancer (NCCN.org).",
            "molecularProfile": {
                "id": 3274,
                "profileName": "ATM mutant"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 17715,
            "approvalStatus": "Guideline",
            "evidenceType": "Risk Factor",
            "efficacyEvidence": "Germline PALB2 mutations are associated with increased risk of developing prostate cancer (NCCN.org).",
            "molecularProfile": {
                "id": 3275,
                "profileName": "PALB2 mutant"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 17716,
            "approvalStatus": "Guideline",
            "evidenceType": "Risk Factor",
            "efficacyEvidence": "Germline CHEK2 mutations are associated with increased risk of developing prostate cancer (NCCN.org).",
            "molecularProfile": {
                "id": 10461,
                "profileName": "CHEK2 mutant"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 17873,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, treatment with Xtandi (enzalutamide) in patients with metastatic castration resistant prostate cancer expressing AR-V7 in circulating tumor cells (n=12) versus those patients without AR-V7 expression (n=19) resulted in a lower PSA response rate (0% vs 53%; P=0.004) and shorter median progression-free survival (PFS) (1.4mo vs 6.0mo; P<0.001), clinical or radiographic PFS (2.1mo vs 6.1mo; P<0.001), and overall survival (5.5mo vs not reached; P=0.002) (PMID: 25184630).",
            "molecularProfile": {
                "id": 32839,
                "profileName": "AR V7_splice"
            },
            "therapy": {
                "id": 1262,
                "therapyName": "Enzalutamide",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15846,
                    "pubMedId": 25184630,
                    "title": "AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25184630"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17874,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, treatment with Zytiga (abiraterone) in patients with metastatic castration resistant prostate cancer expressing AR-V7 in circulating tumor cells (n=6) versus those patients without AR-V7 expression (n=25) resulted in a lower PSA response rate (0% vs 68%; P=0.004) and shorter median progression-free survival (PFS) (1.3mo vs not reached; P<0.001), clinical or radiographic PFS (2.3mo vs not reached; P<0.001), and overall survival (10.6mo vs not reached; P=0.006) (PMID: 25184630).",
            "molecularProfile": {
                "id": 32839,
                "profileName": "AR V7_splice"
            },
            "therapy": {
                "id": 1805,
                "therapyName": "Abiraterone",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15846,
                    "pubMedId": 25184630,
                    "title": "AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25184630"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17963,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, metastatic castrate-resistant prostate cancer patients harboring a Wnt pathway activating alteration (CTNNB1 activating mutation, or APC or RNF43 inactivating mutation) demonstrated shorter median overall survival (23.6 mo vs 27.7 mo) and median time to PSA progression (6.5 mo vs 9.6 mo) compared to patients without Wnt pathway alterations, and APC or RNF43 inactivating mutations were independently associated with increased hazard of PSA progression (aHR 1.83; p=0.004) (PMID: 31176623).",
            "molecularProfile": {
                "id": 1734,
                "profileName": "APC inact mut"
            },
            "therapy": {
                "id": 1805,
                "therapyName": "Abiraterone",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 15936,
                    "pubMedId": 31176623,
                    "title": "Wnt-pathway Activating Mutations Are Associated with Resistance to First-line Abiraterone and Enzalutamide in Castration-resistant Prostate Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31176623"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 17964,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, metastatic castrate-resistant prostate cancer patients harboring a Wnt pathway activating alteration (CTNNB1 activating mutation, or APC or RNF43 inactivating mutation) demonstrated shorter median overall survival (23.6 mo vs 27.7 mo) and median time to PSA progression (6.5 mo vs 9.6 mo) compared to patients without Wnt pathway alterations, and APC or RNF43 inactivating mutations were independently associated with increased hazard of PSA progression (aHR 1.83; p=0.004) (PMID: 31176623).",
            "molecularProfile": {
                "id": 1734,
                "profileName": "APC inact mut"
            },
            "therapy": {
                "id": 1262,
                "therapyName": "Enzalutamide",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 15936,
                    "pubMedId": 31176623,
                    "title": "Wnt-pathway Activating Mutations Are Associated with Resistance to First-line Abiraterone and Enzalutamide in Castration-resistant Prostate Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31176623"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 17965,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, metastatic castrate-resistant prostate cancer patients harboring a Wnt pathway activating alteration (CTNNB1 activating mutation, or APC or RNF43 inactivating mutation) demonstrated shorter median overall survival (23.6 mo vs 27.7 mo) and median time to PSA progression (6.5 mo vs 9.6 mo) compared to patients without Wnt pathway alterations, and APC or RNF43 inactivating mutations were independently associated with increased hazard of PSA progression (aHR 1.83; p=0.004) (PMID: 31176623).",
            "molecularProfile": {
                "id": 8767,
                "profileName": "RNF43 inact mut"
            },
            "therapy": {
                "id": 1805,
                "therapyName": "Abiraterone",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 15936,
                    "pubMedId": 31176623,
                    "title": "Wnt-pathway Activating Mutations Are Associated with Resistance to First-line Abiraterone and Enzalutamide in Castration-resistant Prostate Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31176623"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 17966,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, metastatic castrate-resistant prostate cancer patients harboring a Wnt pathway activating alteration (CTNNB1 activating mutation, or APC or RNF43 inactivating mutation) demonstrated shorter median overall survival (23.6 mo vs 27.7 mo) and median time to PSA progression (6.5 mo vs 9.6 mo) compared to patients without Wnt pathway alterations, and APC or RNF43 inactivating mutations were independently associated with increased hazard of PSA progression (aHR 1.83; p=0.004) (PMID: 31176623).",
            "molecularProfile": {
                "id": 8767,
                "profileName": "RNF43 inact mut"
            },
            "therapy": {
                "id": 1262,
                "therapyName": "Enzalutamide",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 15936,
                    "pubMedId": 31176623,
                    "title": "Wnt-pathway Activating Mutations Are Associated with Resistance to First-line Abiraterone and Enzalutamide in Castration-resistant Prostate Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31176623"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 18707,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I/II trial, Onalespib (AT13387) in combination with Zytiga (abiraterone) and Adasone (prednisone) did not result in objective response or response in PSA in patients with advanced castration-resistant prostate cancer (PMID: 31113841; NCT01685268).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 8816,
                "therapyName": "Abiraterone + Onalespib + Prednisone",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 16393,
                    "pubMedId": 31113841,
                    "title": "Pharmacodynamic and Clinical Results from a Phase I/II Study of the HSP90 Inhibitor Onalespib in Combination with Abiraterone Acetate in Prostate Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31113841"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18990,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AR M896T (reported as M895T) was associated with decreased antagonism and aberrant agonism by Casodex (bicalutamide) in transactivation assays in cultured prostate cancer cells (PMID: 26760770).",
            "molecularProfile": {
                "id": 1494,
                "profileName": "AR M896T"
            },
            "therapy": {
                "id": 1507,
                "therapyName": "Bicalutamide",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 11247,
                    "pubMedId": 26760770,
                    "title": "BAY 1024767 blocks androgen receptor mutants found in castration-resistant prostate cancer patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26760770"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19630,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Zytiga (abiraterone) treatment suppressed activation of AR in CYP17A1-positive, castration-resistant prostate cancer cell lines in culture, and inhibited tumor growth in an Xtandi (enzalutamide)-resistant cell line xenograft model (PMID: 25351916).",
            "molecularProfile": {
                "id": 34334,
                "profileName": "CYP17A1 positive"
            },
            "therapy": {
                "id": 1805,
                "therapyName": "Abiraterone",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17317,
                    "pubMedId": 25351916,
                    "title": "Anticancer activity of a novel selective CYP17A1 inhibitor in preclinical models of castrate-resistant prostate cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25351916"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19631,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, VT-464 treatment improved efficacy over Zytiga (abiraterone) treatment, including increased suppression of Ar activation in CYP17A1-positive, castration-resistant prostate cancer cell lines in culture, and greater tumor growth inhibition and survival in an Xtandi (enzalutamide)-resistant cell line xenograft model (PMID: 25351916).",
            "molecularProfile": {
                "id": 34334,
                "profileName": "CYP17A1 positive"
            },
            "therapy": {
                "id": 2822,
                "therapyName": "VT-464",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17317,
                    "pubMedId": 25351916,
                    "title": "Anticancer activity of a novel selective CYP17A1 inhibitor in preclinical models of castrate-resistant prostate cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25351916"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19699,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with prostate cancer harboring a germline mutation, BRCA2 S1982fs, and a secondary somatic mutation, BRCA2 H1918fs, progressed while being treated with Lynparza (olaparib), and was found via ctDNA testing to have acquired 11 BRCA2 mutations that were predicted to restore the BRCA2 open reading frame, BRCA2 S1982_A1996del, S1985fs, S1989fs, Q1987fs, Q1998fs, A1981_V1986delinsI, F2000fs, S1982_K1984del, E1912fs, and S917_H1918del (PMID: 31501807).",
            "molecularProfile": {
                "id": 34436,
                "profileName": "BRCA2 S917_H1918del BRCA2 E1912fs BRCA2 H1918fs BRCA2 A1981_V1986delinsI BRCA2 S1982_A1996del BRCA2 S1982_K1984del BRCA2 S1982fs BRCA2 S1985fs BRCA2 Q1987fs BRCA2 S1989fs BRCA2 Q1998fs BRCA2 F2000fs"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 16759,
                    "pubMedId": 31501807,
                    "title": "Acquired Resistance to Poly (ADP-ribose) Polymerase Inhibitor Olaparib in BRCA2-Associated Prostate Cancer Resulting From Biallelic BRCA2 Reversion Mutations Restores Both Germline and Somatic Loss-of-Function Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31501807"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19868,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MYCi975 treatment inhibited colony formation in a Myc-positive prostate cancer cell line in culture, and inhibited tumor growth, and increased survival in a mouse model (PMID: 31679823).",
            "molecularProfile": {
                "id": 15187,
                "profileName": "MYC positive"
            },
            "therapy": {
                "id": 9235,
                "therapyName": "MYCi975",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17557,
                    "pubMedId": 31679823,
                    "title": "Small-Molecule MYC Inhibitors Suppress Tumor Growth and Enhance Immunotherapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31679823"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19872,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MYCi975 combined with an anti-PD1 therapy synergistically inhibited tumor growth in a mouse model of prostate cancer (PMID: 31679823).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 9236,
                "therapyName": "MYCi975 + unspecified PD-1 antibody",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 17557,
                    "pubMedId": 31679823,
                    "title": "Small-Molecule MYC Inhibitors Suppress Tumor Growth and Enhance Immunotherapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31679823"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 20290,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KCI807 treatment inhibited growth of AR-positive prostate cancer cell lines in culture, and inhibited tumor growth in a patient-derived xenograft (PDX) model (PMID: 30185422).",
            "molecularProfile": {
                "id": 2795,
                "profileName": "AR positive"
            },
            "therapy": {
                "id": 9310,
                "therapyName": "KCI807",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17793,
                    "pubMedId": 30185422,
                    "title": "Strategy for Tumor-Selective Disruption of Androgen Receptor Function in the Spectrum of Prostate Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30185422"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20302,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KCI807 treatment inhibited growth of an Xtandi (enzalutamide)-resistant prostate cancer cell line expressing AR F877L in culture (PMID: 30185422).",
            "molecularProfile": {
                "id": 26465,
                "profileName": "AR F877L"
            },
            "therapy": {
                "id": 9310,
                "therapyName": "KCI807",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17793,
                    "pubMedId": 30185422,
                    "title": "Strategy for Tumor-Selective Disruption of Androgen Receptor Function in the Spectrum of Prostate Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30185422"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20416,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MI-503 treatment inhibited Men1 and Kmt2a interaction, led to inhibition of AR signaling and induction of apoptosis in KMT2A- and MEN1-positive prostate cancer cell lines in culture, and tumor growth inhibition in cell line xenograft models (PMID: 25822367).",
            "molecularProfile": {
                "id": 35164,
                "profileName": "KMT2A pos MEN1 pos"
            },
            "therapy": {
                "id": 6006,
                "therapyName": "MI-503",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17831,
                    "pubMedId": 25822367,
                    "title": "Targeting the MLL complex in castration-resistant prostate cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25822367"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20420,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MI-503 and Xtandi (enzalutamide) combination treatment resulted in greater tumor growth inhibition compared to MI-503 treatment alone in cell line xenograft models of AR-, KMT2A- and MEN1-positive prostate cancer (PMID: 25822367).",
            "molecularProfile": {
                "id": 35165,
                "profileName": "AR pos KMT2A pos MEN1 pos"
            },
            "therapy": {
                "id": 9344,
                "therapyName": "Enzalutamide + MI-503",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17831,
                    "pubMedId": 25822367,
                    "title": "Targeting the MLL complex in castration-resistant prostate cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25822367"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20453,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KCI807 treatment inhibited colony formation and growth of prostate cancer cell lines expressing AR V7_splice and AR in culture, and inhibited tumor growth in a cell line xenograft model (PMID: 30185422).",
            "molecularProfile": {
                "id": 35181,
                "profileName": "AR V7_splice AR pos"
            },
            "therapy": {
                "id": 9310,
                "therapyName": "KCI807",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17793,
                    "pubMedId": 30185422,
                    "title": "Strategy for Tumor-Selective Disruption of Androgen Receptor Function in the Spectrum of Prostate Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30185422"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20454,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II (TOPARP-B) trial, Lynparza (olaparib) treatment resulted in a composite overall response rate of 83.3% (25/30) and a RECIST objective response rate of 52.4% (11/21) in patients with castration-resistant prostate cancer harboring deleterious mutations or homozygous deletion of BRCA1/2 (PMID: 31806540; NCT01682772).",
            "molecularProfile": {
                "id": 1282,
                "profileName": "BRCA1 inact mut"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17849,
                    "pubMedId": 31806540,
                    "title": "Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31806540"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 20455,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II (TOPARP-B) trial, Lynparza (olaparib) treatment resulted in a composite overall response rate of 83.3% (25/30) and a RECIST objective response rate of 52.4% (11/21) in patients with castration-resistant prostate cancer harboring deleterious mutations or homozygous deletion of BRCA1/2 (PMID: 31806540; NCT01682772).",
            "molecularProfile": {
                "id": 1283,
                "profileName": "BRCA2 inact mut"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17849,
                    "pubMedId": 31806540,
                    "title": "Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31806540"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 20456,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II (TOPARP-B) trial, Lynparza (olaparib) treatment resulted in a composite overall response rate of 83.3% (25/30) and a RECIST objective response rate of 52.4% (11/21) in patients with castration-resistant prostate cancer harboring deleterious mutations or homozygous deletion of BRCA1/2 (PMID: 31806540; NCT01682772).",
            "molecularProfile": {
                "id": 11671,
                "profileName": "BRCA2 del"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17849,
                    "pubMedId": 31806540,
                    "title": "Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31806540"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 20458,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II (TOPARP-B) trial, Lynparza (olaparib) treatment resulted in a composite overall response rate of 25.0% (5/20) and a RECIST objective response rate of 0% (0/18) in patients with castration-resistant prostate cancer harboring deleterious CDK12 mutations (PMID: 31806540; NCT01682772).",
            "molecularProfile": {
                "id": 17964,
                "profileName": "CDK12 inact mut"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17849,
                    "pubMedId": 31806540,
                    "title": "Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31806540"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 20459,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II (TOPARP-B) trial, Lynparza (olaparib) treatment resulted in a composite overall response rate of 57.1% (4/7) and a RECIST objective response rate of 33.3% (2/6) in patients with castration-resistant prostate cancer harboring deleterious PALB2 mutations (PMID: 31806540; NCT01682772).",
            "molecularProfile": {
                "id": 7711,
                "profileName": "PALB2 inact mut"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17849,
                    "pubMedId": 31806540,
                    "title": "Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31806540"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 20460,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II (TOPARP-B) trial, Lynparza (olaparib) treatment resulted in a composite overall response rate of 20.0% (4/20) and a RECIST objective response rate of 0% (0/17) in patients with castration-resistant prostate cancer harboring deleterious mutations in DNA damage response genes, including ARID1A, ATRX, CHEK1/2, FANCA, FANCF, FANCG, FANCI, FANCM, MSH2, NBN, RAD50, and WRN (n=1, 1, 1, 5, 5, 2, 1, 1, 2, 1, 1, 1, 7, respectively) (PMID: 31806540; NCT01682772).",
            "molecularProfile": {
                "id": 9070,
                "profileName": "ARID1A inact mut"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17849,
                    "pubMedId": 31806540,
                    "title": "Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31806540"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20461,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II (TOPARP-B) trial, Lynparza (olaparib) treatment resulted in a composite overall response rate of 20.0% (4/20) and a RECIST objective response rate of 0% (0/17) in patients with castration-resistant prostate cancer harboring deleterious mutations in DNA damage response genes, including ARID1A, ATRX, CHEK1/2, FANCA, FANCF, FANCG, FANCI, FANCM, MSH2, NBN, RAD50, and WRN (n=1, 1, 1, 5, 5, 2, 1, 1, 2, 1, 1, 1, 7, respectively) (PMID: 31806540; NCT01682772).",
            "molecularProfile": {
                "id": 23602,
                "profileName": "ATRX inact mut"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17849,
                    "pubMedId": 31806540,
                    "title": "Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31806540"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20462,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II (TOPARP-B) trial, Lynparza (olaparib) treatment resulted in a composite overall response rate of 20.0% (4/20) and a RECIST objective response rate of 0% (0/17) in patients with castration-resistant prostate cancer harboring deleterious mutations in DNA damage response genes, including ARID1A, ATRX, CHEK1/2, FANCA, FANCF, FANCG, FANCI, FANCM, MSH2, NBN, RAD50, and WRN (n=1, 1, 1, 5, 5, 2, 1, 1, 2, 1, 1, 1, 7, respectively) (PMID: 31806540; NCT01682772).",
            "molecularProfile": {
                "id": 27363,
                "profileName": "CHEK1 inact mut"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17849,
                    "pubMedId": 31806540,
                    "title": "Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31806540"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20463,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II (TOPARP-B) trial, Lynparza (olaparib) treatment resulted in a composite overall response rate of 20.0% (4/20) and a RECIST objective response rate of 0% (0/17) in patients with castration-resistant prostate cancer harboring deleterious mutations in DNA damage response genes, including ARID1A, ATRX, CHEK1/2, FANCA, FANCF, FANCG, FANCI, FANCM, MSH2, NBN, RAD50, and WRN (n=1, 1, 1, 5, 5, 2, 1, 1, 2, 1, 1, 1, 7, respectively) (PMID: 31806540; NCT01682772).",
            "molecularProfile": {
                "id": 5926,
                "profileName": "CHEK2 inact mut"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17849,
                    "pubMedId": 31806540,
                    "title": "Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31806540"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20464,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II (TOPARP-B) trial, Lynparza (olaparib) treatment resulted in a composite overall response rate of 20.0% (4/20) and a RECIST objective response rate of 0% (0/17) in patients with castration-resistant prostate cancer harboring deleterious mutations in DNA damage response genes, including ARID1A, ATRX, CHEK1/2, FANCA, FANCF, FANCG, FANCI, FANCM, MSH2, NBN, RAD50, and WRN (n=1, 1, 1, 5, 5, 2, 1, 1, 2, 1, 1, 1, 7, respectively) (PMID: 31806540; NCT01682772).",
            "molecularProfile": {
                "id": 28030,
                "profileName": "FANCA inact mut"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17849,
                    "pubMedId": 31806540,
                    "title": "Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31806540"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20465,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II (TOPARP-B) trial, Lynparza (olaparib) treatment resulted in a composite overall response rate of 20.0% (4/20) and a RECIST objective response rate of 0% (0/17) in patients with castration-resistant prostate cancer harboring deleterious mutations in DNA damage response genes, including ARID1A, ATRX, CHEK1/2, FANCA, FANCF, FANCG, FANCI, FANCM, MSH2, NBN, RAD50, and WRN (n=1, 1, 1, 5, 5, 2, 1, 1, 2, 1, 1, 1, 7, respectively) (PMID: 31806540; NCT01682772).",
            "molecularProfile": {
                "id": 28027,
                "profileName": "FANCF inact mut"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17849,
                    "pubMedId": 31806540,
                    "title": "Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31806540"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20466,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II (TOPARP-B) trial, Lynparza (olaparib) treatment resulted in a composite overall response rate of 20.0% (4/20) and a RECIST objective response rate of 0% (0/17) in patients with castration-resistant prostate cancer harboring deleterious mutations in DNA damage response genes, including ARID1A, ATRX, CHEK1/2, FANCA, FANCF, FANCG, FANCI, FANCM, MSH2, NBN, RAD50, and WRN (n=1, 1, 1, 5, 5, 2, 1, 1, 2, 1, 1, 1, 7, respectively) (PMID: 31806540; NCT01682772).",
            "molecularProfile": {
                "id": 28026,
                "profileName": "FANCG inact mut"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17849,
                    "pubMedId": 31806540,
                    "title": "Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31806540"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20467,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II (TOPARP-B) trial, Lynparza (olaparib) treatment resulted in a composite overall response rate of 20.0% (4/20) and a RECIST objective response rate of 0% (0/17) in patients with castration-resistant prostate cancer harboring deleterious mutations in DNA damage response genes, including ARID1A, ATRX, CHEK1/2, FANCA, FANCF, FANCG, FANCI, FANCM, MSH2, NBN, RAD50, and WRN (n=1, 1, 1, 5, 5, 2, 1, 1, 2, 1, 1, 1, 7, respectively) (PMID: 31806540; NCT01682772).",
            "molecularProfile": {
                "id": 35184,
                "profileName": "FANCI inact mut"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17849,
                    "pubMedId": 31806540,
                    "title": "Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31806540"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20468,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II (TOPARP-B) trial, Lynparza (olaparib) treatment resulted in a composite overall response rate of 20.0% (4/20) and a RECIST objective response rate of 0% (0/17) in patients with castration-resistant prostate cancer harboring deleterious mutations in DNA damage response genes, including ARID1A, ATRX, CHEK1/2, FANCA, FANCF, FANCG, FANCI, FANCM, MSH2, NBN, RAD50, and WRN (n=1, 1, 1, 5, 5, 2, 1, 1, 2, 1, 1, 1, 7, respectively) (PMID: 31806540; NCT01682772).",
            "molecularProfile": {
                "id": 17689,
                "profileName": "FANCM inact mut"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17849,
                    "pubMedId": 31806540,
                    "title": "Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31806540"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20469,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II (TOPARP-B) trial, Lynparza (olaparib) treatment resulted in a composite overall response rate of 20.0% (4/20) and a RECIST objective response rate of 0% (0/17) in patients with castration-resistant prostate cancer harboring deleterious mutations in DNA damage response genes, including ARID1A, ATRX, CHEK1/2, FANCA, FANCF, FANCG, FANCI, FANCM, MSH2, NBN, RAD50, and WRN (n=1, 1, 1, 5, 5, 2, 1, 1, 2, 1, 1, 1, 7, respectively) (PMID: 31806540; NCT01682772).",
            "molecularProfile": {
                "id": 16861,
                "profileName": "MSH2 inact mut"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17849,
                    "pubMedId": 31806540,
                    "title": "Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31806540"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20470,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II (TOPARP-B) trial, Lynparza (olaparib) treatment resulted in a composite overall response rate of 20.0% (4/20) and a RECIST objective response rate of 0% (0/17) in patients with castration-resistant prostate cancer harboring deleterious mutations in DNA damage response genes, including ARID1A, ATRX, CHEK1/2, FANCA, FANCF, FANCG, FANCI, FANCM, MSH2, NBN, RAD50, and WRN (n=1, 1, 1, 5, 5, 2, 1, 1, 2, 1, 1, 1, 7, respectively) (PMID: 31806540; NCT01682772).",
            "molecularProfile": {
                "id": 16862,
                "profileName": "NBN inact mut"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17849,
                    "pubMedId": 31806540,
                    "title": "Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31806540"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20471,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II (TOPARP-B) trial, Lynparza (olaparib) treatment resulted in a composite overall response rate of 20.0% (4/20) and a RECIST objective response rate of 0% (0/17) in patients with castration-resistant prostate cancer harboring deleterious mutations in DNA damage response genes, including ARID1A, ATRX, CHEK1/2, FANCA, FANCF, FANCG, FANCI, FANCM, MSH2, NBN, RAD50, and WRN (n=1, 1, 1, 5, 5, 2, 1, 1, 2, 1, 1, 1, 7, respectively) (PMID: 31806540; NCT01682772).",
            "molecularProfile": {
                "id": 5730,
                "profileName": "RAD50 inact mut"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17849,
                    "pubMedId": 31806540,
                    "title": "Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31806540"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20472,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II (TOPARP-B) trial, Lynparza (olaparib) treatment resulted in a composite overall response rate of 20.0% (4/20) and a RECIST objective response rate of 0% (0/17) in patients with castration-resistant prostate cancer harboring deleterious mutations in DNA damage response genes, including ARID1A, ATRX, CHEK1/2, FANCA, FANCF, FANCG, FANCI, FANCM, MSH2, NBN, RAD50, and WRN (n=1, 1, 1, 5, 5, 2, 1, 1, 2, 1, 1, 1, 7, respectively) (PMID: 31806540; NCT01682772).",
            "molecularProfile": {
                "id": 28022,
                "profileName": "WRN inact mut"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17849,
                    "pubMedId": 31806540,
                    "title": "Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31806540"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20623,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (TRITON2), activity of Rubraca (rucaparib) was limited in the cohort of patients with metastatic castrate-resistant prostate cancer harboring an ATM mutation presumed to be inactivating, with a radiographic response rate of 10.5% (2/19, including 1 patient with co-occurring CHEK2 alteration) and PSA response rate of 4.1% (2/49), and no radiographic responses in 11 patients with biallelic alterations in ATM or 11 patients with germline ATM alterations (PMID: 32086346; NCT02952534).",
            "molecularProfile": {
                "id": 522,
                "profileName": "ATM inact mut"
            },
            "therapy": {
                "id": 906,
                "therapyName": "Rucaparib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 17973,
                    "pubMedId": 32086346,
                    "title": "Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: analysis from the phase 2 TRITON2 study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/32086346"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 20625,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (TRITON2), activity of Rubraca (rucaparib) was limited in the cohort of patients with metastatic castrate-resistant prostate cancer harboring a CDK12 mutation presumed to be inactivating, with no confirmed radiographic responses in 10 evaluable patients and a PSA response in 1 patient with biallelic CDK12 alterations in the overall population of 15 patients, and a clinical benefit rate of 20% (3/15) at 6 months and 7.1% (1/14) at 12 months (PMID: 32086346; NCT02952534).",
            "molecularProfile": {
                "id": 17964,
                "profileName": "CDK12 inact mut"
            },
            "therapy": {
                "id": 906,
                "therapyName": "Rucaparib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 17973,
                    "pubMedId": 32086346,
                    "title": "Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: analysis from the phase 2 TRITON2 study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/32086346"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 20626,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (TRITON2), activity of Rubraca (rucaparib) was limited in the cohort of patients with metastatic castrate-resistant prostate cancer harboring a CHEK2 mutation presumed to be inactivating, with a radiographic partial response in 1 patient who had a co-occurring ATM alteration out of 9 evaluable patients, and PSA response rate of 16.7% (2/12), and a clinical benefit rate of 37.5% (3/8) at 6 months, with no patients remaining on treatment at 12 months (PMID: 32086346; NCT02952534).",
            "molecularProfile": {
                "id": 5926,
                "profileName": "CHEK2 inact mut"
            },
            "therapy": {
                "id": 906,
                "therapyName": "Rucaparib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 17973,
                    "pubMedId": 32086346,
                    "title": "Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: analysis from the phase 2 TRITON2 study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/32086346"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 20627,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (TRITON2), 2 of 2 patients with deleterious PALB2 alterations demonstrated a PSA response after treatment with Rubraca (rucaparib), with one of those patients demonstrating partial radiographic response that was ongoing 3.9 months, and the other a 47% reduction in tumor volume (PMID: 32086346; NCT02952534).",
            "molecularProfile": {
                "id": 7711,
                "profileName": "PALB2 inact mut"
            },
            "therapy": {
                "id": 906,
                "therapyName": "Rucaparib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17973,
                    "pubMedId": 32086346,
                    "title": "Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: analysis from the phase 2 TRITON2 study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/32086346"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20629,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (TRITON2), 1 of 2 patients with deleterious BRIP1 alterations demonstrated a PSA response and partial radiographic response after treatment with Rubraca (rucaparib), which were ongoing at the time of visit cutoff (PMID: 32086346; NCT02952534).",
            "molecularProfile": {
                "id": 27362,
                "profileName": "BRIP1 inact mut"
            },
            "therapy": {
                "id": 906,
                "therapyName": "Rucaparib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17973,
                    "pubMedId": 32086346,
                    "title": "Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: analysis from the phase 2 TRITON2 study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/32086346"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20631,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (TRITON2), the patient harboring a RAD51B rearrangement demonstrated a PSA response and partial radiographic response after treatment with Rubraca (rucaparib), which were ongoing at the time of visit cutoff (PMID: 32086346; NCT02952534).",
            "molecularProfile": {
                "id": 35272,
                "profileName": "RAD51B rearrange"
            },
            "therapy": {
                "id": 906,
                "therapyName": "Rucaparib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17973,
                    "pubMedId": 32086346,
                    "title": "Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: analysis from the phase 2 TRITON2 study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/32086346"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20633,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, 1 of 4 patients with deleterious FANCA alterations demonstrated a PSA response and complete radiographic response, which were ongoing at the time of visit cutoff (PMID: 32086346; NCT02952534).",
            "molecularProfile": {
                "id": 28030,
                "profileName": "FANCA inact mut"
            },
            "therapy": {
                "id": 906,
                "therapyName": "Rucaparib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17973,
                    "pubMedId": 32086346,
                    "title": "Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: analysis from the phase 2 TRITON2 study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/32086346"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20764,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Xtandi (enzalutamide) treatment resulted in greater inhibition of AR signaling, androgen biosynthesis genes expression, and proliferation in prostate cancer cells harboring TMPRSS2-ERG compared to ERG knockdown cells in culture, and significantly reduced tumor burden in an intratibial xenograft model (PMID: 31638934).",
            "molecularProfile": {
                "id": 35331,
                "profileName": "TMPRSS2 - ERG AR pos"
            },
            "therapy": {
                "id": 1262,
                "therapyName": "Enzalutamide",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18033,
                    "pubMedId": 31638934,
                    "title": "TMPRSS2-ERG fusions confer efficacy of enzalutamide in an in vivo bone tumor growth model.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31638934"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20779,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, overexpressing TMPRSS2-ERG in AR-negative prostate cancer cells did not confer sensitivity to Lynparza (olaparib) in cell culture (PMID: 29465803).",
            "molecularProfile": {
                "id": 35332,
                "profileName": "TMPRSS2 - ERG AR neg"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 18040,
                    "pubMedId": 29465803,
                    "title": "Olaparib is effective in combination with, and as maintenance therapy after, first-line endocrine therapy in prostate cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29465803"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20792,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II (NCI 9012) trial, the presence of ERG rearrangement or ETV1 fusion did not predict PSA response rate, measurable disease response rate, or median progression-free survival in patients with metastatic castration-resistant prostate cancer treated with Veliparib (ABT-888), Zytiga (abiraterone), and Prednisone combination therapy (PMID: 29261439; NCT01576172).",
            "molecularProfile": {
                "id": 35334,
                "profileName": "ERG rearrange"
            },
            "therapy": {
                "id": 5913,
                "therapyName": "Abiraterone + Prednisone + Veliparib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "not predictive",
            "references": [
                {
                    "id": 18044,
                    "pubMedId": 29261439,
                    "title": "Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29261439"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 20793,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II (NCI 9012) trial, the presence of ERG rearrangement or ETV1 fusion did not predict PSA response rate, measurable disease response rate, or median progression-free survival in patients with metastatic castration-resistant prostate cancer treated with Veliparib (ABT-888), Zytiga (abiraterone), and Prednisone combination therapy (PMID: 29261439; NCT01576172).",
            "molecularProfile": {
                "id": 17090,
                "profileName": "ETV1 fusion"
            },
            "therapy": {
                "id": 5913,
                "therapyName": "Abiraterone + Prednisone + Veliparib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "not predictive",
            "references": [
                {
                    "id": 18044,
                    "pubMedId": 29261439,
                    "title": "Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29261439"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 20803,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, the presence of ERG rearrangement was not associated with response to Zejula (niraparib) treatment in patients with castration-resistant prostate cancer (PMID: 23810788; NCT00749502).",
            "molecularProfile": {
                "id": 35334,
                "profileName": "ERG rearrange"
            },
            "therapy": {
                "id": 832,
                "therapyName": "Niraparib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "not predictive",
            "references": [
                {
                    "id": 1986,
                    "pubMedId": 23810788,
                    "title": "The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23810788"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 20804,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, negative PTEN IHC staining was not associated with response to Zejula (niraparib) treatment in patients with castration-resistant prostate cancer (PMID: 23810788; NCT00749502).",
            "molecularProfile": {
                "id": 2077,
                "profileName": "PTEN negative"
            },
            "therapy": {
                "id": 832,
                "therapyName": "Niraparib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "not predictive",
            "references": [
                {
                    "id": 1986,
                    "pubMedId": 23810788,
                    "title": "The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23810788"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 20805,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, the presence of ETV1 rearrangement was not associated with response to Zejula (niraparib) treatment in patients with castration-resistant prostate cancer (PMID: 23810788; NCT00749502).",
            "molecularProfile": {
                "id": 20932,
                "profileName": "ETV1 rearrange"
            },
            "therapy": {
                "id": 832,
                "therapyName": "Niraparib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "not predictive",
            "references": [
                {
                    "id": 1986,
                    "pubMedId": 23810788,
                    "title": "The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23810788"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 20808,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, a patient with prostate cancer harboring a BRCA2 mutation was refractory to Zejula (niraparib) treatment (PMID: 23810788; NCT00749502).",
            "molecularProfile": {
                "id": 1206,
                "profileName": "BRCA2 mutant"
            },
            "therapy": {
                "id": 832,
                "therapyName": "Niraparib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 1986,
                    "pubMedId": 23810788,
                    "title": "The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23810788"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20816,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Birabresib (OTX015) treatment inhibited tumor growth in a cell line xenograft model of prostate cancer (PMID: 27274052).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2034,
                "therapyName": "Birabresib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 17852,
                    "pubMedId": 27274052,
                    "title": "PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27274052"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 20817,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ARV-771 treatment induced apoptosis and inhibited proliferation of prostate cancer cell lines in culture, and inhibited tumor growth and induced regression in a cell line xenograft model (PMID: 27274052).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 9364,
                "therapyName": "ARV-771",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 17852,
                    "pubMedId": 27274052,
                    "title": "PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27274052"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 20937,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, P-PSMA-101 CAR-T cell treatment inhibited tumor growth and increased survival in a FOLH1 (PSMA)-positive prostate cancer cell line xenograft model (Cancer Res 2018;78(16 Suppl):Abstract nr A071).",
            "molecularProfile": {
                "id": 26143,
                "profileName": "FOLH1 positive"
            },
            "therapy": {
                "id": 9528,
                "therapyName": "P-PSMA-101 CAR-T cells",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 18202,
                    "pubMedId": null,
                    "title": "PSMA-specific CARTyrin T-stem cell memory therapy eliminates solid tumor in subcutaneous prostate cancer model",
                    "url": "https://cancerres.aacrjournals.org/content/78/16_Supplement/A071"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT00670046",
            "title": "Valproic Acid in Treating Patients With Progressive, Non-Metastatic Prostate Cancer",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1076,
                    "therapyName": "Valproic acid",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT00892736",
            "title": "Veliparib in Treating Patients With Malignant Solid Tumors That Did Not Respond to Previous Therapy",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 954,
                    "therapyName": "Veliparib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT00942331",
            "title": "Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1295,
                    "therapyName": "Bevacizumab + Cisplatin + Gemcitabine",
                    "synonyms": null
                },
                {
                    "id": 1467,
                    "therapyName": "Cisplatin + Gemcitabine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01254864",
            "title": "Maximum Androgen Depletion",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1817,
                    "therapyName": "Abiraterone + Sunitinib",
                    "synonyms": null
                },
                {
                    "id": 1818,
                    "therapyName": "Abiraterone + Dasatinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01286987",
            "title": "Study of BMN 673, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 682,
                    "therapyName": "Talazoparib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01353625",
            "title": "Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1000,
                    "therapyName": "CC-115",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01436968",
            "title": "Phase 3 Study of ProstAtak Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5171,
                    "therapyName": "Valacyclovir",
                    "synonyms": null
                },
                {
                    "id": 5172,
                    "therapyName": "AdV-tk + Valacyclovir",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01480154",
            "title": "Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1393,
                    "therapyName": "Hydroxychloroquine + MK2206",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01517802",
            "title": "A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1805,
                    "therapyName": "Abiraterone",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01530984",
            "title": "Ipilimumab and GMCSF Immunotherapy for Prostate Cancer",
            "phase": "Phase II",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 1873,
                    "therapyName": "Sargramostim",
                    "synonyms": null
                },
                {
                    "id": 779,
                    "therapyName": "Ipilimumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01540526",
            "title": "Pharmacodynamic Study With FLT-PET/CT in Patients With Prostate/Other Solid Malignancies Treated With High Dose Axitinib",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 649,
                    "therapyName": "Axitinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01543776",
            "title": "Food Effect Study of Abiraterone Acetate for Treatment of Patients With Castration-Resistant Prostate Cancer",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1805,
                    "therapyName": "Abiraterone",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01553188",
            "title": "AMG 386 and Abiraterone for Advanced Prostate Cancer",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2188,
                    "therapyName": "Prednisone",
                    "synonyms": null
                },
                {
                    "id": 1805,
                    "therapyName": "Abiraterone",
                    "synonyms": null
                },
                {
                    "id": 1218,
                    "therapyName": "Trebananib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01576172",
            "title": "Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2748,
                    "therapyName": "Abiraterone + Prednisone",
                    "synonyms": null
                },
                {
                    "id": 5913,
                    "therapyName": "Abiraterone + Prednisone + Veliparib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01587703",
            "title": "A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 784,
                    "therapyName": "GSK525762",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01607905",
            "title": "Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced or Metastatic Solid Tumor Cancer",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1749,
                    "therapyName": "Selinexor",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01620593",
            "title": "Castration Compared to Castration Plus Metformin as First Line Treatment for Patients With Advanced Prostate Cancer",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1031,
                    "therapyName": "Metformin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01674270",
            "title": "Degarelix Neo-Adjuvant Radical Prostatectomy Trial",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1507,
                    "therapyName": "Bicalutamide",
                    "synonyms": null
                },
                {
                    "id": 1814,
                    "therapyName": "Degarelix",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01683994",
            "title": "Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2069,
                    "therapyName": "Cabozantinib + Docetaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01685125",
            "title": "Abiraterone Acetate and Prednisone With or Without Dasatinib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer",
            "phase": "Phase II",
            "recruitment": "Unknown status",
            "therapies": [
                {
                    "id": 717,
                    "therapyName": "Dasatinib",
                    "synonyms": null
                },
                {
                    "id": 1805,
                    "therapyName": "Abiraterone",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01715285",
            "title": "A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC)",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2748,
                    "therapyName": "Abiraterone + Prednisone",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01717053",
            "title": "Abiraterone, Radiotherapy and Short-Term Androgen Deprivation in Unfavorable Localized Prostate Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 795,
                    "therapyName": "Leuprolide",
                    "synonyms": null
                },
                {
                    "id": 1805,
                    "therapyName": "Abiraterone",
                    "synonyms": null
                },
                {
                    "id": 2188,
                    "therapyName": "Prednisone",
                    "synonyms": null
                },
                {
                    "id": 759,
                    "therapyName": "Goserelin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01730118",
            "title": "Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1404,
                    "therapyName": "HER2 Vaccine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01741753",
            "title": "BKM120+Abiraterone Acetate for Metastatic CRPC",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 2499,
                    "therapyName": "Abiraterone + Buparlisib + Prednisone",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01751451",
            "title": "3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1805,
                    "therapyName": "Abiraterone",
                    "synonyms": null
                },
                {
                    "id": 1814,
                    "therapyName": "Degarelix",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01809691",
            "title": "S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2671,
                    "therapyName": "Orteronel",
                    "synonyms": null
                },
                {
                    "id": 1507,
                    "therapyName": "Bicalutamide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01818986",
            "title": "Sipuleucel-T and Stereotactic Ablative Body Radiation (SABR) for Metastatic Castrate-resistant Prostate Cancer (mCRPC)",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2648,
                    "therapyName": "Sipuleucel-T",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01828476",
            "title": "Navitoclax and Abiraterone Acetate With or Without Hydroxychloroquine in Treating Patients With Progressive Metastatic Castrate Refractory Prostate Cancer",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1316,
                    "therapyName": "Hydroxychloroquine",
                    "synonyms": null
                },
                {
                    "id": 2597,
                    "therapyName": "Abiraterone + Navitoclax",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01834651",
            "title": "A Phase II Study of Cabozantinib (XL184) Therapy in Castrate Resistant Prostate Cancer (CRPC) With Visceral Metastases",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 998,
                    "therapyName": "Cabozantinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01864096",
            "title": "The Metformin Active Surveillance Trial (MAST) Study",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1031,
                    "therapyName": "Metformin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01867333",
            "title": "Enzalutamide With or Without Vaccine Therapy for Advanced Prostate Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3069,
                    "therapyName": "PROSTVAC-F/TRICOM",
                    "synonyms": null
                },
                {
                    "id": 1262,
                    "therapyName": "Enzalutamide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01875250",
            "title": "Enzalutamide in Combination With PSA-TRICOM in Patients With Non-Metastatic Castration Sensitive Prostate Cancer",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 4884,
                    "therapyName": "Enzalutamide + PROSTVAC-F/TRICOM + PROSTVAC-V/TRICOM",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01884285",
            "title": "AZD8186 First Time In Patient Ascending Dose Study",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 992,
                    "therapyName": "AZD8186",
                    "synonyms": null
                },
                {
                    "id": 8263,
                    "therapyName": "Abiraterone + AZD8186",
                    "synonyms": null
                },
                {
                    "id": 5868,
                    "therapyName": "AZD8186 + Vistusertib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01913106",
            "title": "HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5172,
                    "therapyName": "AdV-tk + Valacyclovir",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01920061",
            "title": "A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1287,
                    "therapyName": "Dacomitinib + Gedatolisib",
                    "synonyms": null
                },
                {
                    "id": 1286,
                    "therapyName": "Cisplatin + Gedatolisib",
                    "synonyms": null
                },
                {
                    "id": 1285,
                    "therapyName": "Docetaxel + Gedatolisib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01966445",
            "title": "Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2919,
                    "therapyName": "GSK2849330",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01972217",
            "title": "Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2188,
                    "therapyName": "Prednisone",
                    "synonyms": null
                },
                {
                    "id": 1805,
                    "therapyName": "Abiraterone",
                    "synonyms": null
                },
                {
                    "id": 837,
                    "therapyName": "Olaparib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01989546",
            "title": "Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 682,
                    "therapyName": "Talazoparib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01990196",
            "title": "Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 717,
                    "therapyName": "Dasatinib",
                    "synonyms": null
                },
                {
                    "id": 2,
                    "therapyName": "Trametinib",
                    "synonyms": null
                },
                {
                    "id": 1815,
                    "therapyName": "Degarelix + Enzalutamide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01994590",
            "title": "Dovitinib (TKI258) and Abiraterone Acetate in Metastatic Castrate-Resistant Prostate Cancer (mCRPC)",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 721,
                    "therapyName": "Dovitinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02009449",
            "title": "A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1161,
                    "therapyName": "Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 1092,
                    "therapyName": "Carboplatin",
                    "synonyms": null
                },
                {
                    "id": 755,
                    "therapyName": "Gemcitabine",
                    "synonyms": null
                },
                {
                    "id": 720,
                    "therapyName": "Docetaxel",
                    "synonyms": null
                },
                {
                    "id": 848,
                    "therapyName": "Pazopanib",
                    "synonyms": null
                },
                {
                    "id": 1105,
                    "therapyName": "Capecitabine",
                    "synonyms": null
                },
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 700,
                    "therapyName": "Cisplatin",
                    "synonyms": null
                },
                {
                    "id": 2621,
                    "therapyName": "Pegilodecakin",
                    "synonyms": null
                },
                {
                    "id": 619,
                    "therapyName": "Nab-paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02012296",
            "title": "Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2603,
                    "therapyName": "Mifepristone",
                    "synonyms": null
                },
                {
                    "id": 1262,
                    "therapyName": "Enzalutamide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02014337",
            "title": "Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 3053,
                    "therapyName": "Eribulin + Mifepristone",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02020070",
            "title": "Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical Prostatectomy",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 779,
                    "therapyName": "Ipilimumab",
                    "synonyms": null
                },
                {
                    "id": 1814,
                    "therapyName": "Degarelix",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02028988",
            "title": "Enzalutamide + External Beam Rt For Prostate",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1262,
                    "therapyName": "Enzalutamide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02043665",
            "title": "Systemic Treatment Of Resistant Metastatic Disease Employing CVA21 and Pembrolizumab in Non-small Cell Lung Cancer and Bladder Cancer (STORM/ KEYNOTE-200) (STORM)",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2974,
                    "therapyName": "coxsackievirus A21",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02059213",
            "title": "A Phase II Study of Androgen Deprivation Therapy With or Without PD 0332991 in RB-Positive Metastatic Prostate Cancer",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 759,
                    "therapyName": "Goserelin",
                    "synonyms": null
                },
                {
                    "id": 850,
                    "therapyName": "Palbociclib",
                    "synonyms": null
                },
                {
                    "id": 1507,
                    "therapyName": "Bicalutamide",
                    "synonyms": null
                },
                {
                    "id": 795,
                    "therapyName": "Leuprolide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02091531",
            "title": "Dual mTOR Inhibitor MLN0128 in Advanced Castration-Resistant Prostate Cancer (CRPC) Patients",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1282,
                    "therapyName": "Sapanisertib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02115828",
            "title": "A Study of Vismodegib in Men With Metastatic CRPC With Accessible Metastatic Lesions for Tumor Biopsy",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 956,
                    "therapyName": "Vismodegib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02159950",
            "title": "Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2648,
                    "therapyName": "Sipuleucel-T",
                    "synonyms": null
                },
                {
                    "id": 2699,
                    "therapyName": "Tasquinimod",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02218606",
            "title": "Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in Treatment of Metastatic Castration Resistant Prostate Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1571,
                    "therapyName": "Cabazitaxel",
                    "synonyms": null
                },
                {
                    "id": 2748,
                    "therapyName": "Abiraterone + Prednisone",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02234921",
            "title": "Pilot Study of DRibble Vaccine for Prostate Cancer Patients",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1148,
                    "therapyName": "Cyclophosphamide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02259114",
            "title": "A Phase IB Trial With OTX015, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Patients With Selected Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2034,
                    "therapyName": "Birabresib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02265536",
            "title": "A Study of LY3022855 In Participants With Breast or Prostate Cancer",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2004,
                    "therapyName": "LY3022855",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02278185",
            "title": "Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 759,
                    "therapyName": "Goserelin",
                    "synonyms": null
                },
                {
                    "id": 1814,
                    "therapyName": "Degarelix",
                    "synonyms": null
                },
                {
                    "id": 2047,
                    "therapyName": "Histrelin acetate",
                    "synonyms": null
                },
                {
                    "id": 2050,
                    "therapyName": "Triptorelin",
                    "synonyms": null
                },
                {
                    "id": 795,
                    "therapyName": "Leuprolide",
                    "synonyms": null
                },
                {
                    "id": 1262,
                    "therapyName": "Enzalutamide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02279862",
            "title": "Safety and Efficacy Study of Ipilimumab 3 mg/kg Versus Ipilimumab 10 mg/kg in Subjects With Metastatic Castration Resistant Prostate Cancer Who Are Chemotherapy Naive",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 779,
                    "therapyName": "Ipilimumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02312557",
            "title": "Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2666,
                    "therapyName": "Enzalutamide + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02325557",
            "title": "ADXS31-142 Alone and in Combination With Pembrolizumab (MK-3475) in Patients With Prostate Cancer - KEYNOTE-046",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 3050,
                    "therapyName": "ADXS31-142",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02339168",
            "title": "Enzalutamide and Metformin Hydrochloride in Treating Patients With Hormone-Resistant Prostate Cancer",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2202,
                    "therapyName": "Enzalutamide + Metformin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02366494",
            "title": "Micro RNAs to Predict Response to Androgen Deprivation Therapy",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 795,
                    "therapyName": "Leuprolide",
                    "synonyms": null
                },
                {
                    "id": 759,
                    "therapyName": "Goserelin",
                    "synonyms": null
                },
                {
                    "id": 2050,
                    "therapyName": "Triptorelin",
                    "synonyms": null
                },
                {
                    "id": 1507,
                    "therapyName": "Bicalutamide",
                    "synonyms": null
                },
                {
                    "id": 720,
                    "therapyName": "Docetaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02403505",
            "title": "Discovery Stage Clinical Study About Oncology Drugs and Single Nucleotide Polymorphisms",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1262,
                    "therapyName": "Enzalutamide",
                    "synonyms": null
                },
                {
                    "id": 1805,
                    "therapyName": "Abiraterone",
                    "synonyms": null
                },
                {
                    "id": 2188,
                    "therapyName": "Prednisone",
                    "synonyms": null
                },
                {
                    "id": 1814,
                    "therapyName": "Degarelix",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02420652",
            "title": "Metformin Hydrochloride and Aspirin in Treating Patients With Hormone-Dependent Prostate Cancer That Has Progressed After Surgery or Radiation Therapy",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1031,
                    "therapyName": "Metformin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02429193",
            "title": "Biomarkers of Androgen Response and Resistance In Evolution During a Rising PSA (BARRIER-P)",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1262,
                    "therapyName": "Enzalutamide",
                    "synonyms": null
                },
                {
                    "id": 2748,
                    "therapyName": "Abiraterone + Prednisone",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02430480",
            "title": "Using Multiparametric MRI to Evaluate Intraprostatic Tumor Responses and Androgen Resistance Patterns in Newly Diagnosed Prostate Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 759,
                    "therapyName": "Goserelin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02438007",
            "title": "A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC",
            "phase": "Phase III",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1508,
                    "therapyName": "galeterone",
                    "synonyms": null
                },
                {
                    "id": 1262,
                    "therapyName": "Enzalutamide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02452008",
            "title": "Study of TGF-Beta Receptor Inhibitor LY2157299 and Enzalutamide in Metastatic Castration-resistant Prostate Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2409,
                    "therapyName": "Galunisertib",
                    "synonyms": null
                },
                {
                    "id": 1262,
                    "therapyName": "Enzalutamide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02489357",
            "title": "Pembrolizumab and Cryosurgery in Treating Patients With Newly Diagnosed, Oligo-metastatic Prostate Cancer",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1814,
                    "therapyName": "Degarelix",
                    "synonyms": null
                },
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02494921",
            "title": "LEE011 (Ribociclib) in Combination With Docetaxel Plus Prednisone in mCRPC",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3113,
                    "therapyName": "Docetaxel + Filgrastim + Prednisone + Ribociclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02507570",
            "title": "Open Label Phase Two Study of Enzalutamide With Concurrent Administration of Radium Ra 223 Dichloride in Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Symptomatic Bone Metastasis",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1262,
                    "therapyName": "Enzalutamide",
                    "synonyms": null
                },
                {
                    "id": 2001,
                    "therapyName": "Radium Ra 223 dichloride",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02522715",
            "title": "Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Hormone-Resistant Prostate Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3056,
                    "therapyName": "Cabazitaxel + Enzalutamide",
                    "synonyms": null
                },
                {
                    "id": 2188,
                    "therapyName": "Prednisone",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02531516",
            "title": "An Efficacy and Safety Study of JNJ-56021927 (ARN-509) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2649,
                    "therapyName": "Abiraterone + Apalutamide + Prednisone",
                    "synonyms": null
                },
                {
                    "id": 1507,
                    "therapyName": "Bicalutamide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02555189",
            "title": "Enzalutamide With and Without Ribociclib for Metastatic, Castrate-Resistant, Chemotherapy-Naive Prostate Cancer That Retains RB Expression",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 790,
                    "therapyName": "Ribociclib",
                    "synonyms": null
                },
                {
                    "id": 1262,
                    "therapyName": "Enzalutamide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02566772",
            "title": "Study of TAS3681 in Metastatic Castration Resistant Prostate Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4329,
                    "therapyName": "TAS3681",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02575781",
            "title": "A Study of SAR428926 in Patients With Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 4026,
                    "therapyName": "SAR428926",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02594072",
            "title": "Androgen Suppression With Stereotactic Body or External Beam Radiation Therapy (ASSERT) (ASSERT)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 759,
                    "therapyName": "Goserelin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02607228",
            "title": "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 as a Single Agent and In Combination With Enzalutamide in Participants With Metastatic Castrate-Resistant Prostate Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1262,
                    "therapyName": "Enzalutamide",
                    "synonyms": null
                },
                {
                    "id": 3561,
                    "therapyName": "Exemestane + GS-5829",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02614859",
            "title": "Bicalutamide With or Without Metformin for Biochemical Recurrence in Overweight or Obese Prostate Cancer Patients",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1507,
                    "therapyName": "Bicalutamide",
                    "synonyms": null
                },
                {
                    "id": 1031,
                    "therapyName": "Metformin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02616185",
            "title": "A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3565,
                    "therapyName": "PF-06755990 + PF-06755992 + Sunitinib + Tremelimumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02628535",
            "title": "Safety Study of MGD009 in B7-H3-expressing Tumors",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 6631,
                    "therapyName": "MGD009",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02655822",
            "title": "Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5858,
                    "therapyName": "Atezolizumab + CPI-444",
                    "synonyms": null
                },
                {
                    "id": 3571,
                    "therapyName": "CPI-444",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02660034",
            "title": "The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Subjects With Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5883,
                    "therapyName": "BGB-A317 + Pamiparib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02663908",
            "title": "A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1814,
                    "therapyName": "Degarelix",
                    "synonyms": null
                },
                {
                    "id": 795,
                    "therapyName": "Leuprolide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02698176",
            "title": "A Dose Exploration Study With MK-8628 in Participants With Selected Advanced Solid Tumors (MK-8628-006)",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 2034,
                    "therapyName": "Birabresib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02705469",
            "title": "A Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 4032,
                    "therapyName": "ZEN003694",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02711956",
            "title": "A Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 4033,
                    "therapyName": "Enzalutamide + ZEN003694",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02721433",
            "title": "4-weekly Versus 12-weekly Administration of Bone-targeted Agents in Patients With Bone Metastases (REaCT-BTA)",
            "phase": "FDA approved",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 4784,
                    "therapyName": "Denosumab + pamidronate + Zoledronic acid",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02766478",
            "title": "Genistein Supplementation to Mitigate Cardiometabolic Dysfunction in Patients Undergoing Androgen Deprivation Therapy for Prostate Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 757,
                    "therapyName": "Genistein",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02796898",
            "title": "Study of the Efficacy, Safety, and Pharmacokinetics of SM88 in Patients With Prostate Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 5866,
                    "therapyName": "SM88",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02807805",
            "title": "Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4377,
                    "therapyName": "Abiraterone + Niclosamide + Prednisone",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02833883",
            "title": "Use of an Experimental Drug, CC-115, With Enzalutamide in Men With Castration-Resistant Prostate Cancer",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 4459,
                    "therapyName": "CC-115 + Enzalutamide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02854436",
            "title": "An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 832,
                    "therapyName": "Niraparib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02881242",
            "title": "Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2,
                    "therapyName": "Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02887976",
            "title": "Extension of SoluMatrix TM Abiraterone Acetate in Patients Who Completed Study Number CHL-AA-201",
            "phase": "Phase III",
            "recruitment": "Unknown status",
            "therapies": [
                {
                    "id": 4678,
                    "therapyName": "Abiraterone + Methylprednisolone",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02900651",
            "title": "Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9055,
                    "therapyName": "MAK683",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02924766",
            "title": "A Safety and Pharmacokinetics Study of Niraparib Plus Apalutamide in Men With Metastatic Castration-Resistant Prostate Cancer (BEDIVERE)",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 4832,
                    "therapyName": "Apalutamide + Niraparib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02933255",
            "title": "PROSTVAC in Combination With Nivolumab and/or Ipilimumab in Men With Prostate Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4895,
                    "therapyName": "Ipilimumab + PROSTVAC-F/TRICOM + PROSTVAC-V/TRICOM",
                    "synonyms": null
                },
                {
                    "id": 4893,
                    "therapyName": "Ipilimumab + Nivolumab + PROSTVAC-F/TRICOM + PROSTVAC-V/TRICOM",
                    "synonyms": null
                },
                {
                    "id": 4894,
                    "therapyName": "Nivolumab + PROSTVAC-F/TRICOM + PROSTVAC-V/TRICOM",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02935205",
            "title": "Enzalutamide and Indomethacin in Treating Patients With Recurrent or Metastatic Hormone-Resistant Prostate Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4876,
                    "therapyName": "Enzalutamide + Indomethacin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02947165",
            "title": "Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5632,
                    "therapyName": "NIS793 + Spartalizumab",
                    "synonyms": null
                },
                {
                    "id": 5631,
                    "therapyName": "NIS793",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02950064",
            "title": "A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 6336,
                    "therapyName": "BTP-114",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02960022",
            "title": "A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5371,
                    "therapyName": "Abiraterone + Enzalutamide + Prednisone",
                    "synonyms": null
                },
                {
                    "id": 1262,
                    "therapyName": "Enzalutamide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02966587",
            "title": "Durvalumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer",
            "phase": "Phase II",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 1356,
                    "therapyName": "Durvalumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02985957",
            "title": "A Study to Evaluate Preliminary Safety and Efficacy of Nivolumab Plus Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1627,
                    "therapyName": "Ipilimumab + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02987543",
            "title": "Study of Olaparib (Lynparza) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 837,
                    "therapyName": "Olaparib",
                    "synonyms": null
                },
                {
                    "id": 1262,
                    "therapyName": "Enzalutamide",
                    "synonyms": null
                },
                {
                    "id": 1805,
                    "therapyName": "Abiraterone",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03016741",
            "title": "Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer",
            "phase": "FDA approved",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1262,
                    "therapyName": "Enzalutamide",
                    "synonyms": null
                },
                {
                    "id": 2748,
                    "therapyName": "Abiraterone + Prednisone",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03067051",
            "title": "Clinical Study to Assess the Safety and Adequacy of Effectiveness of the SpectraCure P18 System",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3319,
                    "therapyName": "Verteporfin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03098160",
            "title": "Immunotherapy Study of Evofosfamide in Combination With Ipilimumab",
            "phase": "Phase I",
            "recruitment": "Unknown status",
            "therapies": [
                {
                    "id": 5745,
                    "therapyName": "Evofosfamide + Ipilimumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03102606",
            "title": "Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy (Protective-1)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3678,
                    "therapyName": "Plinabulin",
                    "synonyms": null
                },
                {
                    "id": 1476,
                    "therapyName": "Pegfilgrastim",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03120832",
            "title": "Phase 1 Trial of PAN-301-1 in Cancer Patients",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 5704,
                    "therapyName": "PAN-301-1",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03123978",
            "title": "Enzalutamide and Niclosamide in Treating Patients With Recurrent or Metastatic Castration-Resistant Prostate Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5607,
                    "therapyName": "Enzalutamide + Niclosamide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03141671",
            "title": "Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5742,
                    "therapyName": "Bicalutamide + Gonadorelin",
                    "synonyms": null
                },
                {
                    "id": 5743,
                    "therapyName": "Abiraterone + Apalutamide + Gonadorelin + Prednisone",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03150810",
            "title": "Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Subjects With Locally Advanced or Metastatic Solid Tumors",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6124,
                    "therapyName": "Pamiparib + Temozolomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03179410",
            "title": "PD-L1 Inhibition as ChecKpoint Immunotherapy for NeuroEndocrine Phenotype Prostate Cancer (PICK-NEPC)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3144,
                    "therapyName": "Avelumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03188965",
            "title": "First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5962,
                    "therapyName": "BAY1895344",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03199586",
            "title": "Phase 1 Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Solid Tumors (Including Lymphoma)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7358,
                    "therapyName": "NP-G2-044",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03217747",
            "title": "Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6044,
                    "therapyName": "Avelumab + PF-04518600 + Utomilumab",
                    "synonyms": null
                },
                {
                    "id": 6043,
                    "therapyName": "Avelumab + Utomilumab",
                    "synonyms": null
                },
                {
                    "id": 6045,
                    "therapyName": "Avelumab + PF-04518600",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03311555",
            "title": "A Salvage Trial of AR Inhibition With ADT and Apalutamide With Radiation Therapy Followed by Docetaxel in Men With PSA Recurrent Prostate Cancer After Radical Prostatectomy (STARTAR)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5521,
                    "therapyName": "Apalutamide + Docetaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03315871",
            "title": "Combination Immunotherapy in Biochemically Recurrent Prostate Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6391,
                    "therapyName": "CV301 + M7824 + PROSTVAC-F/TRICOM + PROSTVAC-V/TRICOM",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03325127",
            "title": "Outcomes of mCRPC Patients Treated With Ra-223 Concomitant With Abiraterone or Enzalutamide- A Chart Review Study",
            "phase": "Phase I",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 6405,
                    "therapyName": "Abiraterone + Enzalutamide + Radium Ra 223 dichloride",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03330405",
            "title": "Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6436,
                    "therapyName": "Avelumab + Talazoparib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03333616",
            "title": "Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1627,
                    "therapyName": "Ipilimumab + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03344211",
            "title": "Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6479,
                    "therapyName": "Enzalutamide + Radium Ra 223 dichloride",
                    "synonyms": null
                },
                {
                    "id": 1262,
                    "therapyName": "Enzalutamide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03358563",
            "title": "Pilot Trial of Chemohormonal Therapy Followed by Prostatectomy in High Risk Prostate Cancer",
            "phase": "Phase I",
            "recruitment": "Suspended",
            "therapies": [
                {
                    "id": 6554,
                    "therapyName": "Bicalutamide + Degarelix + Docetaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03360006",
            "title": "A Study Evaluating the Safety and Pharmacokinetics of ABBV-744 in Subjects With Advanced Prostate Cancer (CRPC) and Relapsed/Refractory Acute Myeloid Leukemia (AML) Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7366,
                    "therapyName": "ABBV-744",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03363776",
            "title": "An Immuno-Therapy Study of Experimental Medication BMS-986277 Given Alone and in Combination With Nivolumab in Epithelial Cancers",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 6497,
                    "therapyName": "BMS-986277",
                    "synonyms": null
                },
                {
                    "id": 6498,
                    "therapyName": "BMS-986277 + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03363893",
            "title": "Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6828,
                    "therapyName": "ICEC0942",
                    "synonyms": null
                },
                {
                    "id": 8454,
                    "therapyName": "Fulvestrant + ICEC0942",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03367819",
            "title": "Isatuximab in Combination With REGN2810 in Patients With Advanced Malignancies",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 6331,
                    "therapyName": "Isatuximab",
                    "synonyms": null
                },
                {
                    "id": 6335,
                    "therapyName": "Cemiplimab + Isatuximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03409458",
            "title": "A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab (PAVE-1)",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6629,
                    "therapyName": "Avelumab + PT-112",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03418324",
            "title": "Study of TRC105 With Abiraterone and With Enzalutamide in Prostate Cancer Patients Progressing on Therapy",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 6654,
                    "therapyName": "Abiraterone + Carotuximab",
                    "synonyms": null
                },
                {
                    "id": 6655,
                    "therapyName": "Carotuximab + Enzalutamide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03450109",
            "title": "A Study to Assess LY01005 Versus Goserelin Comparator (ZOLADEX) in Patients With Prostate Cancer",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 6742,
                    "therapyName": "LY01005",
                    "synonyms": null
                },
                {
                    "id": 759,
                    "therapyName": "Goserelin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03454451",
            "title": "CPI-006 Alone and in Combination With CPI-444 and With Pembrolizumab for Patients With Advanced Cancers",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6755,
                    "therapyName": "CPI-006",
                    "synonyms": null
                },
                {
                    "id": 6757,
                    "therapyName": "CPI-006 + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 6756,
                    "therapyName": "CPI-006 + CPI-444",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03460977",
            "title": "PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6785,
                    "therapyName": "PF-06821497",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03473925",
            "title": "Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034)",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 6885,
                    "therapyName": "Navarixin + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03477864",
            "title": "Stereotactic Body Radiation Therapy With REGN2810 and/or Ipilimumab Before Surgery in Treating Participants With Progressive Advanced or Oligometastatic Prostate Cancer",
            "phase": "Phase I",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 779,
                    "therapyName": "Ipilimumab",
                    "synonyms": null
                },
                {
                    "id": 6797,
                    "therapyName": "Cemiplimab + Ipilimumab",
                    "synonyms": null
                },
                {
                    "id": 5656,
                    "therapyName": "Cemiplimab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03478904",
            "title": "Study to Compare Capsule and Liquid Formulations of Enzalutamide After Single Dose Administration Under Fasting Conditions in Prostate Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1262,
                    "therapyName": "Enzalutamide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03493945",
            "title": "Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, ALT-803 and Epacadostat (QuEST1).",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6893,
                    "therapyName": "ALT-803 + Epacadostat + FPV-Brachyury + M7824 + MVA-BN-Brachyury",
                    "synonyms": null
                },
                {
                    "id": 6892,
                    "therapyName": "FPV-Brachyury + M7824 + MVA-BN-Brachyury",
                    "synonyms": null
                },
                {
                    "id": 6891,
                    "therapyName": "ALT-803 + FPV-Brachyury + M7824 + MVA-BN-Brachyury",
                    "synonyms": null
                },
                {
                    "id": 6888,
                    "therapyName": "ALT-803 + M7824",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03507608",
            "title": "Assessing Induction of Double Strand Breaks With Androgen Receptor Partial Agonist in Patients on Androgen Suppression",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 742,
                    "therapyName": "Flutamide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03511664",
            "title": "Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer (VISION)",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 7806,
                    "therapyName": "177Lu-PSMA-617",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03517969",
            "title": "ATR Kinase Inhibitor VX-970 and Carboplatin With or Without Docetaxel in Treating Participants With Metastatic Castration-Resistant Prostate Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1834,
                    "therapyName": "Carboplatin + Docetaxel",
                    "synonyms": null
                },
                {
                    "id": 4253,
                    "therapyName": "Carboplatin + VX-970",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03531827",
            "title": "Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6954,
                    "therapyName": "CRLX101 + Enzalutamide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03543189",
            "title": "Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03565445",
            "title": "A Study of ASP1948, Targeting an Immune Modulatory Receptor, in Subjects With Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8423,
                    "therapyName": "ASP1948 + Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 8422,
                    "therapyName": "ASP1948",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03568539",
            "title": "IBI308 in Subjects With Advanced/Metastatic Solid Malignancies",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 6138,
                    "therapyName": "Sintilimab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03572478",
            "title": "Rucaparib and Nivolumab in Patients With Prostate or Endometrial Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6450,
                    "therapyName": "Nivolumab + Rucaparib",
                    "synonyms": null
                },
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 906,
                    "therapyName": "Rucaparib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03592264",
            "title": "This Study is to Evaluate OBI-3424 Safe and Effective Treatment Dose in Subjects With Hepatocellular Carcinoma or Castrate Resistant Prostate Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7164,
                    "therapyName": "OBI-3424",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03674814",
            "title": "Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7488,
                    "therapyName": "Enzalutamide + Relacorilant",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03685591",
            "title": "PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7496,
                    "therapyName": "PF-06952229",
                    "synonyms": null
                },
                {
                    "id": 7498,
                    "therapyName": "Enzalutamide + PF-06952229",
                    "synonyms": null
                },
                {
                    "id": 7497,
                    "therapyName": "Letrozole + Palbociclib + PF-06952229",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03689699",
            "title": "Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7399,
                    "therapyName": "BMS-986253 + Degarelix + Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 7398,
                    "therapyName": "Degarelix + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03709550",
            "title": "Enzalutamide and Decitabine in Treating Patients With Metastatic Castration Resistant Prostate Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 7441,
                    "therapyName": "Decitabine + Enzalutamide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03751436",
            "title": "Enzalutamide With Venetoclax in Treating Patients With Metastatic Castration Resistant Prostate Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7593,
                    "therapyName": "Enzalutamide + Venetoclax",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03761225",
            "title": "Masitinib Plus Docetaxel in Metastatic Castration-resistant Prostate Cancer",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2462,
                    "therapyName": "Docetaxel + Prednisone",
                    "synonyms": null
                },
                {
                    "id": 7818,
                    "therapyName": "Docetaxel + Masitinib + Prednisone",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03777982",
            "title": "A Randomized Phase III Study - Conventional ADT w/ or w/Out Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADT",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2649,
                    "therapyName": "Abiraterone + Apalutamide + Prednisone",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03784677",
            "title": "SOR-C13 in Treating Patients With Advanced Refractory Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7017,
                    "therapyName": "SOR-C13",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03792841",
            "title": "Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 160 in Subjects With mCRPC",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9044,
                    "therapyName": "AMG 160 + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 9043,
                    "therapyName": "AMG 160",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03799003",
            "title": "A Study of ASP1951 in Subjects With Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7772,
                    "therapyName": "ASP1951",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03810105",
            "title": "A Study of Olaparib and Durvalumab in Prostate Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2894,
                    "therapyName": "Durvalumab + Olaparib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03811652",
            "title": "A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 5762,
                    "therapyName": "MEDI7247",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03835533",
            "title": "Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations (PORTER)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8590,
                    "therapyName": "CDX-301 + INO-5151 + Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 8562,
                    "therapyName": "CDX-301 + Nivolumab + Poly ICLC",
                    "synonyms": null
                },
                {
                    "id": 5076,
                    "therapyName": "Nivolumab + NKTR-214",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03860987",
            "title": "Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8023,
                    "therapyName": "Abiraterone + Enzalutamide + Goserelin + Prednisone",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03873805",
            "title": "PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2291,
                    "therapyName": "Cyclophosphamide + Fludarabine",
                    "synonyms": null
                },
                {
                    "id": 9688,
                    "therapyName": "Anti-PSCA(dCH2)BBz-CAR T-cells",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03878524",
            "title": "A Personalized Medicine Study for Patients With Advanced Cancer of the Breast, Prostate, Pancreas or Those With Refractory Acute Myelogenous Leukemia (SMMART)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1104,
                    "therapyName": "Oxaliplatin",
                    "synonyms": null
                },
                {
                    "id": 850,
                    "therapyName": "Palbociclib",
                    "synonyms": null
                },
                {
                    "id": 342,
                    "therapyName": "Vemurafenib",
                    "synonyms": null
                },
                {
                    "id": 917,
                    "therapyName": "Sirolimus",
                    "synonyms": null
                },
                {
                    "id": 1877,
                    "therapyName": "Tretinoin",
                    "synonyms": null
                },
                {
                    "id": 2124,
                    "therapyName": "Celecoxib",
                    "synonyms": null
                },
                {
                    "id": 779,
                    "therapyName": "Ipilimumab",
                    "synonyms": null
                },
                {
                    "id": 907,
                    "therapyName": "Ruxolitinib",
                    "synonyms": null
                },
                {
                    "id": 717,
                    "therapyName": "Dasatinib",
                    "synonyms": null
                },
                {
                    "id": 1805,
                    "therapyName": "Abiraterone",
                    "synonyms": null
                },
                {
                    "id": 1023,
                    "therapyName": "Idelalisib",
                    "synonyms": null
                },
                {
                    "id": 2,
                    "therapyName": "Trametinib",
                    "synonyms": null
                },
                {
                    "id": 770,
                    "therapyName": "Imatinib",
                    "synonyms": null
                },
                {
                    "id": 4,
                    "therapyName": "Erlotinib",
                    "synonyms": null
                },
                {
                    "id": 1092,
                    "therapyName": "Carboplatin",
                    "synonyms": null
                },
                {
                    "id": 837,
                    "therapyName": "Olaparib",
                    "synonyms": null
                },
                {
                    "id": 1080,
                    "therapyName": "Panobinostat",
                    "synonyms": null
                },
                {
                    "id": 688,
                    "therapyName": "Bortezomib",
                    "synonyms": null
                },
                {
                    "id": 623,
                    "therapyName": "Afatinib",
                    "synonyms": null
                },
                {
                    "id": 1715,
                    "therapyName": "Fluorouracil",
                    "synonyms": null
                },
                {
                    "id": 1077,
                    "therapyName": "Vorinostat",
                    "synonyms": null
                },
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 1642,
                    "therapyName": "Leucovorin",
                    "synonyms": null
                },
                {
                    "id": 1262,
                    "therapyName": "Enzalutamide",
                    "synonyms": null
                },
                {
                    "id": 877,
                    "therapyName": "Ponatinib",
                    "synonyms": null
                },
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 735,
                    "therapyName": "Everolimus",
                    "synonyms": null
                },
                {
                    "id": 930,
                    "therapyName": "Sunitinib",
                    "synonyms": null
                },
                {
                    "id": 1571,
                    "therapyName": "Cabazitaxel",
                    "synonyms": null
                },
                {
                    "id": 998,
                    "therapyName": "Cabozantinib",
                    "synonyms": null
                },
                {
                    "id": 792,
                    "therapyName": "Lenvatinib",
                    "synonyms": null
                },
                {
                    "id": 856,
                    "therapyName": "Pertuzumab",
                    "synonyms": null
                },
                {
                    "id": 920,
                    "therapyName": "Sorafenib",
                    "synonyms": null
                },
                {
                    "id": 1562,
                    "therapyName": "Venetoclax",
                    "synonyms": null
                },
                {
                    "id": 667,
                    "therapyName": "Bevacizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03899467",
            "title": "the Safety and Tolerability of Proxalutamide (GT0918) in Subjects With Metastatic Castrate Resistant Prostate Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9600,
                    "therapyName": "Proxalutamide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03934840",
            "title": "Phase 2 of Carbo, Taxel and Abi in Metastatic Castration Prostate Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8948,
                    "therapyName": "Abiraterone + Cabazitaxel + Carboplatin + Prednisone",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03936959",
            "title": "A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 9537,
                    "therapyName": "LY3434172",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03951831",
            "title": "REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8381,
                    "therapyName": "Cemiplimab + Degarelix + Docetaxel + Leuprolide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03970382",
            "title": "A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8527,
                    "therapyName": "NeoTCR-P1 T-cells + Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 8526,
                    "therapyName": "NeoTCR-P1 T-cells",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04009967",
            "title": "Biomarkers for Neoadjuvant Pembrolizumab in Non-Metastatic Prostate Cancer Positive by 18FDG-PET Scanning (PICT-01)",
            "phase": null,
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04019964",
            "title": "Nivolumab in Biochemically Recurrent dMMR Prostate Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04030559",
            "title": "Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects",
            "phase": "Phase II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 832,
                    "therapyName": "Niraparib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04038502",
            "title": "BRcA Deficient Prostate Cancer Treated With Carboplatin or Docetaxel",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1092,
                    "therapyName": "Carboplatin",
                    "synonyms": null
                },
                {
                    "id": 720,
                    "therapyName": "Docetaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04052204",
            "title": "Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8711,
                    "therapyName": "Avelumab + NKTR-214",
                    "synonyms": null
                },
                {
                    "id": 8712,
                    "therapyName": "Avelumab + NKTR-214 + Talazoparib",
                    "synonyms": null
                },
                {
                    "id": 8713,
                    "therapyName": "Avelumab + Enzalutamide + NKTR-214",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04060342",
            "title": "GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8693,
                    "therapyName": "GB1275",
                    "synonyms": null
                },
                {
                    "id": 8694,
                    "therapyName": "GB1275 + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 8695,
                    "therapyName": "GB1275 + Gemcitabine + Nab-paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04087174",
            "title": "A Multi-centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Capivasertib (AZD5363) in Combination With Novel Agents in Patients With Metastatic Prostate Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8724,
                    "therapyName": "Abiraterone + Capivasertib",
                    "synonyms": null
                },
                {
                    "id": 6351,
                    "therapyName": "Capivasertib + Enzalutamide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04089553",
            "title": "An Open-label, Phase II Study of AZD4635 in Patients With Prostate Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4349,
                    "therapyName": "AZD4635 + Durvalumab",
                    "synonyms": null
                },
                {
                    "id": 6592,
                    "therapyName": "AZD4635 + Oleclumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04095273",
            "title": "Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the ATR Inhibitor BAY1895344 in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8754,
                    "therapyName": "BAY1895344 + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04134312",
            "title": "A Phase 1 Open Label Trial of Intravenous Administration of MVA-BN-Brachyury Vaccine in Patients With Advanced Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6889,
                    "therapyName": "MVA-BN-Brachyury",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04143789",
            "title": "Evaluation of AP-002 in Patients With Solid Tumors",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9164,
                    "therapyName": "AP-002",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04145375",
            "title": "Continuation Protocol for ZEN003694 in Patients Experiencing Clinical Benefit While Enrolled in a ZEN003694 Protocol",
            "phase": "Phase Ib/II",
            "recruitment": "Enrolling by invitation",
            "therapies": [
                {
                    "id": 4033,
                    "therapyName": "Enzalutamide + ZEN003694",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04145622",
            "title": "Study of DS-7300a in Participants With Advanced Solid Malignant Tumors",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9154,
                    "therapyName": "DS-7300a",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04148937",
            "title": "A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8894,
                    "therapyName": "LY3475070",
                    "synonyms": null
                },
                {
                    "id": 8895,
                    "therapyName": "LY3475070 + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04157517",
            "title": "A Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics Study",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9149,
                    "therapyName": "TAK-573",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04159896",
            "title": "ESK981 and Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer",
            "phase": "Phase II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 7057,
                    "therapyName": "CEP-11981 + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04182516",
            "title": "Study of NMS-03305293 in Pts With Selected Advanced/Metastatic Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9564,
                    "therapyName": "NMS-03305293",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04207255",
            "title": "Addition of Opaganib to Androgen Antagonists in Patients With mCRPC",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9511,
                    "therapyName": "ABC294640 + Enzalutamide",
                    "synonyms": null
                },
                {
                    "id": 9510,
                    "therapyName": "ABC294640 + Abiraterone",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04221542",
            "title": "Study of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9329,
                    "therapyName": "AMG 509 + Dexamethasone",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04249947",
            "title": "P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9528,
                    "therapyName": "P-PSMA-101 CAR-T cells",
                    "synonyms": null
                },
                {
                    "id": 5992,
                    "therapyName": "Rimiducid",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04250597",
            "title": "Study of GNX102 in Patients With Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 9331,
                    "therapyName": "GNX102",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04253262",
            "title": "A Phase Ib/II Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 9316,
                    "therapyName": "Copanlisib + Rucaparib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04267887",
            "title": "Apalutamide, Abiraterone Acetate, and Prednisone for the Treatment of Metastatic High Risk Castration Sensitive Prostate Cancer",
            "phase": "Phase II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 2649,
                    "therapyName": "Abiraterone + Apalutamide + Prednisone",
                    "synonyms": null
                }
            ]
        }
    ]
}